ビジネスワイヤ(バフェットのBerkshire Hathaway group)

Macnica Partners with Mouser Electronics to Support Enginee… 2017年05月25日 23時00分

YOKOHAMA, Japan--(BUSINESS WIRE)--Macnica, Inc. and Mouser Electronics, Inc. are pleased to announce a new
strategic partnership to deliver the highest levels of service and
support to Japanese design engineers. With the partnership, Macnica and
Mouser are introducing a new co-branded website at http://www.macnica-mouser.jp/.




Macnica is the leading Japanese semiconductor distributor focused on
offering technical support and the continuous advancement of its
technological capabilities. Macnica has been successfully differentiated
its position in the market by focusing on design in activities since its
inception in 1972. Its geographical expansions to Asia, EU, and Americas
started in 2008 to develop business with local customers beyond Japan.
Mouser is the industry's leading New Product Introduction (NPI)
distributor with an e-commerce model that makes it easy for engineers
and buyers to find engineering quantities of the newest products for
their designs. In addition, Mouser offers instant availability of both
development tools and semiconductor products from the leading
manufacturers.



“The online business has become increasingly important to our business.
Mouser is a world-class e-commerce company focused on engineering
quantities and new product introductions,” said Kiyoshi Nakashima,
President and CEO of Macnica. “This joint partnership with Mouser will
allow us to better serve our customers by offering an online presence
combined with vast inventory, world-class fulfillment and Macnica’s
technical support. We look forward to offering new value to Japanese
customers and supporting them throughout their design cycle challenges.”



Through the partnership, customers in Japan can speed time-to-market by
taking advantage of Macnica’s and Mouser’s complementary distribution
models. Mouser will handle new product content and engineering
quantities for prototype development, while Macnica will focus on volume
distribution and technical support for engineers across Japan.



“We are excited to partner with Macnica and leverage our e-commerce and
NPI expertise to serve engineering customers in Japan,” said Glenn
Smith, Mouser President and CEO. “We will be able to maximize our
strengths for mutual benefit and serve Japanese engineers with the
highest levels of service while increasing our brand presence in this
important market.”



With its broad product line and unsurpassed customer service, the
Macnica-Mouser co-branded site strives to empower innovation among
design engineers and buyers by delivering advanced technologies.
Macnica-Mouser co-branded site stocks the world’s widest selection of
the latest semiconductors and electronic components for the newest
design projects. Visit the new Macnica-Mouser site at http://www.macnica-mouser.jp/



About Macnica:



Since its establishment in 1972, Macnica Inc. has specialized in the
supply of wide a variety of high-value-added electronic parts and
network equipment, particularly semiconductors, to the electronics,
information and communications industries. The company is justly known
as a leader in the high-technology fields in which they operate. In
recent years, Macnica has expanded its lineup to provide in-depth
technical support to customers in addition to the supply of devices. Its
customers include Japan’s leading electrical and electronic products
manufacturers. The company has its headquarters in Yokohama, and its 70
sales office are located in USA, Canada, Brazil, United Kingdom,
Germany, Italia, Spain, France, Poland, Hong Kong, Taiwan, Korea, China,
Singapore, Thailand, India, and Malaysia. For more information, visit http://www.macnica.co.jp/en/



About Mouser Electronics:



Mouser Electronics, a subsidiary of TTI, Inc., is part of Warren
Buffett's Berkshire Hathaway family of companies. Mouser is an
award-winning, authorized semiconductor and electronic component
distributor focused on rapid New Product Introductions from its
manufacturing partners for electronic design engineers and buyers. The
global distributor’s website, Mouser.com, is available in multiple
languages and currencies and features more than 4 million products from
over 600 manufacturers. Mouser offers 22 support locations around the
world to provide best-in-class customer service and ships globally to
over 550,000 customers in 170 countries from its 750,000 sq. ft.
state-of-the-art facility south of Dallas, Texas. For more information,
visit www.mouser.com.




Contacts


Macnica, Inc.
Shinichiro Egawa, 81-45-470-8977
Marketing
planning Department
Strategic Marketing Division
egawa-s@macnica.co.jp
FAX:81-45-470-8955



Uhuru to Collaborate with ARM through mbed Cloud Enterprise… 2017年05月25日 21時00分


- Provide Secure IoT Services Utilizing mbed Cloud



TOKYO--(BUSINESS WIRE)--Uhuru Corporation (“Uhuru”, Headquarters: Minato-ku, Tokyo, President &
CEO: Takashi Sonoda) has entered into an agreement with ARM Ltd. (“ARM”,
Headquarters: Cambridge, England URL: https://www.arm.com/),
the world’s leading semiconductor design company, as an enterprise
licensee of the ARM® mbedTM Cloud. Through this agreement,
Uhuru will be able to use mbed Cloud as a base to provide its own
value-added services to its many clients who wish to securely and
efficiently manage internet connected devices. As a technology company
with professionals/technical staff with deep knowledge of IoT assets,
specifications of cloud services, and the architecture of more than 17
billion ARM chips shipped annually*, Uhuru is evolving its business to
support cultivating and edifying the developer community, developing new
partner activities and going forward, creating a new service business
centered on implementing and promulgating mbed Cloud.



* 17.6 billion ARM-based chips shipped in FY2016, according to
Softbank’s Annual Report released March 2017 (Japanese): (http://cdn.softbank.jp/corp/set/data/irinfo/presentations/results/pdf/2017/softbank_presentation_2017_004.pdf)



A new system for the IoT age has been gaining attention – known as “edge
computing”, it is the method where the edge devices themselves are
controlled, rather than all data they collect being uploaded and
processed in the cloud. Through the spread of mbed Cloud, Uhuru aims to
bring to reality a new distributive, collaborative, autonomous model of
continuously evolving things and services by merely updating software on
the edge devices without changing hardware. Uhuru will work with ARM
applying mbed Cloud in the following initiatives:



1. Expanding Uhuru’s own service to promote adoption of mbed Cloud
with manufacturers and system integrators



enebular® is Uhuru’s IoT orchestration service, a data linking platform
to connect various devices and cloud services, which has been adopted
for use at various IoT sites. Starting with this license agreement with
ARM, Uhuru will launch its automated deployment/configuration/management
system necessary for collaborative distributed processing between edge
and cloud running on enebular in cooperation with ARM to respond to
demands and potential needs from manufacturers and system integrators at
IoT implementation and operation sites. Uhuru expects to announce plans
in summer 2017 based on alliance partners’ needs.



2. Cultivating the mbed Cloud Developer Community



Uhuru plans to continue to aggressively(actively) contribute to
expanding the mbed Cloud developer community. Uhuru is moving forward
with plans to involve municipalities/regional governments and others
from the user side in IoT Hackathons, work toward expanding use cases
connecting IoT and edge devices, and cooperate with ARM to increase the
number of mbed Cloud and IoT engineers. As an example, mbed devices are
planned to be the basis for the “Ina LoRaWAN Hackathon” sponsored by
Ina-AI NET in Ina-city (the birthplace of ADSL), Nagano Prefecture.



For more information about Ina LoRaWAN Hackathon (Japanese): http://uhuru.co.jp/lorawan-hackathon/
(event will be held from June 24-25, 2017 and further plans are being
laid for then end of August and the end of October, 2017).
* Please
follow these links for more information about ARM mbed (https://www.mbed.com/en/)
and mbed Cloud (https://cloud.mbed.com/).



* IoT Orchestration Service – enebular®
enebular IoT Orchestration
Service brings automated deployment/configuration/management of the
assets necessary for collaborative distributed control of IoT systems to
reality. Starting with logic and data flow, enebular enables end-to-end
secure deployment of real-time streaming data visualization with
INFOMOTION and machine learning models.
https://enebular.com/



About Uhuru



Uhuru Corporation is a system integration and consulting company focused
on supporting clients’ adoption and utilization of cloud services. Since
its founding, Uhuru has aspired to increase enterprise value at our
clients using creative services inspired by the internet under the
corporate philosophy of “using technology and free thinking to create
the future”. Uhuru continues to transform our customers’ IoT and
marketing businesses based on the enebular® IoT Orchestration Service
and Milkcocoa® IoT messaging service to connect edge devices and cloud
services.
URL: http://uhuru.co.jp/english/




Contacts


Uhuru Corporation
Eric Wolfe, 81-3-6895-1526
General Manager
Global
Initiatives & Alliances
contact@uhuru.jp
FAX:
81-3-6895-1521



SCIEX Sponsored Award Recognizes Notable Contributions to E… 2017年05月25日 20時00分


Arnold O. Beckman Medal and Award Presented to Dr. Shigeru Terabe,
Professor Emeritus of the University of Hyogo in Kamigori, Hyogo, Japan


FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX,
a global leader in life science analytical technologies, has announced
that the MSB Strategic Planning Committee has selected Dr. Shigeru
Terabe, Professor Emeritus of the University of Hyogo in Kamigori,
Hyogo, Japan, as the recipient of the Arnold O. Beckman Medal and Award
for Outstanding Scientific Achievements in the Field of Electro-driven
Separation Techniques. The Medal Ceremony was presented on Tuesday,
March 28th as part of a Special Award Plenary Session at the 33rd
International Symposium on Microscale Bioseparations (MSB 2017).








The Arnold O. Beckman award is given to an individual for remarkable
career achievements, with particular consideration being given to the
development of new methods, techniques and high-impact applications in
the field of electro-driven separations. The award comprises a Medal, a
Diploma and a Monetary Prize.



Professor Terabe earned his undergraduate, masters and doctoral degrees
from Kyoto University, Japan in 1963, 1965 and 1973, respectively.
Professor Terabe began is career at the Shionogi & Company Ltd, where he
was a research chemist. Later, he joined Arizona State University, where
he was a research associate before returning to Kyoto University, Japan
to become an assistant professor. In 1990, he was appointed to the
Faculty at Himeji Institute of Technology, Kamigori, Hyogo, Japan and
has since been engaged in the practice of analytical chemistry. After
retiring, Professor Terabe served as a Research Supervisor of the
program “Precursory Research for Embryonic Science and Technology”
funded by the Japanese government from 2004–2010. In his role, Professor
Terabe assisted 40 top young analytical scientists by funding ca. 5
million USD per year for the project, “Structure Function and
Measurement Analysis.”



Professor Terabe has been a driving force in understanding the
fundamentals of capillary electrophoresis including the introduction of
Micellar Electrokinetic Chromatography and a myriad of its applications,
as well as the development of sweeping, a “stacking” approach for
neutral analytes. His 250 original research publications have been cited
more than 15,000 times altogether ranking him in the top 200 among all
chemists. Professor Terabe has been awarded the ACS Award in
Chromatography in 2004, CASSS Award in 2007, and the Chemical Society of
Japan Award in 2008 in recognition of his contributions to analytical
chemistry. He served as an Editor of Journal of Chromatography for
15 years and in 2011 he was Chairman of the IUPAC International
Congress on Analytical Sciences.



“This annual Medal and Award sponsored by SCIEX recognizes the
achievements of those that have made a momentous impact on capillary
electrophoresis,” said Jeff Chapman, Sr. Director, SCIEX.
“Professor Terabe’s invention of micellar electrokinetic chromatography
has inspired many scientists, both utilizing and building upon this
fundamental methodology.”



“I am humbled to be the recipient of the prestigious Arnold O. Beckman
award, a notable honor that has recognized distinguished colleagues that
have impacted diverse scientific and technical disciplines,” said Dr.
Shigeru Terabe, Professor Emeritus of the University of Hyogo in
Kamigori, Hyogo, Japan
. “Dr. Beckman’s achievements have inspired me
and I would like to express my gratitude to MSB for this esteemed award.”



Learn more about SCIEX
and SCIEX
Capillary Electrophoresis Solutions



About SCIEX



SCIEX helps to improve the world we live in by enabling scientists and
laboratory analysts to find answers to the complex analytical challenges
they face. The company's global leadership and world-class service and
support in the capillary electrophoresis and liquid chromatography-mass
spectrometry industry have made it a trusted partner to thousands of the
scientists and lab analysts worldwide who are focused on basic research,
drug discovery and development, food and environmental testing,
forensics and clinical research.



With over 40 years of proven innovation, SCIEX excels by listening to
and understanding the ever-evolving needs of its customers to develop
reliable, sensitive and intuitive solutions that continue to redefine
what is achievable in routine and complex analysis. For more
information, please visit sciex.com.



SCIEX social: Twitter: @SCIEXnews,
LinkedIn
and Facebook.



For Research Use Only. Not for use in diagnostic procedures.
RUO-MKT-12-5561-A



AB Sciex is operating as SCIEX.



© 2017 AB Sciex. The trademarks mentioned herein are the property of the
AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used
under license.




Contacts


SCIEX
Stacey Sicurella, 508-688-7958
Manager Global Public
Relations and Brand
Stacey.sicurella@sciex.com
or
Editorial
follow-up
Sniper Public Relations on Behalf of SCIEX
Patrick
Farrell, 603-583-5488
pfarrell@sniperpr.com



オープン・コネクティビティー・ファンデーション、アジアの各… 2017年05月25日 19時39分


IoTコンソーシアムが台北国際コンピューター見本市、オートモーティブ・リナックス・サミット、CESアジアにおいて、広いデバイスと業界にまたがる相互運用性のデモを実施


上海 & 東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- モノのインターネット(IoT)の有力な標準化団体であるオープン・コネクティビティー・ファンデーション(OCF)は、近日中にアジアで開催される3つのイベントに参加することを発表します。OCFは、2017年台北国際コンピューター見本市、オートモーティブ・リナックス・サミット、CESアジアにおいて、会員企業によるIoT分野の革新成果を紹介します。これらの革新成果は各種産業、スマートホーム、自動車などの業界に及びます。




2017年台北国際コンピューター見本市:OCFは台北に向かい、6月1日にIII(資訊工業策進会)と共同で半日セミナーを開催し、スマートホームとIoTの革新のための共通フレームワークの開発を促進する機会を探ります。




  • 日程:2017年5月30日~6月3日


  • 開催地:台湾・台北


  • 会場:台北世界貿易中心、会議室3、信義路五段1號



オートモーティブ・リナックス・サミット:日本のOCFに参加して、サムスンのIoTソフトウエアエンジニアであるフィリップ・コバル氏の講演をお聴きください。OCFのIoTivityオープンソースフレームワークと、コネクテッドカー業界における相互運用性について語り、新しい車車間/路車間通信(V2X)のユースケースを設計する際の秘訣についての鋭い知見を披露します。




  • 日程:2017年5月31日~6月2日


  • 開催地:東京


  • 会場:東京コンファレンスセンター、有明3丁目11−1



2017年CESアジア:インテル、ハイアール、VIA、ビーチウッズなどのOCF会員は、OCFのインタラクティブブースにおいて相互運用性の技術を紹介し、IoTivityを通じてシームレスに通信できる認定製品のデモを実施します。




  • 日程:2017年6月7~9日


  • 開催地:中国・上海


  • 会場:ホールN2/2204、上海新国際博覧中心&ケリーホテル



オープン・コネクティビティー・ファンデーションについて



何十億台ものコネクテッドデバイス(電話、コンピューター、センサー)が、メーカー、オペレーティングシステム、チップセット、物理トランスポートに関係なく、相互通信できなければなりません。オープン・コネクティビティー・ファンデーション(OCF)は、それを実現すべく、仕様の策定と、オープンソースプロジェクトへの後援を行います。OCFは、IoT市場の膨大なチャンスを解き放ち、業界としての革新を加速し、単一のオープン仕様に基づくソリューションを創出できるよう開発者や企業を支援します。OCFは、消費者・企業・業界にとってセキュアな相互運用性を確保できるよう支援していきます。オールシーン・アライアンスはこれより、オープン・コネクティビティー・ファンデーションの下で活動することになります。詳細については、 www.openconnectivity.orgをご覧ください。



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。






Contacts


Open Connectivity Foundation
Richard Brown,
(886)-2-2218-5452 #6201
RIBrown@via.com.tw



Japan Market Report for Pulse Oximetry 2017 - Research and … 2017年05月25日 19時34分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan
Market Report for Pulse Oximetry 2017 - MedCore"
report to
their offering.




The market for peripheral pulse oximetry included stand-alone bedside,
handheld and fingertip monitors, as well as reusable and disposable
sensors, and OEM device boards. Elements from the venous and tissue
saturation markets are not explored in the scope of this report.



The market for pulse oximetry sensors represented majority of the total
market. Growth in the total market will primarily be driven by high
volumes of disposable sensors and growth in the OEM circuit devices.
Except for the fingertip segment, the pulse oximetry monitor market is
mature and sales are largely made on a replacement basis. Sensor sales
will increase primarily with the growing incidence of disease and
hospitals admission rates, driven in part by the growing percentage of
individuals over the age of 65.



There continues to be a strong push for more monitoring in both
hospitals (unmonitored wards and medical surgery) and alternate care
settings (long-term care facilities and skilled nursing facilities).
Both disposable and reusable segments will be able to take advantage of
the anticipated growth, although competition between vendors will be
significant. Additionally, although not discusses separately herein, the
retail market for non-PSE-approved pulse oximetry devices continues to
grow as the customers look to take proactive action to better manage
their health or chronic conditions.



While pulse oximetry equipment is already widely used in hospitals, the
market is still expected to grow substantially due to the introduction
of new technologies, and the expanding use of sophisticated
multi-parameter monitoring devices. As these multi-parameter monitoring
devices almost always include pulse oximetry as one of their
capabilities, they account for the bulk of pulse oximetry procedures
performed in hospitals.



General Report Contents




  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends


  • Market Drivers & Limiters for each chapter segment


  • Competitive Analysis for each chapter segment


  • Section on recent mergers & acquisitions



Pulse Oximetry Monitoring Devices - Clinical Trials




  • GE Healthcare


  • Masimo


  • Medtronic


  • Nonin Medical


  • Philips Healthcare


  • St. Jude Medical



For more information about this report visit http://www.researchandmarkets.com/research/9djpd2/japan_market




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Patient
Monitoring Equipment

Japan Market Report for Electroencephalogram Monitoring and… 2017年05月25日 19時13分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan
Market Report for Electroencephalogram Monitoring and Diagnostics 2017 -
MedCore"
report to their offering.




The EEG market is made up of clinical EEG monitors, long-term EEG
monitors and ICU monitors. In 2016, clinical EEG monitoring equipment
represented the single largest segment followed by long-term EEG
monitors and ICU EEG segments.



Presently, the clinical EEG market accounts for most of the diagnostic
EEG market revenue. However, over the forecast period the long-term
monitoring segment will strengthen further to represent a larger share
of the total market, eating away at the market share of clinical EEG
monitors. This shift is driven in part by the high costs associated with
the feature loaded monitor configurations utilized in non-routine
settings. Furthermore, the deployment of new, high-end technologies,
including source imaging and dense array EEG, in addition to expanded
applications for EEG will facilitate further revenue growth across these
developing EEG device markets.



Future growth within the total EEG market is attributable to many
factors. Patient outcome benefits resulting from earlier EEG-based
detections and interventions are being realized and will drive greater
EEG use, particularly in the context of epilepsy monitoring. Expansion
of signal interpretation services and technological advancements
improving usability will make EEG diagnostics more accessible and
increase adoption in both acute and sub-acute care settings. Finally,
the aging population and increase in the prevalence of neurological and
mental disorders will prompt an expansion of EEG procedural volumes.



The diagnostic EEG market has been expanding significantly with revenue
growth driven largely by the ICU monitor, long-term monitor, and, to a
lesser extent, clinical EEG segment since this market is already mature
and will not be very active outside of replacement-driven sales.



General Report Contents




  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends


  • Market Drivers & Limiters for each chapter segment


  • Competitive Analysis for each chapter segment


  • Section on recent mergers & acquisitions



Companies Mentioned




  • A&D Medical


  • Ambu


  • Boston Scientific


  • Cadwell


  • Charmcare Co


  • Contec Medical


  • Contec Medical Systems


  • Creative Medical


  • Edan


  • Electrical Geodesics Inc


  • Fukuda Denshi


  • GE Healthcare


  • Generic Label,


  • Goldway


  • Honeywell


  • Masimo


  • Mediana


  • Medtronic


  • Mekics Co. Ltd


  • Micromed


  • Noraxon


  • Omron Healthcare


  • Phenitec Co


  • Philips Healthcare


  • Robert Bosch Healthcare


  • Rossmax International


  • Schiller


  • Smiths Medical


  • Sorin Medical


  • Spacelabs Healthcare


  • St. Jude Medical


  • Wagner Industrial Electronics


  • Welch Allyn


  • Zondan Medical



For more information about this report visit http://www.researchandmarkets.com/research/pd7s47/japan_market




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Diagnostics,
Medical
Imaging

Japan Market Report for Electromyogram Monitoring and Diagn… 2017年05月25日 18時59分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan
Market Report for Electromyogram Monitoring and Diagnostics 2017 -
MedCore"
report to their offering.




The total market for EMG monitoring included both EMG monitoring devices
and EMG consumables. This report considers the electro-diagnostic market
which includes evoked potential studies (EP), nerve conduction studies
(NCS), needle EMG and the associated consumables.



EMG monitors accounted for majority of the total electromyogram
monitoring market. Within the consumables market, concentric needles
account for majority of the total market segment. Over the forecast
period, consumables will represent a growing proportion of the total
market, due to a greater demand for EMG procedures among the growing
elderly demographic. The monitor market, on the other hand, will remain
flat as the market has reached saturation and continues to operate on a
replacement basis. Slight growth is expected in the total market as
consumable sales increase and prices stabilize across segments.



New electro-diagnostic EMG device purchases will be modest, driven
primarily by replacement sales and alternate care sites are expected to
show little demand moving forward. However, sales of consumables are
expected to continue to rise and cause the market to grow towards the
end of the forecast period. Despite competitive price cutting by
vendors, growth within the market is still expected due to the
established install base and increasing procedural volumes.



Companies Mentioned



- A&D Medical



- Ambu



- Beijing Choice



- Beijing EMG Bearing Co. Ltd.



- Bionet



- Bistos



- Boston Scientific



- Cadwell



- Fukuda Denshi



- GE Healthcare



- Generic Label,



- Goldway



- Honeywell



- Jerry Medical Instruments



- Jumper



- Kellyunion International



- Kernal Medical



- Kwangwon Medical



- Masimo



- Mediana



- Medtronic



- Mekics Co. Ltd



- Micromed



- Mindray



- Natus Medical



- Neuro-Force



- Neurosoft Company



- Nihon Kohden



- Nonin



- Noraxon



- Omron Healthcare



- Phenitec Co



- Philips Healthcare



- Robert Bosch Healthcare



- Rossmax International



For more information about this report visit http://www.researchandmarkets.com/research/3pr5vl/japan_market




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Diagnostics

東芝メモリ株式会社:報道取材現場で使用するための情報漏えい… 2017年05月25日 17時10分


インターフェースロック機能「MamolicaTM(マモリカ)」を使った取り組みで日本テレビと共同で受賞




東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 東芝メモリ株式会社は、日本テレビ放送網株式会社(以下、日本テレビ)と共同で、報道取材現場で使用するための、情報漏えい防止型SDメモリカードの開発で、一般社団法人映像情報メディア学会(以下、映像情報メディア学会)の、「技術振興賞」進歩開発賞(研究開発部門)を受賞しました。「技術振興賞」進歩開発賞(研究開発部門)は、映像情報メディア学会が毎年研究開発、設計等の部門において、映像情報メディアに関する研究、開発により斬新な方式、システム、機器、デバイス等を完成、あるいは実用化し、顕著な効果を示した個人または団体に授与する賞です。






報道取材現場では、SDメモリカード記録型のビデオカメラが多く使用されており、SDメモリカードの紛失や盗難があった場合にも取材映像や個人情報が漏えいしない仕組みの要望がありました。そこで当社は、セット側のビデオカメラに改造を加えたり、専用のアダプタを装着したりせずに、それらの要望に応えることができる製品として、NFC(近距離無線通信)技術を使ったインターフェースロック機能「MamolicaTM」付きSDメモリカード(Read
Lockモデル)を開発しました。



当社従来製品の「MamolicaTM」付きSDメモリカードでは、撮影など新たなデータの書き込みや保存されたデータの読み出しは、スマートフォンなどを用いて特定ユーザーが鍵(ロック)を解除して行う仕組みとなっています。しかし、慌ただしい取材現場では、撮影する度にロック解除を行う余裕がない場合があります。そこで当社は従来製品の機能をベースに、撮影(データの書き込み)は通常のSDメモリカードと同様に常時ロックなしで行いながら、データ読み出しに対してのみ特定ユーザーによるロック機能を設けることができる「Read
Lockモデル」を開発しました。



今回の受賞は、情報漏えい防止型SDメモリカードの開発を行った当社と、情報漏えい防止型SDメモリカードの機能検証、ビデオカメラなど各種セットでの情報漏えい防止型SDメモリカードの互換性の評価や、スマートフォンやPC用の周辺機器の試作などを行った日本テレビの二社からなる開発チームに対して共同で贈られたものです。



*本文に掲載の製品名やサービス名は、それぞれ各社が登録商標または商標として使用している場合があります。



本製品の詳細は下記WEBページをご覧ください。
https://toshiba.semicon-storage.com/jp/product/memory/nfc-sd/mamolica-rl.html



*本資料に掲載されている情報(製品の仕様、サービスの内容およびお問い合わせ先など)は、発表日現在の情報です。予告なしに変更されることがありますので、あらかじめご了承ください。




Contacts


報道関係の本資料に関するお問い合わせ先:
東芝メモリ株式会社
営業企画部
高畑浩二
Tel:
03-3457-3822
e-mail: semicon-NR-mailbox@ml.toshiba.co.jp



Toshiba Launches High Voltage Intelligent Power Device with… 2017年05月25日 15時37分

TOKYO--(BUSINESS WIRE)--Toshiba
Corporation's (TOKYO:6502) Storage & Electronic Devices Solutions Company

today announced the launch of “TPD4207F,” the latest addition to its
line-up of high voltage intelligent power devices (IPDs) in small-size
packages for use in fan motors, including those of air conditioners, air
cleaners and pumps. The new IPD is housed in a small “SOP30” surface
mount package, and achieves an increased current rating of 5A and high
voltage of 600V. Mass production shipments start today.








Utilizing Toshiba’s latest MOSFET technology for reducing power loss,
the 600V Super Junction MOSFET “DTMOSIV series,” the new IPD achieves a
5A rating. This is sufficient to drive the compressor motor of a
refrigerator, which current IPDs cannot do, and will expand the range of
application.



Features
Achieves 600V and 5A rating
in a compact surface-mount device package.



Applications
Refrigerator compressor
motors, etc.



Follow the link below for more on the new product.
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TPD4207F&region=apc&lang=en



Follow the link below for more on Toshiba IPDs.
https://toshiba.semicon-storage.com/ap-en/product/linear/ipd.html



Customer Inquiries:
Power Device Sales & Marketing Department
Tel:
+81-3-3457-3933
https://toshiba.semicon-storage.com/ap-en/contact.html



Information in this document, including product prices and
specifications, content of services and contact information, is correct
on the date of the announcement but is subject to change without prior
notice.



About Toshiba
Toshiba Corporation, a
Fortune Global 500 company, channels world-class capabilities in
advanced electronic and electrical product and systems into three focus
business fields: Energy that sustains everyday life, that is cleaner and
safer; Infrastructure that sustains quality of life; and Storage that
sustains the advanced information society. Guided by the principles of
The Basic Commitment of the Toshiba Group, “Committed to People,
Committed to the Future”, Toshiba promotes global operations and is
contributing to the realization of a world where generations to come can
live better lives.



Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global
network of 550 consolidated companies employing 188,000 people
worldwide, with annual sales surpassing 5.6 trillion yen (US$50
billion). (As of March 31, 2016.)
To find out more about Toshiba,
visit www.toshiba.co.jp/index.htm




Contacts


Media Inquiries:
Toshiba Corporation
Storage & Electronic
Devices Solutions Company
Digital Marketing Department
Chiaki
Nagasawa, +81-3-3457-4963
semicon-NR-mailbox@ml.toshiba.co.jp



東芝:600V耐圧/5A定格の高耐圧インテリジェントパワーデバイス… 2017年05月25日 15時35分

東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 株式会社東芝ストレージ&デバイスソリューション社は、エアコンや空気清浄機、ポンプなどのファンモータ駆動用インテリジェントパワーデバイスのラインアップに、電流定格を向上した小型面実装のSOP30パッケージ製品「TPD4207F」を追加し、本日より量産出荷を開始します。






新製品は、当社中高耐圧MOSFETの最新世代品、600V系スーパージャンクションMOSFET
DTMOSⅣシリーズを搭載し、低損失化を図ることで電流定格5Aを実現しました。これにより、従来製品では対応困難であった冷蔵庫用コンプレッサモータなどの駆動を可能にし、適用応用範囲を拡大しました。





新製品の主な特長



・小型面実装パッケージにて600V耐圧/5A定格を実現



応用機器



・ 冷蔵庫用コンプレッサモータ、他



新製品のさらに詳しい仕様については下記WEBページをご覧ください。
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TPD4207F&region=jp&lang=ja



東芝のインテリジェントパワーデバイス(IPD)製品の詳細については下記WEBページをご覧ください。
https://toshiba.semicon-storage.com/jp/product/linear/ipd.html



お客様からの製品に関するお問い合わせ先:
パワーデバイス営業推進部
Tel: 03-3457-3933
https://toshiba.semicon-storage.com/jp/contact.html



*本資料に掲載されている情報(製品の価格/仕様、サービスの内容及びお問い合わせ先など)は、発表日現在の情報です。予告なしに変更されることがありますので、あらかじめご了承ください。




Contacts


報道関係の本資料に関するお問い合わせ先:
株式会社東芝 ストレージ&デバイスソリューション社
デジタルマーケティング部
長沢千秋
Tel:
03-3457-4963
e-mail: semicon-NR-mailbox@ml.toshiba.co.jp

NTT Communications Won 3 Categories at Asia Communication A… 2017年05月25日 15時00分

TOKYO--(BUSINESS WIRE)--NTT Communications Corporation (NTT Com), the ICT solutions and
international communications business within the NTT Group (TOKYO:9432),
announced today that it was named Operator of the Year, and was also
recognized in the category of Wholesale Operator of the Year and The
Connected Asia Award at the Asia Communication Awards (ACA) 2017 in
Singapore on May 24th.








Launched in 2011 by Total Telecom, ACA recognizes the companies and
individuals driving the success of the Asian-based telecom industry to a
global audience. A panel of telecom experts selected winners in 18
categories.



NTT Com was named Operator of the Year for the third time. The award
recognizes that a provider demonstrated a strong service portfolio,
investment in network and service development, a growing and satisfied
customer base, and execution of a clear and ambitious strategic plan.
“Many telcos have tried to transform their business and have ended up
going backwards. NTT Communications on the other hand is inching its way
into the new digital world,” said one judge.



Wholesale Operator of the Year is one of the most fiercely contested at
the Asia Communication Awards and NTT Com won this category for the
second year in a row. The award recognizes NTT Com’s continuous
investment and improvement in network infrastructure in APAC, such as
launch of Asia Pacific Gateway (APG) submarine cable in October 2016 and
Kizuna Submarine Cable-Laying vessel in March 2017, while keeping the
high customer retention rate through its Tier-1 Global
IP Network
. One judge said NTT Com showed an “excellent approach to
global engagement, which is the mark of a good operator.”



NTT Com received The Connected Asia Award for its IoT
Platform
. This award highlights NTT Com’s contribution to business
transformation and productivity improvement of enterprise customers by a
solution that fits in all use cases, leveraging the company’s globally
deployed network, cloud and data center as well as its partnership with
application platform providers and device vendors. “In terms of sheer
scope, NTT Communications is the Connected Asia leader,” declared one
member of the panel.



For more information about NTT Com’s awards and recognition, visit www.ntt.com/strength/leader/data/awards.html.



About NTT Communications Corporation



NTT Communications provides consultancy, architecture, security and
cloud services to optimize the information and communications technology
(ICT) environments of enterprises. These offerings are backed by the
company’s worldwide infrastructure, including the leading global tier-1
IP network, the Arcstar Universal One™ VPN network reaching 196
countries/regions, and over 140 secure data centers worldwide. NTT
Communications’ solutions leverage the global resources of NTT Group
companies including Dimension Data, NTT DOCOMO and NTT DATA.



www.ntt.com
| Twitter@NTT
Com
| Facebook@NTT
Com
| LinkedIn@NTT
Com




Contacts


For more information
NTT Communications Corporation
Ms.
Yuko Miyamoto / Ms. Hana Tsuchiya,
+81 3 6700 4010
Public
Relations
ar-cp@ntt.com



Toshiba Tec Unveils World's First Monochrome Multi-function… 2017年05月25日 14時00分

TOKYO--(BUSINESS WIRE)--#toshibatec--Toshiba
Tec Corporation
(TOKYO:6588) today unveils the world’s first hybrid
multi-function peripheral (MFP), the e-STUDIO5008LP
series
, which prints regular black prints as well as erasable blue
prints within one device. The unique and eco-conscious product will be
available this July.








The e-STUDIO5008LP series, driven by Toshiba Tec's e-BRIDGE Next
platform, is the newest addition to the company's state-of-the-art MFP
line designed for businesses seeking to operate more ecologically,
economically and efficiently. The e-STUDIO5008LP series enables the
reuse of paper via Toshiba Tec’s proprietary erasable blue toner that
may be erased by the heat of the hybrid MFP or the optional paper
reusing device, the e-STUDIO RD301. The system limits paper consumption
without restricting prints and reduces costs and the organizations' eco
footprint.



Businesses often print for temporary needs such as proofreading a
document, reviewing an email or reading a fax. In these instances, the
e-STUDIO5008LP series provides users the flexibility to select erasable
blue toner while using regular black toner for producing more permanent
documents. To simplify use, the product's rule-based printing feature
allows customers to define multiple rules for automatically selecting
the toner mode by application. The product's e-BRIDGE Paper Reuse Report
capability generates a summary of paper reduction and average paper
usage to succinctly convey an organization's environmental contribution
at a glance.



The e-STUDIO5008LP series is designed with “Together
Information
” in mind, Toshiba Tec's vision of how people and
organizations create, record, share, manage and display ideas and data.
This is reflected in the company's global message for its new product: Connect,
Integrate, Simplify and Reuse
.
The company strives to be one of
the world’s leading eco-conscious companies based on the company's Three
Greens philosophy: Greening of Products, Greening of Process, and Green
Management.



Toshiba Tec also seeks to attain Toshiba’s “Excellent ECPs
(Environmentally Conscious Products)” certification with every product
it designs and manufactures. The e-STUDIO5008LP series has earned the
“Excellent ECPs" designation, which is Toshiba’s internal certification
awarded to products achieving the highest level of environmental
performance in the industry at the time of release.



“Our team is proud to announce our hybrid MFP, the signature model of
our environmentally-conscious products. Thanks to our unique paper
reusing technology, our latest MFP may generate regular as well as
erasable prints within one product. We believe it will help our
customers function more ecologically while still operating in an
efficient and economical manner,” says Sachio Koyama, General Manager of
Products, Marketing & Service Division, Printing Solutions Business
Group, Toshiba Tec. With the increase of environmental awareness,
Toshiba Tec believes the product will contribute to our customers’
business and to the environment. Toshiba Tec will continue to deliver
the most competitive products and solutions to support customers more
than ever.



About Toshiba Tec



Toshiba Tec Corporation is a Toshiba’s group company, a leading provider
of technology solutions, operating across multiple industries – ranging
from retail, education and business services to hospitality and
manufacturing. With headquarters in Japan and over 80 subsidiaries
worldwide, Toshiba Tec Corporation helps organizations transform the way
they create, record, share, manage and display information.



Please visit http://www.toshibatec.co.jp/en/
For
Global site please visit http://www.toshibatec.com/global/



Unless otherwise specified and/or credited all images, artwork, text and
graphics, logos and logotypes are the copyright and/or trademark of the
respective owners. All rights reserved.




Contacts


Media Contact
Toshiba Tec Corporation
Toshihiko “Tommy”
Minato, +81-(0)50-3681-5528
Marketing Department
Products,
Marketing & Service Division
Printing Solutions Business Group
Toshihiko_Minato@toshibatec.co.jp

三井化学、世界初の柔軟高強度不織布「エアリファ™」を開発 2017年05月25日 13時34分


~当社独自の紡糸技術を駆使し、「柔らかさ」と「強さ」を兼ね備えた肌に優しい不織布を実現~


東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 三井化学株式会社(所在:東京都港区、社長:淡輪
敏)は、この度、当社独自のポリオレフィン紡糸技術を駆使した、世界初の柔軟高強度不織布「エアリファ™」を開発いたしました。






今回開発した新製品「エアリファ™」は、「柔らかさ」と「強さ」を兼ね備えた肌に優しい高機能不織布です。当社独自のポリオレフィン紡糸技術を駆使し、繊維を薄肉の中空構造にすることにより、ソフト感、均一性を向上させたことを特長としており、これまでの技術では両立できなかった「柔らかさ」と「強さ」の機能共存を実現しています。





また、繊維を薄肉中空構造とすることで、使用するプラスチック原料を削減し、地球環境問題へも配慮した、環境対応型の不織布です。



尚、新製品の名称「エアリファ™」は、非常に軽く柔らかな(airy)布・生地(fabric)を意味しています。



当社はこれまでに、主に紙オムツなどの衛生用品向けに、嵩高で柔軟性の高い不織布、伸縮機能に優れた不織布、今回の「エアリファ™」等の高機能不織布を開発してまいりました。今後も、当社はアジアでのリーダーの地位をより強固にするべく、お客様からの品質向上のご要請に応えるソリューション・プロバイダーとして、新しい高機能不織布を開発し、人々のQOL
(Quality of Life) の向上に貢献してまいります。




Contacts


<本件に関する問合わせ>
三井化学株式会社
コーポレートコミュニケーション部
河本崇志
TEL:03-6253-2100

Mitsui Chemicals Develops AIRYFA™ The World's First Flexibl… 2017年05月25日 13時32分


Achieving a skin-friendly nonwoven that has materialized softness and
strength by capitalizing on the proprietary spinning technology




TOKYO--(BUSINESS WIRE)--Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: Tsutomu Tannowa)
has successfully developed AIRYFA™, the world’s first flexible nonwoven
with high strength by exploiting its proprietary polyolefin spinning
technology.








AIRYFA™ is a high-performance nonwoven that is gentle on skin,
simultaneously materializing softness and strength. By capitalizing on
the company’s proprietary polyolefin spinning technology and producing
this thin textile with a hollow structure that is characterized by a
superior soft feeling and evenness, Mitsui Chemicals has simultaneously
realized both softness and strength, which the conventional technology
could not achieve.



This is an eco-friendly nonwoven that takes global environmental issues
into consideration since the thin textile with a hollow structure
reduces the amount of plastic used as a raw material. The name AIRYFA™
is intended to represent airy (very light and soft) fabric.



Mitsui Chemicals has developed various high-performance nonwovens, such
as bulky and highly flexible nonwovens, nonwovens with excellent
elasticity, and the new nonwoven AIRYFA™ for sanitary goods, including
disposable diapers. To reinforce its leadership in Asia, Mitsui
Chemicals, as a solution provider capable of meeting customers’ requests
for quality improvement, will continue to contribute to an enhanced
Quality of Life (QOL) while further developing new high-performance
nonwovens.




Contacts


Mitsui Chemicals, Inc.
Takashi Kawamoto, +81-3-6253-2100
Corporate
Communications Division

SAISON INFORMATION SYSTEMS : HULFT Holds the Second Largest… 2017年05月25日 11時00分

TOKYO--(BUSINESS WIRE)--SAISON INFORMATION SYSTEMS CO., LTD. (Headquarters: Toshima-ku, Tokyo;
President: Kazuhiro Uchida; hereafter “SAISON INFORMATION SYSTEMS”) has
today announced that HULFT now holds the second-largest worldwide sales
share (*1) according to All Enterprise Software Market Share (Managed
File Transfer Suites Segment), Worldwide, 2016,
a report of the
survey on the managed file transfer (MFT) (*2) market published by
Gartner Inc. Sold and supplied by SAISON INFORMATION SYSTEMS, HULFT
already holds the largest market share in the domestic market (*3) and
in the Asian market (*4).








Aspiring to consistently provide domestic and overseas customers with
attractive products and services under the HULFT brand, SAISON
INFORMATION SYSTEMS has since its launch in 1993 been working to provide
the software with multilingual support, to offer 24/7/365 customer
support in English, Chinese and Japanese, to cultivate sales channels in
the worldwide market, to establish a partner program and to enhance the
product lineup and functions and cultivate markets.



In addition, SAISON INFORMATION SYSTEMS has set up HULFT business bases
in Shanghai in 2011, Beijing in 2015, Singapore in 2015 to cover the
ASEAN region, and California in 2016 to expand the HULFT business
globally. Today, a total of 189,600 copies are used by 8,700 corporate
customers in 43 countries around the world. (*5)



SAISON INFORMATION SYSTEMS believes that the recent survey results
reflect its efforts to improve its products to better address its
international customers’ problems and be easier to use.



Gartner Inc. reports in this research that the worldwide MFT market grew
at an annual rate of 7.4% in 2016, with sales, or market size, of nearly
873 million dollars, or 94 billion yen. SAISON INFORMATION SYSTEMS will
continue to ensure the safety and reliability of data that flow through
the global IT infrastructure and will provide safety and security for
the evolving network infrastructure in line with the ever-growing MFT
market.



HULFT



(Product details: https://www.hulft.com/en/hulft-mft)
Compatible
with an ever-growing range of platforms since its launch in 1993, HULFT
is file transfer middleware equipped with all the functions customers
need to share files between business systems. There are currently
189,600 (*5) HULFT licenses in use by 8,700 companies in 43
countries worldwide, spanning a wide range of industries. In addition to
sending, receiving and managing file transfer jobs, HULFT also include
peripheral functions essential to transferring files, including security
and data integration before and after transfer.






































 


References and Remarks



*1

 

Source: Gartner Inc.: Market Share: All Software Markets, Worldwide,
2016

*2


MFT: file transfer software with a focus on reliability and security
with functions suited to file transfer between intra-business and
inter-business systems, such as a prohibition on the transfer of any
but designated files and recovery in the event of failure in transfer

*3


Source: Fuji Chimera Research Institute, Inc.: New Market of
Software Business (2015 Edition) (package and value basis)

*4


Source: IDC, Nov 2015, “Worldwide Managed File Transfer Software
Market Shares, 2014: Year of Steady Growth” (#259975)

*5


As of the end of March 2017

 


Gartner Inc. neither recommends any specific vendor, product or service
included in Gartner Research publications nor advises anyone to choose
top-rated vendors or vendors with other ratings only. Gartner Research
publications represent the views of Gartner Research and do not
represent facts. Gartner Inc. does not provide any explicit or implicit
guarantee, including that of merchantability of this research or that of
suitability of this research to any particular purpose.



Trademarks
- HULFT and all HULFT related products are registered
trademarks of SAISON INFORMATION SYSTEMS CO., LTD.
- Names of other
companies, products and services are registered trademarks or trademarks
of the respective companies.



SAISON INFORMATION SYSTEMS CO., LTD.



Headquarters: Sunshine 60 (21F), 3-1-1 Higashi-Ikebukuro, Toshima-ku,
Tokyo 170-6021, Japan
Established: September 1, 1970
President:
Kazuhiro Uchida (President and CEO)
Capital: ¥1,367 million
Business
activities: Financial systems, Retail service systems and IT solutions,
HULFT
Securities code: 9640 (Tokyo Stock Exchange, JASDAQ Standard
Market)
Website: http://home.saison.co.jp/english/






Contacts


HULFT Pte.Ltd.
Yasuko Sakurai / Takayuki Gunji, +65-6248-4625
hulft@saison.co.jp
or
SAISON
INFORMATION SYSTEMS CO., LTD.
Masaaki Takayama, +81-3-3988-5301
info@hulft.com



Open Connectivity Foundation to Showcase Internet of Things… 2017年05月25日 09時00分


IoT consortium to demonstrate interoperability across devices and
industries at Computex Taipei, The Automotive Linux Summit and CES Asia


SHANGHAI & TOKYO--(BUSINESS WIRE)--The Open Connectivity Foundation (OCF), a leading Internet
of Things (IoT) standards body
, is announcing its participation at
three upcoming events throughout Asia. At Computex 2017, Automotive
Linux Summit and CES Asia, OCF will showcase member innovations in the
IoT space, spanning industries including industrial, smart home and
automotive.




Computex
2017:
OCF is headed to Taipei to host a half-day seminar with
III (Institute for Information Industry) on June 1st, and
explore opportunities for promoting the development of a common
framework for Smart Home and IoT innovation.




  • Date: May 30 – June 3, 2017


  • Location: Taipei, Taiwan


  • Meeting Room #3, Taipei World Trade Center, No. 1 Section 5, Xinyi Rd



Automotive
Linux Summit:
Join OCF in Japan to hear Samsung’s IoT
software engineer Phillipe Coval speak on OCF’s open source framework, IoTivity,
and interoperability in the connected car industry, and provide insights
on the keys to designing new vehicle-to-everything (V2X) use cases.




  • Date: May 31 – June 2, 2017


  • Location: Tokyo, Japan


  • Booth #: 3 Chome 11-1 Ariake – Tokyo Conference Center



CES
Asia 2017:
OCF members such as Intel, Haier, VIA, and
Beechwoods will showcase interoperability from OCF’s interactive booth,
with demos of their certified products, capable of communicating
seamlessly through IoTivity.




  • Date: June 7-9, 2017


  • Location: Shanghai, China


  • Booth #: Hall N2 /2204 – Shanghai New International Expo Centre &
    Kerry Hotel



About the Open Connectivity Foundation



Billions of connected devices (phones, computers and sensors) should be
able to communicate with one another regardless of manufacturer,
operating system, chipset or physical transport. The Open Connectivity
Foundation (OCF) is creating a specification and sponsoring an open
source project to make this possible. OCF will unlock the massive
opportunity in the IoT market, accelerate industry innovation and help
developers and companies create solutions that map to a single open
specification. OCF will help ensure secure interoperability for
consumers, business, and industry. The AllSeen Alliance now operates
under the Open Connectivity Foundation. For more information, please
visit www.openconnectivity.org.






Contacts


Open Connectivity Foundation
Richard Brown,
(886)-2-2218-5452 #6201
RIBrown@via.com.tw

Quidel Receives PMDA Approval for Its Point-of-Care Sofia® … 2017年05月25日 07時30分

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced today it has received approval from
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for Quidel’s
Sofia® Influenza A+B Fluorescent Immunoassay (FIA) to be used with the
Sofia® Fluorescent Immunoassay Analyzer.




Sofia is the brand name for Quidel’s instrumented immunoassay system.
The easy-to-use Sofia Analyzer and Sofia Influenza A+B FIA combine
unique software and fluorescent chemistry to yield an automatic,
objective result that is readily available on the instrument’s screen,
in a hard-copy printout, and in a transmissible electronic form that can
network via an LIS system to hospital and medical center databases.



The Sofia FIA employs advanced lateral flow and immunofluorescence
technologies to provide enhanced clinical sensitivity for influenza A
and B. The Sofia Analyzer provides for high-throughput batching methods,
and other features designed to facilitate use in a variety of healthcare
settings, including hospitals, medical centers, small clinics and
doctors’ offices. These features help ensure a reliable, objective,
rapid, and accurate diagnostic result.



It is estimated that there were between 13 million to 16 million
confirmed cases of Influenza in Japan every year between 2010 and 2014.1



We are pleased to have received approval in Japan for our Sofia
Influenza A+B assay, and are excited about the opportunity to expand
Sofia’s international footprint,” said Douglas Bryant, president and
chief executive officer of Quidel Corporation.



The Sofia® Fluorescent Immunoassay Analyzer, Sofia® Group A Strep Assay,
and Sofia® RSV assay are also currently available for sale in Japan.



_____________________________________________________________________________________



1. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146520



About Quidel Corporation



Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct
Detection, Thyretain® and InflammaDry® leading brand names, as well as
under the new Solana®, AmpliVue® and Lyra® molecular
diagnostic brands, Quidel’s products aid in the detection and diagnosis
of many critical diseases and conditions, including, among others, influenza,
respiratory
syncytial virus
, Strep A, herpes, pregnancy, thyroid
disease
and fecal
occult blood
. Quidel’s research and development engine is also
developing a continuum of diagnostic solutions from advanced
lateral-flow and direct fluorescent antibody to molecular diagnostic
tests to further improve the quality of healthcare in physicians’
offices and hospital and reference laboratories. For more information
about Quidel’s comprehensive product portfolio, visit quidel.com.



This press release contains forward-looking statements within the
meaning of the federal securities laws that involve material risks,
assumptions and uncertainties. Many possible events or factors could
affect our future financial results and performance, such that our
actual results and performance may differ materially from those that may
be described or implied in the forward-looking statements. As such, no
forward-looking statement can be guaranteed. Differences in actual
results and performance may arise as a result of a number of factors
including, without limitation, our reliance on development of new
technologies, fluctuations in our operating results resulting from the
timing of the onset, length and severity of cold and flu seasons,
seasonality, government and media attention focused on influenza and the
related potential impact on humans from novel influenza viruses, adverse
changes in competitive conditions in domestic and international markets,
the reimbursement system currently in place and future changes to that
system, changes in economic conditions in our domestic and international
markets, lower than anticipated market penetration of our products, the
quantity of our product in our distributors’ inventory or distribution
channels, changes in the buying patterns of our distributors, and
changes in the healthcare market and consolidation of our customer
base; our development and protection of proprietary technology rights;
our development of new technologies, products and markets; our reliance
on a limited number of key distributors; our reliance on sales of our
influenza diagnostics tests; our ability to manage our growth strategy,
including our ability to integrate companies or technologies we have
acquired or may acquire; intellectual property risks, including but not
limited to, infringement litigation; our inability to settle conversions
of our Convertible Senior Notes in cash; the effect on our operating
results from the trigger of the conditional conversion feature of our
Convertible Senior Notes; our need for additional funds to finance our
capital or operating needs; the financial soundness of our customers and
suppliers; acceptance of our products among physicians and other
healthcare providers; competition with other providers of diagnostic
products; adverse actions or delays in new product reviews or related to
currently-marketed products by the U.S. Food and Drug Administration
(the “FDA”); changes in government policies; compliance with other
government regulations, such as safe working conditions, manufacturing
practices, environmental protection, fire hazard and disposal of
hazardous substances; third-party reimbursement policies; our ability to
meet demand for our products; interruptions in our supply of raw
materials; product defects; business risks not covered by insurance and
exposure to other litigation claims; interruption to our computer
systems; competition for and loss of management and key personnel;
international risks, including but not limited to, compliance with
product registration requirements, exposure to currency exchange
fluctuations and foreign currency exchange risk sharing arrangements,
longer payment cycles, lower selling prices and greater difficulty in
collecting accounts receivable, reduced protection of intellectual
property rights, political and economic instability, taxes, and
diversion of lower priced international products into U.S. markets;
dilution resulting from future sales of our equity; volatility in our
stock price; provisions in our charter documents, Delaware law and the
indenture covering our Convertible Senior Notes that might delay or
impede stockholder actions with respect to business combinations or
similar transactions; and our intention of not paying dividends.
Forward-looking statements typically are identified by the use of terms
such as “may,” “will,” “should,” “might,” “expect,” “anticipate,”
“estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,”
and similar words, although some forward-looking statements are
expressed differently. The risks described in reports and registration
statements that we file with the Securities and Exchange Commission (the
“SEC”) from time to time, should be carefully considered. You are
cautioned not to place undue reliance on these forward-looking
statements, which reflect management’s analysis only as of the date of
this press release. Except as required by law, we undertake no
obligation to publicly release the results of any revision or update of
these forward-looking statements, whether as a result of new
information, future events or otherwise.




Contacts


Quidel Contact:
Quidel Corporation
Randy Steward
Chief
Financial Officer
(858) 552-7931
or
Media and Investors
Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023
rargueta@quidel.com



RMBキャピタルは、株式会社昭文社の報酬委員会設置を歓迎します 2017年05月25日 06時00分

シカゴ--(BUSINESS WIRE)--(ビジネスワイヤ) -- 株式会社昭文社(コード番号9475
東証第一部)は、平成29年5月12日付リリースにおいて、報酬諮問委員会の設置について取締役会にて決議した旨発表しました。RMBキャピタルは、コーポレート・ガバナンスの改善・強化という観点から指名・報酬委員会の設置について昨年の株主総会以降も昭文社経営陣に提案を行い、対話を重ねてまいりました。当社は、昭文社におけるこの度の報酬委員会設置の決定を歓迎するとともに、株主の声に耳を傾け、迅速に行動した経営陣を高く評価しております。当社は、報酬委員会の設置によって昭文社のコーポレートガバナンスが更に改善されるものと確信しています。また、指名委員会の設置についても早期の設置に向け経営陣と対話を継続していく予定です。







Contacts


RMBキャピタル
日本株ポートフォリオ・マネジャー
細水政和
mhosomizu@rmbcap.com

RMB Capital Welcomes Shobunsha’s Decision to Install a Comp… 2017年05月25日 06時00分

CHICAGO--(BUSINESS WIRE)--On May 19, 2017, Shobunsha Publications, Inc. (9475 JP, TSE 1st
section) announced that its board of directors approved a plan to
install a compensation committee, effective in June 2017. RMB Capital
has made proposals to the management of Shobunsha to set up a
compensation committee since the annual general shareholders’ meeting
last year. We welcome the decision by the board of directors to install
the committee, and we highly appreciate the prompt action by the
management of Shobunsha to reflect shareholders’ opinions. We firmly
believe that the standard of the corporate governance at Shobunsha will
be further elevated by the installment of the committee. We will
continue to engage with the firm’s management to encourage them to also
add a nomination committee in the near future.





Contacts


RMB Capital
Masakazu Hosomizu
Japan Portfolio Manager
mhosomizu@rmbcap.com

NetJapan Partners with Distributor Runexy Corp. Expanding A… 2017年05月25日 01時50分

TOKYO--(BUSINESS WIRE)--NetJapan Inc., publisher of backup, disaster recovery, and
virtualization software solutions, has entered into a Distributor
Agreement with Runexy Corporation. Runexy is an established Japanese
corporation with extensive background in distributing some of the most
dependable data protection solutions in the Japanese market.




A backup strategy is vital to protect systems, and critical data for
businesses and home users. A recent large-scale ransomware attack has
been spreading across a number of countries and industries, and is
causing serious damage. A solid backup strategy, such as ActiveImage
Protector, is one of the most effective methods of protection against
ransomware threats.



Background



NetJapan develops, markets and supports the ActiveImage Protector suite
of products in North America, Europe and the Asia-Pacific region and
Japan through contracted resellers and partners.



Runexy has been among the first to introduce prominent, cutting-edge
technologies to the Japanese market; focusing on distribution of
packaged software, and providing exceptional technical support.



This partnership not only benefits both companies but will expand the
availability of high-quality backup and disaster recovery solutions and
services to a wider range of users.



What is ActiveImage Protector?



ActiveImage Protector is a live imaging backup and recovery solution for
Windows and Linux physical and virtual environments. Using sector-based
disk imaging technology, ActiveImage Protector backs up the entire disk
drive which includes the system volume, all applications, user data and
saves the created backup as an image file.



In the event of system failure, users can recover individual files and
folders or restore the entire disk drive. If necessary, recovery of a
hard disk drive or files and folders may be restored to a physical or
virtual machine of dissimilar hardware from the source machine.



In addition to backup and recovery of on-premise servers and
workstations, ActiveImage Protector supports backup and recovery of
Cloud servers.



ActiveImage Protector is now attracting attention as an affordable
backup and disaster recovery solution that safeguards data against a
ransomware threat.



By listening to users, we have improved the technology in an effort to
offer better performance in a quality solution. With improved
performance of the backup engine and increased compression with the
addition of Inline Data Deduplication we have received good positive
feedback.


Contacts


NetJapan Inc.
North America
Carol Cornell
+1 909-332-3773
sales@netjapan.com

BizVibe: Innovation Dominating the Food and Beverage Indust… 2017年05月25日 01時45分

LONDON--(BUSINESS WIRE)--#B2B--Shifting demographics, changing consumer needs, and creative products
are behind some of the biggest trends in food and beverage products
around the world. Details on these trends are some of this week’s top
stories on BizVibe. BizVibe is the world’s
smartest B2B marketplace
 and allows users to discover high
quality leads, contact prospects, and source quotes in real time and can
now connect on-the-go via BizVibe’s
mobile app
.








Innovation is at the forefront of Canada’s food
trends



Recent findings by BrandSpark international, compiled in their annual
Best New Product Awards report, show that Canadians tend to embrace
innovation when it comes to food products. 75%
of Canadians surveyed said that they like trying new products
,
and one in every two Canadian consumers looks for new or innovative
products when shopping.



BrandSpark’s findings also show that food product manufacturers need to
better understand and accommodate price-sensitivity from consumers. 40%
of Canadian consumers reported being financially comfortable, but just
as many say that they are living paycheque to paycheque.



Connect
with over 17,000 food and beverage companies in Canada



Sake trends are abundant in Japan’s food and
beverage industry



New flavours and uses for sake are currently some of the top
food and beverage trends in Japan
. Sake jelly has become
extremely popular, as has one-cup sake. One of the more creative sake
trends involves combining sake with instant ramen.



Soft drinks are also rapidly gaining popularity in Japan, with the
industry currently being valued at USD 32 billion a year. Shifting
population demographics and a growing demand for functional food and
beverages are some of the key drivers behind these trends.



Connect
with nearly 1,000 food and beverage companies in Japan



Access to vegan and vegetarian food products is
increasing



Vegan
and vegetarian food options
are rapidly becoming more accessible
and readily available for consumers, especially those in North America
and Europe. Fast-casual restaurants in these regions are offering a
greater number of vegan and vegetarian options, and the prevalence and
variety of meat substitutes is increasing. According to Global Meat
News, the global meat substitute market grow at a CAGR of 8.4% until
2020, when it will be worth over USD 5 billion.



Additionally, a greater number of mainstream grocery stores are stocking
vegan cheese products, vegan desserts, and other vegan packaged food
products.



Connect
over 220,000 food and beverage companies worldwide



In addition to healthcare and fitness companies, BizVibe is home to a
total of 7
million companies
across a variety of industries. The BizVibe
platform allows you to discover the highest quality leads and make
meaningful connections with your companies of interest in real time. Claim
your company profile
for free and let BizVibe connect you with
potential business partners.



About BizVibe



BizVibe is home to over seven million company profiles across 700+
industries. The single-minded focus of BizVibe’s platform is to make
networking easier. Over the years, we've searched far and wide to figure
out how businesses connect and enable trade. That first interaction is
usually fraught with the uncertainty of finding a potential partner vs.
a potential nightmare. With this in mind, we've designed a robust set of
tools to help companies generate leads, shortlist prospects, network
with businesses from around the world and trade seamlessly.



BizVibe is headquartered in Toronto, and has offices in London,
Bangalore and Beijing. For more information on the BizVibe network,
please contact
us
.




Contacts


BizVibe
Jesse Maida
BizVibe Media & Marketing Executive
media@bizvibe.com

Humavox and Asahi Kasei Microdevices Present New Health Tra… 2017年05月25日 00時19分


Humavox and AKM have teamed up to create a wearable integrated
module with unique new sensing technology that supports wireless
charging and health tracking applications


NEW YORK--(BUSINESS WIRE)--#cuttingthecord--Humavox,
(http://www.humavox.com/)
a leader in the wireless charging space, has partnered with Asahi Kasei
Microdevices (AKM) to create the first module for wearables equipped
with seamless wireless charging capabilities and health tracking
functionality. The new module demo is infused with a Photoplethysmogram
(PPG) chip and includes a BLE transmitter, ultra low power consumption
voltage detector, and Humavox’s wireless charging. The module will be
will be on display in wearable devices at the ICFF
Expo
in New York from May 21 - 24.




Humavox is making wireless charging tangible for widespread use in
wearables and IoT. With new tech hitting the market constantly, the
amount of chargers in our lives continuously grows. Humavox’s wireless
charging technology eliminates this frustration over tangled cords. The Humavox
ETERNA Platform
enables any object, such as a backpack or bowl to be
transformed into a charging station. Just toss your Humavox-enabled
wearable in and charging instantly begins.



AKM, a Japanese company specializing in Radio Frequency (RF) chips,
creates semiconductors found in numerous top tiered OEM products in the
consumer electronics, automotive, and telecommunications market. The new
chip developed by AKM shows that Humavox’s wireless charging technology
can easily be integrated into wearables, and truly revolutionizes the
wearable world by presenting a seamless user experience. The chip comes
equipped with both Humavox’s wireless charging technology and the
ability to track various health features. Instead of buying a wearable
and shopping separately for a wireless charger, users can now get it all
in one. Similarly, wearable manufacturers can use this chip technology
to incorporate wireless charging into fitness tracking wearables.



The result of Humavox’s wireless charging technology coupled with AKM’s
new chip is a health tracking wearable that will also exhibit Humavox’s
“drop and charge” capabilities.



“This is yet another great step in making Humavox technology accessible
to the consumers, I’m proud to collaborate with AKM, one of the best
global semiconductor companies, to develop the first ever chip equipped
with wireless charging and health tracking capabilities.” Says Omri
Lachman, CEO and Co-Founder of Humavox, “I expect more collaborations
like this to come in the future as the efficacy of wireless charging
spreads.”



About Humavox



Humavox is an innovative developer of groundbreaking technology in the
field of wireless
power
. With its ETERNA platform, Humavox uses near-field radio
frequency (RF) technology, and provides users with a simple and
intuitive charging experience (“drop & charge”). The technology can be
implemented in the smallest of devices, such as hearables, wearables and
IoT devices. Humavox was founded in 2010 by Omri Lachman and Asaf
Elssibony, and is based in Israel. For more information, visit http://www.humavox.com.




Contacts


Company Media Contact:
Alona Stein, +972 50-7782344(Cell)
Blonde
2.0 for Humavox
alona@blonde20.com

L&Tテクノロジー・サービシズが、HfSのインダストリー4.0ブルー… 2017年05月24日 22時28分


スマート製造、製造IoT、製造自動化、ビジュアルデータ分析、ロボット工学、デジタルクローン、3D印刷などに関する確固とした能力が評価される




印バンガロール--(BUSINESS WIRE)--(ビジネスワイヤ) --
世界有数のエンジニアリング・サービス専門企業のL&Tテクノロジー・サービシズ・リミテッド(NSE:LTTS)は、サービス・リサーチ企業(The
Services Research
Company™)のHfSリサーチが初めて実施したインダストリー4.0サービス・ブループリント評価で、“ウィナーズ・サークル”に属する企業として位置付けられたと発表しました。HfSリサーチは、ビジネスサービスおよびテクノロジーサービス業界を対象とした世界的な独立系アナリスト企業です。






HfSによると、L&Tテクノロジー・サービシズは製造データ分析、ロボット、製造自動化、デジタル・クローン・シミュレーション、3D印刷、製造IoT、サイバーセキュリティー、製造業AR(拡張現実)、製造業ビジュアル分析などの分野で確固とした能力を備えていると評価されました。



HfSは本報告書のために、12のサービスプロバイダーの使用事例、そして顧客が製造現場で生産性を向上できるように支援する、いくつかのエンドツーエンドのデジタル化プロセス分野を評価しました。L&Tテクノロジー・サービシズはHfSのウィナーズ・サークルに選ばれた唯一のエンジニアリングサービス専門企業です。



LTTSは、スマートな部品や機械からデジタル化・ネットワーク化された工場まで、スマート製造のバリューチェーン全体で顧客と協力してきました。そして現在は、企業が製造プロセスの最適化、サプライチェーンの合理化、在庫およびリソース管理の強化を通じてインダストリー4.0を導入し、競争的優位性を確保できるようにしています。



本報告書のインダストリー4.0ビジョンは、コストと効率の改善、時間の削減、製造の柔軟性など、さまざまな製造関連分野を網羅しています。インダストリー4.0は製造に対してよりスマートなアプローチを採用し、テクノロジーを使って企業全体をデジタル化した製造業務と接続することで、より優れた自律性と柔軟性の実現を目指しています。



HfSの報告書は、LTTSがIoTプラットフォームのUBIQWEISE、仮想シミュレーションツールのVISIT、エネルギー監視ソリューションのWAGES、そして工場向け拡張現実ソリューションのInspectARなど、幅広い独自の技術とプラットフォームを開発したことに注目しています。これらのソリューションは当社の顧客がインダストリー4.0の導入を促進し、その恩恵を実現する上で貢献します。



HfSリサーチのインド担当マネジングディレクターのPareekh
Jain氏は、次のように述べています。「L&Tテクノロジー・サービシズのプラント設計に関する深い理解と、製品や製造をよりスマートにしてきた実績によって、ウィナーズ・サークルにおける地位を確立しました。LTTSはエンジニアリングに関する卓越した伝統と、熟練した労働力により、複雑な工場の問題を解決できます。LTTSは現在、製造業界における複数のサブ垂直市場で顧客と取り組んでおり、同社はその横断的な垂直市場に関する知識を活用して、革新をさらに進めています。」



L&Tテクノロジー・サービシズ・リミテッドの最高経営責任者(CEO)兼マネジングディレクターのケシャブ・パンダ博士は、次のように語っています。「インダストリー4.0は、産業革新と工場革新の新時代を支える基盤となります。ウィナーズ・サークル内に位置付けられたことは、世界中のスマート製造分野のお客さまに利用されている、当社のサービスおよびソリューションが充実していることを実証しています。」



パンダ博士は次のようにつけ加えています。「L&Tテクノロジー・サービシズは今後も、当社のデジタルエンジニアリングソリューションを通じて、未来の工場を作るために一体化する必要がある技術とエンジニアリングのさまざまな分野に取り組んでいきます。」



L&Tテクノロジー・サービシズ・リミテッドについて:



ラーセン&トゥブロの子会社であるL&Tテクノロジー・サービシズ・リミテッドは、エンジニアリングおよび研究開発(ER&D)サービスに重点を置き、フォーチュン500企業を含む世界中の顧客に対応しています。L&Tテクノロジー・サービシズはエンジニアリングサービス専門の一流企業として、多様な工業製品、医療機器、交通、電気通信・ハイテク、プロセス業界の製品およびプロセス開発のライフサイクル全体にわたり、コンサルティング・設計・開発・テストのサービスを提供しています。L&Tテクノロジー・サービシズのデジタルエンジニアリングのポートフォリオは、スマートな製品やサービスの開発に役立ち、スマート製造のためのサービスとソリューションを顧客に提供します。また当社はソフトウエアエンジニアリング、組み込みシステム、機械および製造エンジニアリング、バリュー・エンジニアリング、プラントおよびプロセス・エンジニアリング向けのサービスとソリューションも提供しています。



インドに本社を構えるL&Tテクノロジー・サービシズ・リミテッドは2017年3月31日時点で、従業員を1万1000人以上抱え、インドと海外に12の配送センター、インド、北米、欧州、中東、アジアに27の販売拠点、インドに34の研究所を有しています。L&Tテクノロジー・サービシズの詳しい情報については、www.LntTechservices.comにログオンしてください。



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。


Contacts


L&T Technology Services Limited
Aniruddha Basu, +91-80-67675173
Aniruddha.Basu@LntTechservices.com

ESG Extends its Leadership Position in the Retail Energy Ma… 2017年05月24日 21時48分

NORWELL, Mass. & ATLANTA--(BUSINESS WIRE)--Energy Services Group, LLC (ESG), the retail energy industry’s leading
provider of SaaS solutions to empower energy choice globally, announced
today that it has expanded its North American business through the
acquisition of iSIGMA.




Following the recent acquisition of UK-based Utiligroup which extended
ESG’s global footprint and product capabilities, ESG has further
solidified its leadership position in the billing and Customer
Information System (CIS) space by adding iSIGMA’s innovative solutions.
As the North American retail energy sector continues to mature, offering
an end-to-end business solution that provides the underlying platform
for retail energy providers of all sizes and across geographies is a key
differentiator for ESG.



“ESG is committed to offering best-in-class technology solutions and
services to energy resellers which, in turn, enables them to grow
profitably and better serve their retail, commercial and industrial
customers,” said Phil Galati, ESG’s CEO. “Retailers who use iSIGMA for
billing and CIS can now work with one partner to provide a full suite of
solutions to power their businesses domestically as well as in the UK
and Japan.”



“We have always looked for new ways to add value to our customers,”
added Nag Ramachandran, CEO at iSIGMA. “By joining forces with ESG, our
customers have access to a broader base of solutions and geographic
coverage to help them grow their businesses.”



About Energy Services Group, LLC
Energy Services Group (ESG)
is the retail energy industry’s leading provider of SaaS-based
transaction management (EDI), billing and CIS, wholesale energy
management, and sales and pricing solutions. Offering the industry’s
only end-to-end business process solution, ESG provides comprehensive
and proven support for the unique business process needs of start-up
retail suppliers, established global suppliers of natural gas and
electricity – and to everyone in between.



ESGʼs superior technology and experienced operations staff have helped
clients achieve consistent growth and profitability for more than 18
years. ESG delivers solutions that ensure rapid market entry, reduce
regulatory and operational risks, improve overall business performance,
and deliver superior financial results. ESGʼs 300 plus retail supplier
clients support over 15 million residential, commercial and industrial
customers in production behind over 150 electric and gas utilities in
the US, Canada and Japan. For more information, please visit: http://www.energyservicesgroup.net.



About iSIGMA
For twenty years iSIGMA has provided advanced
SaaS solutions to meet the most demanding challenges that utilities and
energy resellers face in service of their customers. Since 1997, iSIGMA
has been providing a powerful, fully integrated web-based Customer Care
and Billing solution with impressive functionality and flexibility to
Retail Energy Providers, TDSPs, Investor Owned Utilities, Energy
Aggregators, Co-ops and Municipals in the regulated and deregulated
markets. iSIGMA, based in Atlanta, Georgia, continues to provide
innovative flexible solutions to accommodate the most demanding customer
care and billing challenges across all deregulated US markets.




Contacts


Energy Services Group
Lisa Cabral, 617-549-1521
lcabral@energyservicesgroup.net

ドンペが中等度および重度の成人神経栄養性角膜炎患者の治療薬… 2017年05月24日 21時06分



  • 中等度および重度の成人神経栄養性角膜炎患者の治療薬としてデザインされたOxervate®は、欧州委員会の承認を得れば、本適応症で初めて承認されたバイオ医薬品となる。


  • 神経栄養性角膜炎は人口1万人当たり5人未満1が罹患する希少な眼疾患で、本疾患の承認済み医薬品は存在しない。


  • CHMPは迅速審査制度を通じて審査を完了。迅速審査は、有効な治療選択肢が存在しない深刻な疾患を対象に開発される革新的医薬品の一部に対して認められる。


  • Oxervate®は2015年に欧州で神経栄養性角膜炎を治療するための希少疾病用医薬品に指定された。


ミラノ--(BUSINESS WIRE)--(ビジネスワイヤ) --
バイオ医薬品企業のドンペは本日、欧州医薬品庁(EMA)の医薬品評価委員会(CHMP)が、中等度および重度の成人神経栄養性角膜炎患者の治療薬としてOxervate®(cenegermin点眼薬)の市販承認を推奨する肯定的意見を発出したと発表しました。神経栄養性角膜炎は障害をもたらす希少な眼疾患で、視力低下につながる場合があります。現時点ではこの疾患に対する満足のいく治療法は存在しません。CHMPは本病状に伴うリスクと、実現可能な治療選択肢が欠如していることを理由に、迅速審査制度を通じた審査を完了しました。審査は2016年11月に開始し、肯定的意見を採択して先週完了しました。




神経栄養性角膜炎の原因は、三叉神経(眼の解剖学的構造と機能を担う神経の1つ)の障害と関連しており、この障害は角膜知覚の喪失をもたらす場合があります。最重症型では角膜の潰瘍・融解・穿孔の原因となり、患者の視認能力を損ねるおそれがあります2



EMAの希少疾病用医薬品委員会(COMP)が確認して欧州委員会が承認した場合、Oxervate®は本適応症で承認された世界初のバイオ希少疾病用医薬品となります。



有効成分の名称はCenegerminで、ノーベル賞受賞者のリータ・レーヴィ=モンタルチーニが発見したヒト神経成長因子(NGF)の組み換え体です。本タンパク質は、人体が自然に産生するもので、神経細胞の発生・維持・生存に関与しています3。神経栄養性角膜炎患者に点眼薬の形で投与するOxervate®は、眼の正常な治癒プロセスを回復して角膜損傷の修復を助けます。



Oxervate®は組み換えDNA技術を通じて製造されますが、細菌に遺伝子(DNA)を導入し、細菌がヒト神経成長因子を産生できるようにします。



CHMPの結論は、中等度および重度の神経栄養性角膜炎患者204人が参加した2件の第2相臨床試験から得られたデータに基づいています。両試験とも、8週間後に完全な角膜治癒を達成した患者の人数は、Oxervate®治療を受けた患者の方がプラセボ投与を受けた患者よりも多いことを示しました。Oxervate®による治療で最も多く観察された有害反応は、眼痛、眼炎、流涙(涙液分泌)増加、まぶた痛、眼の異物感でした。



ドンペのEugenio Aringhieri最高経営責任者(CEO)は、次のように述べています。「当社は大きな満足をもってCHMPの意見を歓迎します。当社にとって、この希少疾患を持つ患者にOxervate®を提供できるようになることは大きな成果です。当社の研究活動のおかげで手に入る初のバイオ治療薬となります。今回の決定は、この疾患で苦しんでいる人々に対し、非常に有望な治療法への道を開くものです。当社は将来的な目標として、他の病状における潜在力を引き続き検討し、さらに多くの患者がこの革新的な治療法の恩恵を受けられるようにします。」



ドンペのSergio Dompé会長は、次のように説明しています。「この神経成長因子を、発見から有望な治療薬へと初めて導いたことは、『メイド・イン・イタリア』の研究の価値をさらに裏付けるものです。私が今、心に抱いて感謝するのは、情熱をもってOxervate®の開発に当たった研究者のチームです。特にリータ・レーヴィ=モンタルチーニ教授の優れた直感、すなわち教授がノーベル賞を受賞した理由である神経成長因子に端を発して、この研究プロジェクトが始まりました。」



欧州委員会の最終決定が下されるまでの間、Oxervate®は依然として治験薬のままとなります。本薬はいずれの国でも市販承認は取得していません。



ドンペについて



ドンペはイタリアの大手バイオ医薬品企業の一角を占めています。ドンペは社会的影響が大きく、治療選択肢が欠けている疾患のための革新的な治療薬ソリューションの開発に傾注しています。イタリアを拠点とするドンペはミラノに本社を置き、糖尿病、臓器移植、眼科疾患、腫瘍など、未充足の治療ニーズがある分野に研究活動を集中させています。アブルッツォ州ラクイラの工業センターにある世界レベルのバイオテクノロジー工場は、世界の約40カ国の市場を対象にプライマリケア用医薬品の開発に当たっています。ドンペはアルバニア、フランス、ドイツ、英国、スペイン、米国(ニューヨーク)にも営業所を構えています。



詳細情報についてはwww.dompe.comwww.dompetrials.comをご覧ください。



将来見通しに関する記述



本プレスリリースで言及している一定の情報は、予想される将来の業績と一致しない場合があります。ドンペは、本リリースで表明している見解が正当で合理的であると固く信じています。ただし一部の情報は、当社の研究開発活動と、規制当局が実施しなければならない検証との関係で、ある程度の不確実性に左右されます。従って、リリース発表の時点で、ドンペは予想される業績が上述の情報と一致すると保証することはできません。



1 M. Sacchetti, and A. Lambiase, Diagnosis and management of
neurotrophic keratitis. Clin Ophthalmol 8 (2014) 571-9.
2
Idem
3 R. Levi Montalcini, The nerve growth
factor 35 years later
, Science 1987



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。




Contacts


Dompé
Laura Sprea, +39 02 58383567 | +39 3355745188
Corporate
Communications Senior Specialist

laura.sprea@dompe.com



Trend Micro to Host Third Annual Capture the Flag Competiti… 2017年05月24日 21時04分


Capture the Flag aims to grow vital industry knowledge in young
professionals


DALLAS--(BUSINESS WIRE)--Trend
Micro Incorporated
(TYO:
4704
; TSE:
4704
), a global leader in cybersecurity solutions, today announced
it will host Trend Micro CTF 2017 - Raimund Genes Cup, the third annual
Capture the Flag (CTF) cybersecurity competition. Trend Micro CTF
targets young professionals in the cybersecurity industry to enhance
their practical skills in areas such as cybercrimes, targeted attacks,
Internet of Things (IoT) and Industrial Control Systems (ICS).




“Our goal is to support and strengthen the skillset of professionals
entering the industry to better prepare and protect against today’s most
pressing threats,” said Eva Chen, chief executive officer for Trend
Micro. “To accomplish our mission of making the digital world safer for
everyone, we must support engineers in developing and stretching their
cybersecurity knowledge in these specific, relevant areas.”



The competition comprises an online qualifying event and finals held in
Tokyo, Japan. The online qualifier is in a “Jeopardy” format,
challenging players to solve challenges in various categories, such as
SCADA, IoT and targeted attacks. The top ten teams from the online
qualifier will advance to compete in the final, which will be played
with a combination of “attack and defense” and Jeopardy formats. The
final winning team will be awarded JPY 1,000,000 (approximately
US$8,700), Zero Day Initiative Rewards Program1 points, and
automatic qualification for HITCON CTF 2017 Final to be held in Taipei,
Taiwan.



Trend Micro CTF 2017 - Raimund Genes Cup - Online
Qualifier




  • Dates: June 24-25, 2017 (Game starts at 12:00 a.m. ET, June 24, 2017)


  • Requirements: Participants must be at least 20 years old


  • Format: Jeopardy


  • Venue: Online


  • Team registration: May 23-June 25, 2017



Trend Micro CTF 2017 - Raimund Genes Cup - The
Final




  • Dates: November 11-12, 2017 (JST)


  • Requirements: The top ten teams from the online event will qualify and
    receive travel support for attending the finals. Additionally, winners
    from Egypt National CTF will compete. Each team may have a maximum of
    four players.


  • Format: A combination of Attack and Defense and Jeopardy


  • Venue: BELLESALLE Nishi Shinjuku, Tokyo, Japan



Prizes:




  • First Place Team:



    • JPY1,000,000 (approximately US$8,700) per team


    • 15,000 Zero Day Initiative Rewards Program points per player
      (these points result in eligibility for benefits, including a
      one-time bonus of US$2,000)


    • Automatic qualification for HITCON CTF 2017 Final to be held in
      Taipei, Taiwan




  • Second Place Team:



    • JPY300,000 (approximately US$2,600) per team




  • Third Place Team:



    • JPY200,000 (approximately US$1,700) per team





To register for the online qualifier and for more information about
Trend Micro CTF 2017 - Raimund Genes Cup, please visit: www.trendmicro.com/tmctf.



About Trend Micro



Trend Micro Incorporated, a global leader in cybersecurity solutions,
helps to make the world safe for exchanging digital information. Our
innovative solutions for consumers, businesses, and governments provide
layered security for data centers, cloud environments, networks, and
endpoints. All our products work together to seamlessly share threat
intelligence and provide a connected threat defense with centralized
visibility and control, enabling better, faster protection. With more
than 5,000 employees in over 50 countries and the world’s most advanced
global threat intelligence, Trend Micro enables organizations to secure
their journey to the cloud. For more information, visit www.trendmicro.com.



1 For details on Zero Day Initiative Rewards Program, please
see http://zerodayinitiative.com/about/benefits/.


Contacts


Trend Micro Incorporated
Erin Johnson, 972-499-6627
publicrelations@trendmicro.com

MHI Aerospace Systems Corp. Selects AdaCore’s QGen for Mode… 2017年05月24日 21時00分


QGen to be used on safety-critical avionics project


YOKOHAMA, Japan--(BUSINESS WIRE)--#QGen--Automotive Engineering Exposition--AdaCore
today announced that MHI
Aerospace Systems Corporation
(MASC), a member of the Mitsubishi
Heavy Industries Group, has selected the QGen
toolset to develop the software for the Throttle
Quadrant Assembly
(TQA) system. This avionics research project is
being conducted to meet the Level C objectives in the DO-178C safety
standard for airborne software and its DO-331 supplement on Model-Based
Development and Verification. The use of a qualified code generator can
help save significant effort in developing and verifying the software,
and the future availability of qualification material from AdaCore
factored strongly in MASC’s decision to choose QGen. The QGen code
generator can be qualified at the highest Tool Qualification Level,
TQL-1 (equivalent to a development tool in DO-178B).




“The QGen product is specifically targeted to model-based development in
safety-critical control systems,” said Juan-Carlos Bernedo, QGen Product
Manager at AdaCore. “However, model-based development raises some
important questions: how to verify the model’s safety properties, such
as freedom from run-time errors, and how to know that the properties are
preserved in the generated code. QGen and its supporting TQL-1
qualification material help to answer these questions, and we’re pleased
that MASC’s Throttle Quadrant Assembly project will be taking advantage
of these benefits.”



“We chose QGen as our Auto Code Generator because we believe TQL-1
qualification will reduce the effort of our verification activities that
comply with DO-331,” said Hiroyuki Kakamu, General Manager of MASC. “As
part of the TQA project, we discussed DO-331 compliance with AdaCore’s
engineers. Based on these discussions, we developed a Model-Based Design
process that complies with DO-331 based on the use of QGen.”



QGen’s qualifiable and customizable code generator processes a safe
subset of Simulink® and Stateflow® models and
generates optimized source code in the safety-oriented programming
languages SPARK (a formally analyzable Ada subset) and MISRA C. QGen
incorporates static model verification, processor-in-the-loop (PIL)
testing on a real target or through emulation on the host robust, and
powerful model-level debugging support for back-to-back testing between
simulation and target execution.



About the Throttle Quadrant Assembly project



TQA is a product of Tamagawa Seiki Co., Ltd., for light airplanes.
Tamagawa Seiki Co., Ltd., is a Japanese manufacturer that develops a
variety of products for the airplane and automotive markets. In 2014
they and MASC developed the TQA product controlled by software that was
written manually, not using MBD. In 2016 they initiated a research
project to redevelop the TQA using MBD technologies, and they verified
that it had good enough functionality and performance as compared with
the original TQA.



About AdaCore



Founded in 1994, AdaCore supplies software development and verification
tools for mission-critical, safety-critical and security-critical
systems. Four flagship products highlight the company’s offerings:




  • The GNAT
    Pro
    development environment for Ada, a complete toolset for
    designing, implementing, and managing applications that demand high
    reliability and maintainability,


  • The CodePeer
    advanced static analysis tool, an automatic Ada code reviewer and
    validator that can detect and eliminate errors both during development
    and retrospectively on existing software,


  • The SPARK
    Pro
    verification environment, a toolset based on formal
    methods and oriented toward high-assurance systems, and


  • The QGen
    model-based development tool suite for safety-critical control
    systems, providing a qualifiable and customizable code generator, a
    static verifier for Simulink® and Stateflow®
    models, and a model-level debugger.



Over the years customers have used AdaCore products to field and
maintain a wide range of critical applications in domains such as
commercial avionics, automotive, railway, space, military systems, air
traffic management/control, medical devices and financial services.
AdaCore has an extensive and growing worldwide customer base; see www.adacore.com/customers/
for further information.



AdaCore products are open source and come with expert online support
provided by the developers themselves. The company has North American
headquarters in New York and European headquarters in Paris. www.adacore.com



About MHI Aerospace Systems Corporation



Founded in 1986, MHI Aerospace Systems Corp. is a member of the MHI
Group dedicated to custom computer programming services for the
aerospace industry. It is located in Nagoya, Japan. Lately MASC has been
conducting various activities related to DO-178C certification such as
researching the standards, discussing with DERs, consulting to Japan’s
equipment manufacturers, etc. Now MASC is a leading company for DO-178C
technologies in Japan.


Contacts


Press
press-info@adacore.com
http://www.adacore.com
http://twitter.com/AdaCoreCompany
or
AdaCore
EU:
Emma
Adby, +33 1 49 70 87 82
Marketing Operations Manager
or
US:
Jessie
Glockner, +1-646-532-2723
Public Relations Representative

Renesas R-Car Starter Kit Adopted as a Standard Reference P… 2017年05月24日 21時00分


R-Car Starter Kit Supports the Latest Unified Code Base 3.0 64-Bit
Software Environment




SANTA CLARA, Calif.--(BUSINESS WIRE)--#IVI--Renesas Electronics Corporation (TSE:6723), a premier supplier of
advanced semiconductor solutions, today announced that Automotive Grade
Linux (AGL) has adopted the Renesas R-Car Starter Kit as one of its
standard reference platforms for software development. AGL is a
collaborative open source project that is bringing together automakers,
suppliers and technology companies to build a Linux-based, open software
platform for automotive applications that can serve as the de facto
industry standard. Its adoption of the Renesas R-Car Starter Kit makes
it easy for software developers to acquire the hardware environment that
runs software developed by this project and allows them to quickly and
easily develop in-vehicle infotainment (IVI) application software for
next-generation connected cars.








The R-Car Starter Kit supports the Unified Code Base (UCB) 3.0, which
the AGL project released in January 2017. The R-Car Starter Kit enables
the up-to-date 64-bit software development environment, which unlike the
earlier 32-bit environment, allows the latest IT solutions, including
container technology (Note 1), to be applied seamlessly to automotive
applications.



In addition, two IVI development expansion boards from a Renesas partner
(Note 2) that can be used with the R-Car Starter Kit will be available
in July 2017. The standard expansion board includes multiple displays
and a wide range of network interfaces and the advanced model provide
interfaces that can be expanded to up to eight channels of camera input
as well as high-speed/large-capacity storage.



Software developers can easily maintain IVI software development with
the latest software development environment platform that will serve as
the industry standard, and the expansion boards optimized for IVI
development. This platform and board access, along with the support
provided by the free-of charge Renesas libraries and the R-Car ecosystem
that consists of over 190 companies, allows software developers to
quickly develop IVI application software and reduce costs.



Renesas will participate as a gold sponsor, in the Automotive Linux
Summit (ALS) to be held from May 31, 2017 at the Tokyo Conference
Center. In addition to an exhibition of the latest AGL development
environments, Renesas will demonstrate its state-of-the-art connected
car cockpit that connect to cloud IT services.



"Renesas is a passionate and active supporter of open source and
understands the impact that Automotive Grade Linux will have on
development and enabling rapid innovation across the industry,” said Dan
Cauchy, Executive Director of Automotive Grade Linux, The Linux
Foundation. “By adopting the Renesas R-Car Starter Kit as one of our
standard reference platforms, developers will be able to quickly and
easily develop applications using the AGL Unified Code Base.”



"We are pleased that our R-Car Starter Kit has been adopted as one of
the standard reference platforms by the AGL project dedicated to
creating industry-standard advanced open source software," said Masahiro
Suzuki, Vice President, Head of Automotive Information Solution Business
Division, Renesas Electronics Corporation. "Software developers will now
have access to both R-Car Starter Kit hardware and AGL Unified Code
Base, which allows them to put all their efforts into developing even
higher level specialized software. Renesas hopes to contribute to
increasing the pace of innovation of new IVI developments across the
industry.”



(Note 1) Containers are a type of virtualization technology that are
incorporated into systems where they are combined with the execution
environment that the applications require. This technology has received
much attention in recent years from the IT industry since it can
significantly reduce software management costs.



(Note 2) Products of SHIMAFUJI Electric Incorporated



For more information on Renesas, follow Renesas Electronics America at
@RenesasAmerica on Twitter and http://www.facebook.com/RenesasAmerica.



About Renesas Electronics Corporation



Renesas Electronics Corporation (TSE:
6723
) delivers trusted embedded design innovation with complete
semiconductor solutions that enable billions of connected, intelligent
devices to enhance the way people work and live—securely and safely. The
number one global
supplier of microcontrollers, and a leader in Analog & Power and SoC
products, Renesas provides the expertise, quality, and comprehensive
solutions for a broad range of Automotive, Industrial, Home Electronics
(HE), Office Automation (OA) and Information Communication Technology
(ICT) applications to help shape a limitless future. Learn more at renesas.com.



(Remarks) All registered trademarks or trademarks are the property of
their respective owners.


Contacts


Voce Communications, Porter Novelli Company
Clint Gordy,
415-975-2268



Takeda Showcases Broadened Oncology Portfolio Through Data … 2017年05月24日 21時00分


Takeda to Share Data at the American Society of Clinical
Oncology (ASCO) Annual Meeting, the Congress of the European Hematology
Association (EHA) and the International Conference on Malignant Lymphoma
(ICML) –



− Data Underline Takeda’s Mission to Address the Unmet Needs of
Patients Across a Wide Range of Cancers –


CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:
4502
) today announced that the company will feature new clinical
analyses and outcomes research during three upcoming medical meetings:
the 53rd Annual Meeting of the American Society of Clinical Oncology
(ASCO), June 2-6 in Chicago, the 22nd Congress of the European
Hematology Association (EHA), June 22-25 in Madrid, and the
International Conference on Malignant Lymphoma 2017 (ICML), June 14-17
in Lugano, Switzerland. Presentations at this year’s meetings will
highlight Takeda’s ongoing commitment to patients with hematologic
cancers, while demonstrating a broadened portfolio with the recent
addition of new targeted therapies and pipeline assets in solid tumors.




“Takeda Oncology’s presence at these upcoming medical meetings
demonstrates our relentless pursuit to deliver innovations for patients
with cancer,” said Christophe Bianchi, M.D., President, Takeda Oncology.
“The data we are presenting highlight the depth and breadth of our
recently expanded portfolio, now including both hematological
malignancies and solid tumors with the recent approval of ALUNBRIG™
(brigatinib) for metastatic non-small cell lung cancer, and brings us
one step closer to our aspiration to cure cancer.”



At ASCO, Takeda will present patient-reported outcomes and quality of
life findings from the pivotal Phase 2 ALTA (ALK in Lung
Cancer Trial of AP26113) trial of ALUNBRIG™,
which recently received Accelerated Approval from the U.S. Food and Drug
Administration for the treatment of patients with anaplastic lymphoma
kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who
have progressed on or are intolerant to crizotinib. Approximately two to
eight percent of patients with metastatic NSCLC have a rearrangement in
the ALK gene. Results from an analysis of the drug’s activity in
crizotinib-resistant ALK+ NSCLC patients according to ALK plasma
mutation status will also be featured.



Both ASCO and EHA will feature findings from studies of Takeda medicines
for the treatment of a variety of blood cancers, including lymphoma,
multiple myeloma and chronic myeloid leukemia. Data from the Phase 3
ALCANZA study of ADCETRIS (brentuximab vedotin) in CD30-positive
cutaneous T-cell lymphoma will be presented at both ASCO and EHA.
Several Phase 1 and 2 studies investigating NINLARO (ixazomib) in
patients with newly diagnosed multiple myeloma will be presented at EHA,
including two oral presentations which evaluated ixazomib plus
lenalidomide and dexamethasone followed by maintenance with single-agent
ixazomib. In addition, ASCO and EHA will highlight five-year data from
the Phase 2 PACE trial of ICLUSIG® (ponatinib) in heavily
pretreated chronic phase chronic myeloid leukemia.



Among the nine Takeda-sponsored abstracts accepted for presentation
during ASCO 2017 and 15 abstracts at EHA 2017, selected highlights
include:



ASCO Annual Meeting 2017



ADCETRIS (brentuximab vedotin):




ALUNBRIG (brigatinib):




ICLUSIG (ponatinib):




EHA 22nd Congress



ADCETRIS (brentuximab vedotin):




NINLARO (ixazomib):




ICLUSIG (ponatinib):




For more information, please see ASCO (https://am.asco.org/program)
and EHA (http://www.eha-2017.org/)
online programs. Abstracts for ICML will be released on June 7.



About ADCETRIS® (brentuximab vedotin)



ADCETRIS is being evaluated broadly in more than 70 ongoing clinical
trials, including three Phase 3 studies, the ongoing ECHELON-1 trial in
frontline classical Hodgkin lymphoma and the ongoing ECHELON-2 trial in
frontline mature T-cell lymphomas, as well as the completed ALCANZA
trial in cutaneous T-cell lymphoma for which a supplemental BLA is
planned in mid-2017.



ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached
by a protease-cleavable linker to a microtubule disrupting agent,
monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary
technology. The ADC employs a linker system that is designed to be
stable in the bloodstream but to release MMAE upon internalization into
CD30-positive tumor cells.



ADCETRIS for intravenous injection has received approval from the FDA
for three indications: (1) regular approval for the treatment of
patients with classical Hodgkin lymphoma after failure of autologous
hematopoietic stem cell transplantation (auto-HSCT) or after failure of
at least two prior multi-agent chemotherapy regimens in patients who are
not auto-HSCT candidates, (2) regular approval for the treatment of
classical Hodgkin lymphoma patients at high risk of relapse or
progression as post-auto-HSCT consolidation, and (3) accelerated
approval for the treatment of patients with systemic anaplastic large
cell lymphoma (sALCL) after failure of at least one prior multi-agent
chemotherapy regimen. The sALCL indication is approved under accelerated
approval based on overall response rate. Continued approval for the
sALCL indication may be contingent upon verification and description of
clinical benefit in confirmatory trials. Health Canada granted ADCETRIS
approval with conditions for relapsed or refractory Hodgkin lymphoma and
sALCL.



ADCETRIS was granted conditional marketing authorization by the European
Commission in October 2012 for two indications: (1) for the treatment of
adult patients with relapsed or refractory CD30-positive Hodgkin
lymphoma following autologous stem cell transplant (ASCT), or following
at least two prior therapies when ASCT or multi-agent chemotherapy is
not a treatment option, and (2) the treatment of adult patients with
relapsed or refractory sALCL. The European Commission extended the
current conditional marketing authorization of ADCETRIS and approved
ADCETRIS for the treatment of adult patients with CD30-positive Hodgkin
lymphoma at increased risk of relapse or progression following ASCT.



ADCETRIS has received marketing authorization by regulatory authorities
in 66 countries for relapsed or refractory Hodgkin lymphoma and sALCL.
See important safety information below.



Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the
terms of the collaboration agreement, Seattle Genetics has U.S. and
Canadian commercialization rights and Takeda has rights to commercialize
ADCETRIS in the rest of the world. Seattle Genetics and Takeda are
funding joint development costs for ADCETRIS on a 50:50 basis, except in
Japan where Takeda is solely responsible for development costs.



ADCETRIS (brentuximab vedotin) Global Important Safety Information



CONTRAINDICATIONS



ADCETRIS is contraindicated for patients with hypersensitivity to
brentuximab vedotin and its excipients. In addition, combined use of
ADCETRIS with bleomycin is contraindicated as it causes pulmonary
toxicity.



SPECIAL WARNINGS & PRECAUTIONS



Progressive multifocal leukoencephalopathy (PML): John Cunningham
virus (JCV) reactivation resulting in PML and death can occur in
patients treated with ADCETRIS. PML has been reported in patients who
received ADCETRIS after receiving multiple prior chemotherapy regimens.



Patients should be closely monitored for new or worsening neurological,
cognitive, or behavioral signs or symptoms, which may be suggestive of
PML. Suggested evaluation of PML includes neurology consultation,
gadolinium-enhanced magnetic resonance imaging of the brain, and
cerebrospinal fluid analysis for JCV DNA by polymerase chain reaction or
a brain biopsy with evidence of JCV. ADCETRIS dosing should be held for
any suspected case of PML and should be permanently discontinued if a
diagnosis of PML is confirmed.



Pancreatitis: Acute pancreatitis has been observed in patients
treated with ADCETRIS. Fatal outcomes have been reported. Patients
should be closely monitored for new or worsening abdominal pain, which
may be suggestive of acute pancreatitis. Patient evaluation may include
physical examination, laboratory evaluation for serum amylase and serum
lipase, and abdominal imaging, such as ultrasound and other appropriate
diagnostic measures. ADCETRIS should be held for any suspected case of
acute pancreatitis. ADCETRIS should be discontinued if a diagnosis of
acute pancreatitis is confirmed.



Pulmonary Toxicity: Cases of pulmonary toxicity, some with fatal
outcomes, have been reported in patients receiving ADCETRIS. Although a
causal association with ADCETRIS has not been established, the risk of
pulmonary toxicity cannot be ruled out. New or worsening pulmonary
symptoms should be promptly evaluated and treated appropriately.



Serious infections and opportunistic infections: Serious
infections such as pneumonia, staphylococcal bacteremia, sepsis/septic
shock (including fatal outcomes), and herpes zoster, and opportunistic
infections such as Pneumocystis jiroveci pneumonia and oral
candidiasis have been reported in patients treated with ADCETRIS.
Patients should be carefully monitored during treatment for emergence of
possible serious and opportunistic infections.



Infusion-related reactions (IRR): Immediate and delayed IRR, as
well as anaphylaxis, have occurred with ADCETRIS. Patients should be
carefully monitored during and after an infusion. If anaphylaxis occurs,
administration of ADCETRIS should be immediately and permanently
discontinued and appropriate medical therapy should be administered. If
an IRR occurs, the infusion should be interrupted and appropriate
medical management instituted. The infusion may be restarted at a slower
rate after symptom resolution. Patients who have experienced a prior IRR
should be premedicated for subsequent infusions. IRRs are more frequent
and more severe in patients with antibodies to ADCETRIS.



Tumor lysis syndrome (TLS): TLS has been reported with ADCETRIS.
Patients with rapidly proliferating tumor and high tumor burden are at
risk of TLS. These patients should be monitored closely and managed
according to best medical practice.



Peripheral neuropathy (PN): ADCETRIS treatment may cause PN, both
sensory and motor. ADCETRIS-induced PN is typically cumulative and
reversible in most cases. Patients should be monitored for symptoms of
PN, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a
burning sensation, neuropathic pain, or weakness. Patients experiencing
new or worsening PN may require a delay and a dose reduction or
discontinuation of ADCETRIS.



Hematological toxicities: Grade 3 or Grade 4 anemia,
thrombocytopenia, and prolonged (equal to or greater than one week)
Grade 3 or Grade 4 neutropenia can occur with ADCETRIS. Complete blood
counts should be monitored prior to administration of each dose.



Febrile neutropenia: Febrile neutropenia has been reported.
Patients should be monitored closely for fever and managed according to
best medical practice if febrile neutropenia develops.



Stevens-Johnson syndrome (SJS): SJS and toxic epidermal
necrolysis (TEN) have been reported with ADCETRIS. Fatal outcomes have
been reported. If SJS or TEN occurs, treatment with ADCETRIS should be
discontinued and appropriate medical therapy should be administered.



Gastrointestinal (GI) Complications: GI complications, some with
fatal outcomes, including intestinal obstruction, ileus, enterocolitis,
neutropenic colitis, erosion, ulcer, perforation and haemorragh, have
been reported. New or worsening GI symptoms should be promptly evaluated
and treated appropriately.



Hepatotoxicity: Elevations in alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) have been reported. Serious cases of
hepatotoxicity, including fatal outcomes, have also occurred. Liver
function should be tested prior to treatment initiation and routinely
monitored in patients receiving ADCETRIS. Patients experiencing
hepatotoxicity may require a delay, dose modification, or
discontinuation of ADCETRIS.



Hyperglycemia: Hyperglycemia has been reported during trials in
patients with an elevated body mass index (BMI) with or without a
history of diabetes mellitus. However, any patient who experiences an
event of hyperglycemia should have their serum glucose closely
monitored. Anti-diabetic treatment should be administered as appropriate.



Renal and Hepatic Impairment: There is limited experience in
patients with renal and hepatic impairment. Available data indicate that
MMAE clearance might be affected by severe renal impairment, hepatic
impairment, and by low serum albumin concentrations. The recommended
starting dose in patients with hepatic impairment or severe renal
impairment is 1.2 mg/kg administered as an intravenous infusion over 30
minutes every 3 weeks. Patients with renal or hepatic impairment should
be closely monitored for adverse events.



Sodium content in excipients: This medicinal product contains a
maximum of 2.1 mmol (or 47 mg) of sodium per dose. To be taken into
consideration for patients on a controlled sodium diet.



INTERACTIONS
Patients who are receiving a strong CYP3A4 and
P-gp inhibitor, concomitantly with ADCETRIS may have an increased risk
of neutropenia and should be closely monitored. Co-administration of
ADCETRIS with a CYP3A4 inducer did not alter the plasma exposure of
ADCETRIS but it appeared to reduce plasma concentrations of MMAE
metabolites that could be assayed. ADCETRIS is not expected to alter the
exposure to drugs that are metabolized by CYP3A4 enzymes.



PREGNANCY: Women of childbearing potential should be using two
methods of effective contraception during treatment with ADCETRIS and
until 6 months after treatment. There are no data from the use of
ADCETRIS in pregnant women, although studies in animals have shown
reproductive toxicity. ADCETRIS should not be used during pregnancy
unless the benefit to the mother outweighs the potential risks to the
fetus. If a pregnant woman needs to be treated, she should be clearly
advised on the potential risk to the fetus.



LACTATION (breast-feeding): There are no data as to whether
ADCETRIS or its metabolites are excreted in human milk, therefore a risk
to the newborn/infant cannot be excluded. With the potential risk, a
decision should be made whether to discontinue breast-feeding or
discontinue/abstain from therapy with ADCETRIS.



FERTILITY: In nonclinical studies, ADCETRIS treatment has
resulted in testicular toxicity, and may alter male fertility. Men being
treated with this medicine are advised not to father a child during
treatment and for up to 6 months following the last dose.



ADVERSE REACTIONS
Serious adverse drug reactions were:
pneumonia, acute respiratory distress syndrome, headache, neutropenia,
thrombocytopenia, constipation, diarrhea, vomiting, nausea, pyrexia,
peripheral motor neuropathy, peripheral sensory neuropathy,
hyperglycemia, demyelinating polyneuropathy, tumor lysis syndrome, and
Stevens-Johnson syndrome.



In the clinical studies of ADCETRIS, adverse reactions defined as very
common (≥1/10) were: infection, upper respiratory tract infection,
neutropenia, PN (sensory and motor), cough, dyspneoa, diarrhea, nausea,
vomiting, constipation, abdominal pain, alopecia, pruritus, myalgia,
arthralgia, fatigue, chills, pyrexia, infusion-related reactions and
weight decreased. Adverse reactions defined as common (≥1/100 to <1/10)
were: Sepsis/septic shock, herpes zoster, pneumonia, herpes simplex,
anemia, thrombocytopenia, hyperglycemia, dizziness, demyelinating
polyneuropathy, ALT/AST increased, rash, and back pain.



About NINLAROTM (ixazomib) capsules



NINLAROTM (ixazomib) is an oral proteasome
inhibitor which is also being studied across the continuum of multiple
myeloma treatment settings as well as systemic light-chain (AL)
amyloidosis. It was the first oral proteasome inhibitor to enter Phase 3
clinical trials and to receive approval. NINLARO was approved by the
U.S. Food and Drug Administration (FDA) in November 2015 following a
priority review. In the U.S., NINLARO is indicated in combination with
lenalidomide and dexamethasone for the treatment of patients with
multiple myeloma who have received at least one prior therapy.



Ixazomib was granted orphan drug designation in multiple myeloma in both
the U.S. and Europe in 2011 and for AL amyloidosis in both the U.S. and
Europe in 2012. Ixazomib received Breakthrough Therapy status by the
U.S. FDA for relapsed or refractory systemic light-chain (AL)
amyloidosis in 2014.



The comprehensive ixazomib clinical development program, TOURMALINE,
further reinforces Takeda's ongoing commitment to developing innovative
therapies for people living with multiple myeloma worldwide and the
healthcare professionals who treat them. TOURMALINE includes a total of
five ongoing pivotal trials – four, which together are investigating
every major multiple myeloma patient population, and one in light-chain
amyloidosis:




  • TOURMALINE-MM1, investigating ixazomib vs. placebo, in combination
    with lenalidomide and dexamethasone in relapsed and/or refractory
    multiple myeloma


  • TOURMALINE-MM2, investigating ixazomib vs. placebo, in combination
    with lenalidomide and dexamethasone in patients with newly diagnosed
    multiple myeloma


  • TOURMALINE-MM3, investigating ixazomib vs. placebo as maintenance
    therapy in patients with newly diagnosed multiple myeloma following
    induction therapy and autologous stem cell transplant (ASCT)


  • TOURMALINE-MM4, investigating ixazomib vs. placebo as maintenance
    therapy in patients with newly diagnosed multiple myeloma who have not
    undergone ASCT; this study is currently enrolling


  • TOURMALINE-AL1, investigating ixazomib plus dexamethasone vs.
    physician choice of selected regimens in patients with relapsed or
    refractory AL amyloidosis; this study is currently enrolling



In addition to the TOURMALINE program, ixazomib is being evaluated in
multiple therapeutic combinations for various patient populations in
investigator initiated studies globally.



NINLAROTM (ixazomib): Global Important Safety
Information



SPECIAL WARNINGS AND PRECAUTIONS



Thrombocytopenia has been reported with NINLARO (28% vs. 14% in
the NINLARO and placebo regimens, respectively) with platelet nadirs
typically occurring between Days 14-21 of each 28-day cycle and recovery
to baseline by the start of the next cycle. It did not result in an
increase in hemorrhagic events or platelet transfusions. Monitor
platelet counts at least monthly during treatment with NINLARO and
consider more frequent monitoring during the first three cycles. Manage
with dose modifications and platelet transfusions as per standard
medical guidelines.



Gastrointestinal toxicities have been reported in the NINLARO and
placebo regimens respectively, such as diarrhea (42% vs. 36%),
constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs.
11%), occasionally requiring use of antiemetic and anti-diarrheal
medications, and supportive care.



Peripheral neuropathy was reported with NINLARO (28% vs. 21%
in the NINLARO and placebo regimens, respectively). The most commonly
reported reaction was peripheral sensory neuropathy (19% and 14% in the
NINLARO and placebo regimens, respectively). Peripheral motor neuropathy
was not commonly reported in either regimen (< 1%). Monitor patients for
symptoms of peripheral neuropathy and adjust dosing as needed.



Peripheral edema was reported with NINLARO (25% vs. 18% in
the NINLARO and placebo regimens, respectively). Evaluate patients for
underlying causes and provide supportive care, as necessary. Adjust the
dose of dexamethasone per its prescribing information or the dose of
NINLARO for severe symptoms.



Cutaneous reactions occurred in 19% of patients in the NINLARO
regimen compared to 11% of patients in the placebo regimen. The most
common type of rash reported in both regimens was maculo-papular and
macular rash. Manage rash with supportive care, dose modification or
discontinuation.



Hepatotoxicity, drug-induced liver injury, hepatocellular
injury, hepatic steatosis, and hepatitis cholestatic have been
uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and
adjust dose for Grade 3 or 4 symptoms.



Pregnancy- NINLARO can cause fetal harm. Advise male and females
patients of reproductive potential to use contraceptive measures during
treatment and for an additional 90 days after the final dose of NINLARO.
Women of childbearing potential should avoid becoming pregnant while
taking NINLARO due to potential hazard to the fetus. Women using
hormonal contraceptives should use an additional barrier method of
contraception.



Lactation- It is not known whether NINLARO or its metabolites are
excreted in human milk. There could be potential adverse events in
nursing infants and therefore breastfeeding should be discontinued.



SPECIAL PATIENT POPULATIONS
Hepatic Impairment: Reduce
the NINLARO starting dose to 3 mg in patients with moderate
or severe hepatic impairment.
Renal Impairment: Reduce the
NINLARO starting dose to 3 mg in patients with severe renal impairment
or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not
dialyzable and, therefore, can be administered without regard to the
timing of dialysis.



DRUG INTERACTIONS
Co-administration of strong CYP3A inducers
with NINLARO is not recommended.



ADVERSE


Contacts


Takeda Pharmaceutical Company Limited
Japanese Media
Tsuyoshi
Tada, +81 (0) 3-3278-2417
tsuyoshi.tada@takeda.com
or
European
Media

Kate Burd, +44 7974 151510
kate.burd@takeda.com
or
Media
outside Japan/EU

Amy Atwood, +1-617-551-3683
amy.atwood@takeda.com
or
Liza
Heapes, +1-617-621-2315
liza.heapes@ariad.com
or
Sara
Noonan, +1-617-551-3683
sara.noonan@takeda.com





Read full story here

GORE® EXCLUDER® Iliac Branch Endoprosthesis Approved in Jap… 2017年05月24日 20時00分


Gore designed All-in-One System to preserve iliac artery blood flow
in patients with iliac or aortoiliac aneurysms




FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W.
L. Gore & Associates, Inc. (Gore)
announced the first implants
in Japan of the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE). Gore
has received Shonin approval from the Japanese Ministry of Health,
Labour and Welfare to market the IBE and is currently in discussion
regarding reimbursement for this region. The IBE is the first
off-the-shelf iliac branch solution approved in Japan and the only
device indicated for the endovascular treatment of common iliac artery
aneursyms or aortoiliac aneursyms.







With more than 2,500 commercial implants worldwide, the device is a
complete, fully engineered system (Gore designed iliac branch and
internal iliac components), which received CE Mark in 2013, registration
in Australia and New Zealand in 2015, and FDA and Health Canada approval
in 2016.



Used in conjunction with the GORE® EXCLUDER® AAA Endoprosthesis, the IBE
preserves blood flow in the external and internal iliac arteries. The
IBE leverages the design and experience acquired from more than 20 years
and 285,000 patients treated* with the GORE EXCLUDER AAA Endoprosthesis
and utilizes the same durable, expanded polytetrafluoroethylene (ePTFE)
graft and nitinol stent material. The IBE offers an All-in-One System
with improved outcomes for the treatment of iliac artery aneurysms while
preserving flow to the iliac arteries. Preservation of blood flow in the
internal iliac arteries is found to avoid pelvic flow disruption and
reduce the rate of complications that can include buttock claudication,
sexual dysfunction, and colonic ischemia.



“Providing a simple and straightforward procedure, the IBE preserves
flow to the internal iliac arteries during EVAR,” said Takao Ohki, MD,
PhD, Chairman and Professor of the Department of Surgery at Jikei
University School of Medicine in Tokyo, who successfully performed the
first two implants in Japan. “In many patients, it is imperative that
iliac artery blood flow be maintained when possible to avoid
complications that can result when these arteries are sacrificed. The
IBE will not only reduce complications but also expand the indication
for less invasive endovascular treatment for patients that were rejected
due to the inability to preserve internal iliac arteries. This is
excellent news for Japanese patients.”



The IBE system provides a treatment range of 6.5-13.5 mm for the
internal iliac arteries, and a treatment range of 6.5-25 mm for the
external iliac arteries. The delivery profile of the loaded catheter
allows the use of a 16 Fr introducer sheath for the iliac branch
component, and a flexible 12 Fr, reinforced introducer sheath for the
internal iliac component.



“We are pleased to receive approval of this device in regions worldwide
as it continues to provide an iliac branch solution for a patient group
with a previously unmet treatment need,” said Eric Zacharias, Vascular
Business Leader. “Together with physicians, we have spent the past 20
years determining patient needs and continually working to improve our
aortic family of devices to provide solutions physicians trust and
patients count on. The IBE is an exciting innovation that stems from our
mission to effectively treat aortic aneurysms through minimally invasive
means.”



* Based on the number of Trunk-Ipsilateral Leg components distributed.



ABOUT GORE MEDICAL PRODUCTS



Gore Medical Products Division engineers devices that treat a range of
cardiovascular and other health conditions. With more than 40 million
medical devices implanted over the course of more than 40 years, Gore
builds on its legacy of improving patient outcomes through research,
education and quality initiatives. Product performance, ease of use and
quality of service provide sustainable cost savings for physicians,
hospitals and insurers. Gore is joined in service with clinicians and
through this collaboration we are improving lives. www.goremedical.com



ABOUT GORE



W. L. Gore & Associates is a global materials science company dedicated
to transforming industries and improving lives. Founded in 1958, Gore
has built a reputation for solving complex technical challenges in the
most demanding environments — from revolutionizing the outerwear
industry with GORE-TEX® fabric to creating medical devices that improve
and save lives to enabling new levels of performance in the aerospace,
pharmaceutical and mobile electronics markets, among other industries.
The company is also known for its strong, team-oriented culture and
continued recognition from the Great Place to Work® Institute.
Headquartered in Newark, Del., Gore employs approximately 10,000
Associates and generates annual revenues that exceed $3 billion. www.gore.com



Products listed may not be available in all markets. GORE®,
EXCLUDER®, and designs are trademarks of W. L. Gore & Associates.
AWO584-EN1
MAY 2017




Contacts


Bliss Integrated Communication for Gore Medical
Claire LaCagnina,
212-840-8079
Claire@blissintegrated.com
or
Liz
DeForest, 212-584-5477
Liz@blissintegrated.com

The Bank of Tokyo-Mitsubishi UFJ, Ltd. Announces Changes of… 2017年05月24日 18時51分

TOKYO--(BUSINESS WIRE)--The Bank of Tokyo-Mitsubishi UFJ, Ltd. hereby announces the following
changes of representative directors.































 


1. Changes effective June 14, 2017



Name

 

New Position

 

 Current Position

Takashi Oyamada

 

Director

 

President & CEO


(Representative Director)



Kanetsugu Mike


President & CEO


(Representative Director)




Deputy President



Contacts


The Bank of Tokyo-Mitsubishi UFJ, Ltd.
Jun Kobayashi,
+81-3-3240-1111
Chief Manager
Corporate Administration Division



Jury Verdict of $256,450,000.00 against Nissan Motor Accept… 2017年05月24日 17時50分

LOS ANGELES--(BUSINESS WIRE)--#amnonsiegel--On May 22, 2017, in Nissan Motor Acceptance
Corporation v. Superior Auto of Fremont, LLC, et al.
, Orange
County Superior Court Case No. 30-2009-00305125-CU-BC-CJC, a jury
awarded $256,450,000 against Nissan Motor Acceptance Corporation (NMAC).
NMAC is the financing arm and a subsidiary of Nissan Motor Limited, the
worldwide manufacturer of the Nissan automobile brand. The jury awarded
$121,900,000 in compensatory damages; and the jury determined Nissan’s
conduct to be so reprehensible that they found by clear and convincing
evidence that Nissan acted with fraud, malice or oppression and awarded
$134,550,000 in punitive damages.







The plaintiffs are the Superior Automotive Group, a group of Nissan and
Toyota dealerships owned by auto dealer Michael Kahn. Superior was
financed by NMAC and, in 2009, was put out of business by NMAC during
the recession. The plaintiffs prevailed on claims for fraud by
concealment and negligent misrepresentation. Amnon Siegel, lead trial
lawyer for Superior and Mr. Kahn, said: “I want to thank the jury for
their hard work and diligence. After eight years, this was a hard-fought
and well-deserved victory and vindication for Michael Kahn. I’m happy
for Mr. Kahn and his family.”



The case was originally filed in 2009, tried to a jury before a
different Judge in 2011 at which time NMAC obtained a $40 million
judgment on its contract claim, then the fraud claims were reversed on
appeal in 2014 and remanded for retrial. A copy of the California Court
of Appeal opinion reversing and remanding the case for retrial is
attached.



Superior Auto Group and Mr. Kahn are represented by Miller Barondess,
LLP located in Los Angeles, California; their trial lawyer is partner
Amnon Siegel assisted by associate Adithya Mani. Per Skip Miller, the
firm’s managing partner, “I’m pleased by this result and very proud of
Amnon for his hard work in bringing in this verdict; and most of all,
I’m happy for Mike Kahn. He finally obtained justice for what was done
to him, his business and his family. Mike is a great guy, and a great
car dealer, and he deserves this so he can get his life back.”




Contacts


Miller Barondess, LLP
Skip Miller, 310-552-5251
smiller@millerbarondess.com

Japan Persimmons Market Report 2017 - Analysis and Forecast… 2017年05月24日 17時05分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan:
Persimmons - Market Report - Analysis And Forecast To 2025"

report to their offering.




The report provides an in-depth analysis of the Persimmons market in
Japan. It presents the latest data of the Market value, consumption,
domestic production, exports and imports, price dynamics and food
balance. The report shows the sales data, allowing you to identify the
key drivers and restraints. You can find here a strategic analysis of
key factors influencing the market. Forecasts illustrate how the market
will be transformed in the medium term.



Key Topics Covered:



1. Introduction



1.1 Report Description



1.2 Research Methodology



2. Executive Summary



2.1 Key Findings



2.2 Market Trends



3. Market Overview



3.1 Market Value



3.2 Per Capita Consumption



3.3 Market Forecast To 2025



4. Production



4.1 Production In 2007-2015



4.2 Harvested Area In 2007-2013



4.3 Yield In 2007-2013



5. Imports



5.1 Imports In 2007-2015



5.2 Imports By Countries



5.3 Import Prices By Countries



6. Exports



6.1 Exports In 2007-2015



6.2 Exports By Countries



6.3 Export Prices By Countries



7. Prices And Price Development



7.1 Producer Prices



7.2 Producer Prices Index



For more information about this report visit http://www.researchandmarkets.com/research/fsw63m/japan_persimmons




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Fruit
and Vegetables

Mitsubishi Electric Corporation Unveils New Technologies at… 2017年05月24日 12時35分

TOKYO--(BUSINESS WIRE)--Mitsubishi
Electric Corporation
(TOKYO:6503) announced new technologies,
outlined below, at its annual Research and Development Open House held
today at Tokyo International Forum in Tokyo, Japan.




No. 3109
Mitsubishi Electric
Consolidates AI Technology under “Maisart” Brand

Making
devices smarter and life more secure, intuitive and convenient



The company announced today its new “Maisart” brand encompassing the
company’s proprietary artificial intelligence (AI) technology, including
its compact AI, automated design deep-learning algorithm and
extra-efficient smart-learning AI.



Full release text: http://www.MitsubishiElectric.com/news/2017/0524-b.html



No. 3110
Mitsubishi Electric
Develops Solution to Visualize Radio Waves to Support IoT System

Enables
optimal placement of wireless equipment to be designed fast and
inexpensively



The company has developed a radio wave visualization solution for
ascertaining, with high speed and high precision, the intensity of radio
waves when designing the optimal placement of wireless communication
equipment.



Full release text: http://www.MitsubishiElectric.com/news/2017/0524-c.html



No. 3111
Mitsubishi Electric
Develops Smart-learning Algorithm for Extra-efficient AI

Dramatically
reduces number of trials required for precise machine-learned AI control



The company announced today that it has developed a proprietary
deep-reinforcement algorithm for artificial-intelligence (AI) machine
control that requires just one-fiftieth the number of trials compared to
conventional AI control methods.



Full release text: http://www.MitsubishiElectric.com/news/2017/0524-d.html



No. 3112
Mitsubishi Electric
Separates Simultaneous Speech of Multiple Unknown Speakers Recorded with
One Microphone

Speech-separation technology achieved with
proprietary “Deep Clustering” AI method



The company announced today that it has created the world’s first
technology that separates, and then reconstructs with high quality, the
simultaneous speech of multiple unknown speakers recorded with a single
microphone in real time.



Full release text: http://www.MitsubishiElectric.com/news/2017/0524-e.html



No. 3113
Mitsubishi Electric
Uses Illumination for Building Guidance Systems

Illuminated
projections are expected to streamline in-building traffic



The company announced today an innovative in-building guidance system
that uses illuminated projections to provide building visitors with
directions and detailed elevator-status information.



Full release text: http://www.MitsubishiElectric.com/news/2017/0524-f.html



No. 3114
Mitsubishi Electric
Develops Unique Technology for Electromagnetic-field and Large-coupled
Analysis of Turbine Generators



The company announced today the development of what it believes is the
world’s-first technology for determining the operational status of power
generators using electromagnetic-field analysis of up to an
unprecedented 30 million meshes and coupled-numerical analysis.



Full release text: http://www.MitsubishiElectric.com/news/2017/0524-g.html




Contacts


Media Inquiries
Mitsubishi Electric Corporation
Takeyoshi
Komatsu, +81-3-3218-2346
Public Relations Division
prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/news/



ミツバチワークスがライムライトのCDNサービスを採用し、コンテ… 2017年05月24日 11時00分


~ 運用管理の負荷を軽減し、新サービスの拡充・開発にエンジニアリソースを更に充当 〜


日東京--(BUSINESS WIRE)--(ビジネスワイヤ)--
世界最大規模のプライベート・ネットワーク経由で配信されるコンテンツ・デリバリー・ネットワーク(CDN)を提供するライムライト・ネットワークスの日本法人であるライムライト・ネットワークス・ジャパン株式会社(本社:東京都港区、代表:田所 隆幸)は、ミツバチワークス株式会社(本社:東京都渋谷区、以下、ミツバチワークス)が同社のCDNサービスを導入し、コンテンツ配信基盤を更に強化したと明らかにしました。




ミツバチワークスは、「Decolog」ブログやマガジンなどのメディアサービス、「@
GIRL」「プロトラベラー」といったマネジメントサービスを軸に、Webサービスの開発から、雑誌の出版、インフルエンサーマーケティングまで、多彩な事業を展開しています。増え続けるサービス利用者に安定してサービスを提供しつつ、高精細な画像が多用されるなどのコンテンツ容量の拡大に対応するため、コンテンツ配信基盤を増強し続けてきました。その結果、Web、データベース、キャッシュサーバを増設し続け、一時はサーバー台数が400台以上に膨らみました。このためコスト面だけでなく、運用管理の負荷も増加していたため、ハードウェアの増強による対応には限界を感じていました。



そこで、ミツバチワークスは、高品質で安定した配信を可能にするCDNを導入し、2010年から利用を開始しました。ただし、料金体系がトラッフィック容量の増減に柔軟に対応する設定ではなかったため、一部のサービスについてはCDNを利用せず、自社で運用を続けていました。



その後、ミツバチワークスは、自社で行っていたコンテンツ配信を全てCDNに移行するため、柔軟な契約形態とコスト体系のライムライト・ネットワークスを採用しました。ミツバチワークスのプログラマーである守安成人氏は次のように述べています。「コストは下がっても性能は落ちることなく、安定したコンテンツ配信が実現できています。ライムライトのCDNに移行したことで、日々の業務で自社コンテンツ配信サーバーの運用管理や障害対応に煩わされることがなくなり、新サービスの企画や、そのためのシステム開発により多くの時間を充てられるようになりました」



高品質で安定した配信だけでなく、ライムライト・ネットワークスのCDNサービスにおける管理の容易性、手厚いサポートも高く評価されました。今後も、ミツバチワークスは、ライムライト・ネットワークスの技術を活用し、多彩なデバイスでユーザーエクスペリエンスを高めるためウェブサイトの最適な表示を実現していきます。また、ユーザーがさらに安心してサービスを使えるようにコンテンツのSSL対応も検討していきます。



ミツバチワークスのサービスにおいて、コンテンツ配信は中核となるものです。今後、提供していく新サービスについてもこれは変わらず、ライムライト・ネットワークスに引き続きサポートしてもらいたいと考えています」と、守安氏は述べています。



実際の事例はこちらから



【ライムライト・ネットワークス・ジャパン株式会社について】
ライムライト・ネットワークス・ジャパン株式会社は、ビジネス、エンターテイメントの新しい形を実現するコンテンツ配信パートナーである米国ライムライト・ネットワークス社(本社:米国アリゾナ州 

NASDAQ上場証券コード:LLNW)の日本法人として2007年に設立されました。実績のあるライムライト・ネットワークスの独自アーキテクチャーは、お客様が配信を希望される様々なフォーマットのコンテンツをPC、各種モバイルデバイスに対し最も効率の良い方法で配信いたします。
https://jp.limelight.com/




Contacts


【お客様からのお問い合わせ先】および【メディアの皆様のお問い合わせ先】
ライムライト・ネットワークス・ジャパン株式会社
マーケティング本部 

Tel: 03-5571-4230
Email: info-jp@llnw.com

InAuth Announces Asia/Pacific Market Expansion 2017年05月24日 08時00分


Company Poised to Deliver Next-Generation Device Intelligence
Solutions Across the Region


BOSTON--(BUSINESS WIRE)--InAuth, a leading provider of digital device intelligence solutions for
a mobile-first world, today announced its expansion into the Japan &
Asia Pacific (JAPA) regions, bringing its device authentication tools
into one of the fastest-growing regions for mobile transactions. The
move is part of the company’s aggressive, multi-pronged growth strategy
to expand its geographic footprint beyond North America.



In addition to the opening of the JAPA markets, InAuth maintains offices
in Boston, where it is headquartered, as well as California and London,
which serves Europe and the Middle East. Today, InAuth solutions are in
use by some of the world’s most widely recognized brands. The company
was acquired by American Express in December 2016.



“The Asia-Pacific region is experiencing explosive growth in mobile
transactions across every sector, from financial institutions and
payment processors, to e-commerce and m-commerce providers,” said Mark
Dawes, InAuth General Manager for JAPA. “Organizations must implement
next-generation device intelligence solutions to combat fraud and reduce
risk and exposure, as well as enable them to innovative and fully
leverage the mobile channel. We look forward to bringing our advanced
solutions to this region and helping businesses protect themselves and
their customers.”



“We are excited about our expansion into this region and the many
opportunities to work with industry-leading businesses to help them
better protect their mobile and browser channels,” said InAuth President
Lisa Stanton. “We enter this market recognizing businesses’ need for
advanced insights and intelligence to reduce fraud risk in their digital
channels, as well as protect their brand reputation and customers. With
a growing client base of marquis global brands, strong strategic
partnerships and an experienced management team now in place, InAuth is
well-positioned to help organizations in this region successfully
navigate the complexities of a mobile-first world.”



About InAuth
InAuth is a leading digital device intelligence
company for a mobile-first world. InAuth delivers advanced device
identification, risk detection, and analysis capabilities possible to
help organizations limit risk, remove friction, and reduce fraud within
their digital channels. With safer digital transactions, banks, payment
networks, merchants, healthcare providers, governments, and other
organizations are better positioned to capture new revenue opportunities
and compete more effectively in an “always-on” world. For more
information, visit www.InAuth.com.




Contacts


Technology PR Solutions
Neal Stein, 321-473-7407
nealjstein@techprsolutions.com

Japan Salt And Pure Sodium Chloride Market Report 2017 - An… 2017年05月24日 01時46分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan:
Salt And Pure Sodium Chloride - Market Report - Analysis And Forecast To
2025"
report to their offering.




The report provides an in-depth analysis of the market for Salt And Pure
Sodium Chloride in Japan. It presents the latest data of the market
size, consumption, domestic production, exports and imports, price
dynamics and trends in the industry. The report shows the sales data,
allowing you to identify the key drivers and restraints. You can find
here a strategic analysis of key factors influencing the market.
Forecasts illustrate how the market will be transformed in the medium
term.



Product coverage: Salt (including table salt and denatured salt) and
pure sodium chloride, whether or not in aqueous solution or containing
added anti-caking or free-flowing agents.



Key Topics Covered:



1. Introduction



1.1 Report Description



1.2 Research Methodology



2. Executive Summary



2.1 Key Findings



2.2 Market Trends



3. Market Overview



3.1 Market Volume And Value



3.2 Market Structure



3.3 Trade Balance



3.4 Per Capita Consumption



3.5 Market Forecast To 2025



4. Production



4.1 Production In 2007-2015



5. Imports



5.1 Imports In 2007-2015



5.2 Imports By Countries



5.3 Import Prices By Countries



6. Exports



6.1 Exports In 2007-2015



6.2 Exports By Regions And Countries



6.4 Export Prices By Countries



For more information about this report visit http://www.researchandmarkets.com/research/ff5bh9/japan_salt_and




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Salts

Japan Market Report for Multi-Parameter Vital Sign Monitori… 2017年05月24日 01時02分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan
Market Report for Multi-Parameter Vital Sign Monitoring 2017 - MedCore"

report to their offering.




The total market for multi-parameter vital sign monitoring included
low-acuity, mid-acuity and high-acuity patient monitors, in addition to
the associated central stations.



Growth in the total market will remain steady over the forecast period,
motivated by continued investment in multi-parameter monitoring devices
despite budgetary constraints. This trend reflects the strong push
across all levels of healthcare to increase monitoring efforts as a
means of improving patient safety and reducing complications through
enhanced care provision. Optimism is restricted, however, as hospitals
look to curb excess capital expenditure in light of new, value-based,
healthcare reimbursement models and the financial uncertainty this will
bring over the forecast period. Moreover, competitive pricing pressures
are expected to persist as a result of low-cost foreign competitors that
have been able to seize share in a cost conscious market.



Future growth in the market will be driven primarily by the expansion of
the mid-acuity monitoring market as patients are being transferred out
of higher acuity areas more quickly. Mid-acuity monitors, which are
capable of performing invasive monitoring while maintaining a
transportable size, are well positioned to play a role in addressing
this on-going trend. Low-acuity monitoring, on the other hand, will
remain largely stable as the market has become a replacement market of
old equipment.



Key Topics Covered:



Japan Patient Monitoring Equipment Market Overview



1. Research Methodology



2. Product Assessment



3. Multi-Parameter Vital Sign Monitoring Market



Companies Mentioned




  • A&D Medical


  • Bionet


  • Bistos


  • Boston Scientific


  • Cadwell


  • Charmcare Co


  • Contec Medical


  • Fukuda Denshi


  • GE Healthcare


  • Generic Label,


  • Goldway


  • Honeywell


  • Jerry Medical Instruments


  • Jumper


  • Kellyunion International


  • Kernal Medical


  • Kwangwon Medical


  • Masimo


  • Mediana


  • Medtronic


  • Mekics Co. Ltd


  • Nihon Kohden


  • Nonin


  • Noraxon


  • Rossmax International


  • Schiller


  • Smiths Medical


  • Sorin Medical


  • Spacelabs Healthcare


  • St. Jude Medical


  • Utech Co.


  • Votem Co.


  • Wagner Industrial Electronics


  • Welch Allyn


  • Zondan Medical



For more information about this report visit http://www.researchandmarkets.com/research/cbp94v/japan_market




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Patient
Monitoring Equipment

Otsuka and Proteus Digital Health® Resubmit Application to … 2017年05月23日 22時00分



  • Potential new Digital Medicine consists of Otsuka’s ABILIFY®
    (aripiprazole) embedded with the Proteus ingestible sensor, for
    serious mental illness



  • Drug/device product digitally records medication ingestion and,
    with patient consent, shares information with patient’s healthcare
    providers and selected family and friends



  • If approved by the FDA, Digital Medicine would provide patients and
    physicians with an objective, personalized measure of medication
    adherence and activity level, as well as self-reported rest and mood
    1


TOKYO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health®
(Proteus) today announce that the United States Food and Drug
Administration (FDA) has acknowledged receipt of the New Drug
Application (NDA) resubmission for the drug-device combination product
of ABILIFY® (aripiprazole) embedded with a Proteus ingestible
sensor in a single tablet. The NDA resubmission will now be reviewed by
the FDA, with an anticipated action date by the agency in the fourth
quarter of 2017.







The FDA requested additional information, including further human
factors investigations. The goal of human factors testing is to evaluate
use-related risks and confirm that individuals can use the system safely
and effectively.2



If approved, this Digital Medicine would securely measure patient
medication-taking patterns, as well as select physiological data and
self-reported behavioral information. This information would help enable
individuals along with their healthcare professional team to better
manage their serious mental illness. With the patient’s consent, this
information could be shared with their healthcare professional team and
selected family and friends, with the goal of allowing physicians to be
more informed in making treatment decisions that are specific to the
patient's needs. This Digital Medicine would be used in the treatment of
adults with schizophrenia, acute treatment of manic and mixed episodes
associated with bipolar I disorder, and as adjunctive therapy for the
treatment of major depressive disorder.



This Digital Medicine is comprised of FDA-approved ABILIFY with the only
FDA-cleared ingestible sensor, the size of a grain of sand, embedded
inside a single tablet at the point of manufacture.3 The
Proteus ingestible sensor activates when it reaches stomach fluids and
communicates with the patch, which is a wearable sensor that detects and
records the ingestion of the ABILIFY tablet, and select physiological
data, such as activity level. A mobile patient application, or medical
app, displays the data collected by the patch to allow individuals to
review their objective medication intake and activity level, as well as
enter self-reported measures of rest and mood. A web-based portal for
healthcare professionals and selected family and friends displays this
information for the duration of treatment.



About ABILIFY®
(aripiprazole)



Discovered by Otsuka Pharmaceutical Co., Ltd., ABILIFY was the first
available dopamine partial agonist and is indicated for the treatment of
schizophrenia in adults, for the acute treatment of manic or mixed
episodes associated with Bipolar I Disorder as monotherapy and as an
adjunct to lithium or valproate in adults, and for use as an adjunctive
therapy to antidepressants in adults with Major Depressive Disorder who
have had an inadequate response to antidepressant therapy. ABILIFY
tablets are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg
strengths.



About the Proteus Digital Health® Ingestible
Sensor and Wearable Sensor Patch



The Proteus ingestible sensor and wearable sensor patch have been
cleared by the Food and Drug Administration (FDA) for use in the United
States, CE marked per the Medical Device Directive for use in the
European Union and approved by the CFDA for use in China. More
information is available at www.proteus.com.



INDICATIONS and IMPORTANT SAFETY INFORMATION for ABILIFY® (aripiprazole)



INDICATIONS



ABILIFY is indicated for:




  • Treatment of Schizophrenia in adults


  • Acute treatment of manic or mixed episodes associated with Bipolar I
    Disorder as monotherapy and as an adjunct to lithium or valproate in
    adults


  • Use as an adjunctive therapy to antidepressants in adults with Major
    Depressive Disorder who have had an inadequate response to
    antidepressant therapy



IMPORTANT SAFETY INFORMATION



WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
DEMENTIA-RELATED PSYCHOSIS



Elderly patients with dementia-related psychosis treated with
antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death
compared to placebo (4.5% vs 2.6%, respectively). Although the causes of
death were varied, most of the deaths appeared to be cardiovascular
(e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in
nature. ABILIFY is not approved for the treatment of patients with
dementia-related psychosis.



WARNING: SUICIDAL THOUGHTS AND BEHAVIORS



Antidepressants increased the risk compared to placebo of suicidal
thinking and behavior (suicidality) in children, adolescents, and young
adults in short-term studies of Major Depressive Disorder (MDD) and
other psychiatric disorders. Anyone considering the use of adjunctive
ABILIFY or another antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did
not show an increased risk of suicidality in adults beyond age 24.
Depression and certain other psychiatric disorders are themselves
associated with increases in the risk of suicide. Patients of all ages
who are started on antidepressant therapy should be monitored
appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be
advised of the need for close observation and communication with the
prescriber. ABILIFY is not approved for use in pediatric patients with
depression.



Contraindication Known hypersensitivity reaction to
ABILIFY. Reactions have ranged from pruritus/urticaria to anaphylaxis.



Cerebrovascular Adverse Events, Including Stroke – Increased
incidence of cerebrovascular adverse events (e.g., stroke, transient
ischemic attack), including fatalities, have been reported in clinical
trials of elderly patients with dementia-related psychosis treated with
ABILIFY.



Neuroleptic Malignant Syndrome (NMS) A potentially fatal
symptom complex sometimes referred to as NMS may occur with
administration of antipsychotic drugs, including ABILIFY. Rare cases of
NMS occurred during ABILIFY treatment. Signs and symptoms of NMS include
hyperpyrexia, muscle rigidity, altered mental status, and evidence of
autonomic instability (e.g., irregular pulse or blood pressure,
tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may
include elevated creatinine phosphokinase, myoglobinuria
(rhabdomyolysis), and acute renal failure. The management of NMS should
include: 1) immediate discontinuation of antipsychotic drugs and other
drugs not essential to concurrent therapy; 2) intensive symptomatic
treatment and medical monitoring; and 3) treatment of any concomitant
serious medical problems for which specific treatments are available.



Tardive Dyskinesia (TD) – The risk of developing TD (a syndrome
of abnormal, involuntary movements) and the potential for it to become
irreversible are believed to increase as the duration of treatment and
the total cumulative dose of antipsychotic increase. The syndrome can
develop, although much less commonly, after relatively brief treatment
periods at low doses. Prescribing should be consistent with the need to
minimize TD. There is no known treatment for established TD, although
the syndrome may remit, partially or completely, if antipsychotic
treatment is withdrawn.



Metabolic Changes – Atypical antipsychotic drugs have been
associated with metabolic changes that include:




  • Hyperglycemia/Diabetes Mellitus – Hyperglycemia, in some cases
    extreme and associated with ketoacidosis, coma, or death, has been
    reported in patients treated with atypical antipsychotics including
    ABILIFY. Patients with diabetes should be regularly monitored for
    worsening of glucose control; those with risk factors for diabetes
    should undergo baseline and periodic fasting blood glucose testing.
    Any patient treated with atypical antipsychotics should be monitored
    for symptoms of hyperglycemia including polydipsia, polyuria,
    polyphagia, and weakness. Patients who develop symptoms of
    hyperglycemia should also undergo fasting blood glucose testing. In
    some cases, hyperglycemia has resolved when the atypical antipsychotic
    was discontinued; however, some patients required continuation of
    anti-diabetic treatment despite discontinuation of the suspect drug.


  • Dyslipidemia – Undesirable alterations in lipids have been
    observed in patients treated with atypical antipsychotics.


  • Weight Gain – Weight gain has been observed with atypical
    antipsychotic use. Clinical monitoring of weight is recommended.



Pathological Gambling and Other Compulsive Behaviors Intense
urges, particularly for gambling, and the inability to control
these urges have been reported while taking ABILIFY. Other compulsive
urges (e.g., eating, sexual, or shopping) have been reported less
frequently. Prescribers should ask patients or their caregivers
specifically about, and closely monitor for, the development of new or
intense compulsive urges. Consider dose reduction or stopping ABILIFY,
if such urges develop.



Orthostatic Hypotension – ABILIFY may cause orthostatic
hypotension and should be used with caution in patients with known
cardiovascular disease, cerebrovascular disease, or conditions which
would predispose them to hypotension.



Falls – Antipsychotics may cause somnolence, postural
hypotension, motor and sensory instability, which may lead to falls
causing fractures or other injuries. For patients with diseases,
conditions, or medications that could exacerbate these effects, complete
fall risk assessments when initiating treatment and recurrently during
therapy.



Leukopenia, Neutropenia, and Agranulocytosis – Leukopenia,
neutropenia, and agranulocytosis have been reported. In patients with a
history of clinically significant low white blood cell count
(WBC)/absolute neutrophil count (ANC) or history of drug-induced
leukopenia/neutropenia, perform a complete blood count (CBC) frequently
during the first few months of therapy. Consider discontinuing ABILIFY
at the first sign of a clinically significant decline in WBC in the
absence of other causative factors. Monitor patients with clinically
significant neutropenia for fever or other symptoms or signs of
infection and treat promptly if such symptoms or signs occur.
Discontinue ABILIFY in patients with severe neutropenia (ANC <1000/mm3)
and follow their WBC counts until recovery.



Seizures/Convulsions – ABILIFY should be used with caution in
patients with a history of seizures or with conditions that lower the
seizure threshold.



Potential for Cognitive and Motor Impairment – ABILIFY may impair
judgment, thinking, or motor skills. Instruct patients to avoid
operating hazardous machinery, including automobiles, until they are
certain ABILIFY does not affect them adversely.



Body Temperature Regulation – Disruption of the body’s ability to
reduce core body temperature has been attributed to antipsychotic
agents. Advise patients regarding appropriate care in avoiding
overheating and dehydration. Appropriate care is advised for patients
who may exercise strenuously, may be exposed to extreme heat, receive
concomitant medication with anticholinergic activity, or are subject to
dehydration.



Suicide The possibility of a suicide attempt is inherent
in psychotic illnesses, Bipolar Disorder, and Major Depressive Disorder.
Close supervision of high-risk patients should accompany drug therapy.
Prescriptions should be written for the smallest quantity consistent
with good patient management in order to reduce the risk of overdose.



Dysphagia – Esophageal dysmotility and aspiration have been
associated with antipsychotic drug use, including ABILIFY; use caution
in patients at risk for aspiration pneumonia. Aspiration pneumonia is a
common cause of morbidity and mortality in elderly patients, in
particular those with advanced Alzheimer’s dementia.



Alcohol Advise patients to avoid alcohol while taking
ABILIFY.



Concomitant Medication – Dosage adjustments are recommended in
patients who are CYP2D6 poor metabolizers and in patients taking
concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4
inducers. When the coadministered drug is withdrawn from the combination
therapy, ABILIFY dosage should then be adjusted to its original level.
When the coadministered CYP3A4 inducer is withdrawn, ABILIFY dosage
should be reduced to the original level over 1 to 2 weeks. For patients
who are known CYP2D6 poor metabolizers, administer half of usual dose.
For patients who are known CYP2D6 poor metabolizers taking concomitant
strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin),
administer a quarter of usual dose. For patients taking strong CYP2D6
(e.g., quinidine, fluoxetine, paroxetine) or CYP3A4 inhibitors (e.g.,
itraconazole, clarithromycin), administer half of usual dose. For
patients taking strong CYP2D6 and CYP3A4 inhibitors, administer a
quarter of usual dose. For patients taking strong CYP3A4 inducers (e.g.,
carbamazepine, rifampin), double usual dose over 1 to 2 weeks.



Commonly observed adverse reactions: (≥5% incidence and at least
twice the rate of placebo for ABILIFY vs placebo, respectively):




  • Adult patients with Major Depressive Disorder (adjunctive treatment to
    antidepressant therapy): akathisia (25% vs 4%), restlessness (12% vs
    2%), insomnia (8% vs 2%), constipation (5% vs 2%), fatigue (8% vs 4%),
    and blurred vision (6% vs 1%)


  • Adult patients (monotherapy) with Bipolar Mania: akathisia (13% vs
    4%), sedation (8% vs 3%), tremor (6% vs 3%), restlessness (6% vs 3%),
    and extrapyramidal disorder (5% vs 2%)


  • Adult patients (adjunctive therapy with lithium or valproate) with
    Bipolar Mania: akathisia (19% vs 5%), insomnia (8% vs 4%), and
    extrapyramidal disorder (5% vs 1%)


  • Adult patients with Schizophrenia: akathisia (8% vs 4%)



Dystonia – Symptoms of dystonia may occur in susceptible
individuals during the first days of treatment and at low doses.



Pregnancy – Neonates exposed to antipsychotic drugs, including
ABILIFY, during the third trimester of pregnancy are at risk for
extrapyramidal and/or withdrawal symptoms. These complications have
varied in severity, from being self-limited to requiring intensive care
and prolonged hospitalization. ABILIFY should be used during pregnancy
only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers – ABILIFY is present in human breast milk. A
decision should be made whether to discontinue nursing or to discontinue
the drug, taking into account the importance of the drug to the mother
and any potential risks to the infant.



To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America
Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).



Please see accompanying FULL
PRESCRIBING INFORMATION
, including BOXED WARNING.



About Otsuka Pharmaceutical Co., Ltd.



Otsuka Pharmaceutical is a global healthcare company with the corporate
philosophy: “Otsuka-people creating new products for better health
worldwide.” Otsuka researches, develops, manufactures and markets
innovative products, with a focus on pharmaceutical products for the
treatment of diseases and nutraceutical products for the maintenance of
everyday health.



In pharmaceuticals, Otsuka is a leader in the challenging area of mental
health and also has research programs on several under-addressed
diseases including tuberculosis, a significant global public health
issue. These commitments illustrate how Otsuka is a “big venture”
company at heart, applying a youthful spirit of creativity in everything
it does.



Otsuka Pharmaceutical is a subsidiary of Otsuka Holdings Co., Ltd.
headquartered in Tokyo, Japan. The Otsuka group of companies employed
45,000 people worldwide and had consolidated sales of approximately USD
11 billion (€ 9.9 billion) in 2016.



All Otsuka stories start by taking the road less travelled. Learn more
about Otsuka Pharmaceutical Company on its global website at https://www.otsuka.co.jp/en.
Learn more about Otsuka in the U.S. at www.otsuka-us.com
and connect with us on Twitter at @OtsukaUS.



About Proteus Digital Health®



Headquartered in Redwood City, Calif., Proteus is privately held and
funded by leading institutional and corporate investors, including:
Novartis, Otsuka, Medtronic and Kaiser Permanente. For more information,
visit www.proteus.com.
Connect with us on Twitter @ProteusDH.



1 Rohatagi S et al. Optimization of a Digital Medicine System
in Psychiatry. J Clin Psychiatry 2016;77(9):e1101-1107.
2
U.S. Food & Drug Administration. Premarket Information - Device Design
and Documentation Processes. https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HumanFactors/ucm119190.htm.
Updated 9/15/2016. Accessed April 11, 2017.
3 U.S. Food
& Drug Administration. 510(k) Premarket Notification. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K133263.
Accessed April 21, 2017.




Contacts


Otsuka
In U.S.
Kimberly Whitefield,
+1-609-535-9259
Corporate Communications
kimberly.whitefield@otsuka-us.com
or
Outside
U.S.

Jeffrey Gilbert
+81 3 6361 7379
+81 80 8728 6039
Leader,
Pharmaceutical PR
gilbert.jeffrey@otsuka.co.jp
or
Proteus
Digital Health

Emily Fox, +1-408-425-7097
Corporate
Communications
efox@proteus.com



Dompé Receives Positive CHMP Opinion in Europe For Oxervate… 2017年05月23日 22時00分



  • Designed to treat moderate or severe neurotrophic keratitis in
    adults, if approved by the European Commission, Oxervate® would be the
    first biotechnological treatment authorized for this indication.



  • Neurotrophic keratitis is a rare eye disease which affects less
    than 5 in 10,000
    1 people. There
    is no approved drug for this condition.



  • CHMP completed its review through an accelerated assessment.
    This is allowed for some innovative drugs developed for serious
    illnesses for which no effective therapeutic option is available.



  • In 2015, Oxervate® was designated as orphan drug in Europe for
    the treatment of neurotrophic keratitis.



MILAN--(BUSINESS WIRE)--Today, the biopharmaceutical company Dompé has announced that the
Committee for Human Medicinal Products (CHMP) of EMA (European Medicines
Agency) has released a positive opinion, recommending the marketing
authorization for Oxervate® (cenegermin eye drops), for the
treatment of adult patients with moderate or severe neurotrophic
keratitis. This is a rare and disabling eye condition that can lead to
the loss of vision. As of today, no satisfactory treatment is available
for this disease. Due to the risks related to this pathology and to the
lack of viable therapeutic options, CHMP completed its review through an
accelerated assessment. It began in November 2016 and ended with a
positive opinion last week.




The origin of neurotrophic keratitis is related to a trigeminal nerve
impairment (one of the nerves responsible for the eye anatomy and
function), which can lead to the loss of corneal sensitivity. In its
most serious forms, it can cause ulcers, melting and corneal
perforation, affecting the visual ability of patients2.



If confirmed by EMA’s Committee for Orphan Medicinal Products (COMP) and
approved by the European Commission, Oxervate® would be the first
biotechnology orphan drug in the world authorized for this indication.



Cenegermin, the name of the active agent, is the recombinant
version of the human nerve growth factor (NGF) discovered by
Nobel Laureate Rita Levi Montalcini. This protein is naturally produced
by the human body and is implicated in the development, maintenance and
survival of nerve cells3. Administered in the form of eye
drops to patients with neurotrophic keratitis, Oxervate® helps restore
the normal healing processes of the eye and repair the corneal damage.



Oxervate® is produced through the recombinant DNA technology, with the
introduction of a gene (DNA) into bacteria to allow these latter to
produce the human nerve growth factor.



CHMP conclusions are based on data from two phase II clinical trials
involving 204 patients with moderate and severe neurotrophic keratitis.
Both studies have shown that after eight weeks, a higher number of
Oxervate® treated patients reached a complete corneal healing vs
patients on placebo. The most common adverse reactions observed with
Oxervate® include eye pain, eye inflammation, increased lacrimation
(secretion of tears), eyelid pain and foreign body sensation in the eye.



"We welcome the CHMP opinion with great satisfaction. To us, making
Oxervate® available to patients who live with this rare disease is a
major achievement. It would be the first biotech treatment obtained
thanks to our research efforts"
, said Eugenio Aringhieri,
Dompé’s Chief Executive Officer
. "This decision paves the
way to the significant prospect of a therapy for those suffering from
this disease. In the future, our goal is to keep investigating its
potential in other pathologies, to allow more and more patients to
benefit from this innovative therapeutic approach".



"Having been the first to turn the discovery of the Nerve Growth
Factor into a potential therapy is a further confirmation of the value
of ‘Made in Italy’ research"
, explained Sergio Dompé,
Chairman of Dompé
. "At this time my thoughts and gratitude go to
the team of researchers who passionately developed Oxervate®, and
especially to Professor Rita Levi Montalcini for her great intuition,
from which this research project stems, namely the neuronal growth
factor for which she received the Nobel Prize."



Until the European Commission’s final decision, Oxervate® remains an
investigational therapy. Its marketing authorization has not been
granted yet in any country.



About Dompé



Dompé is one of the leading biopharmaceutical companies in Italy. It
focuses on the development of innovative therapeutic solutions for
diseases with a high social impact for which therapeutic options are
lacking. Based in Italy, Dompé has its headquarters in Milan. Its
research efforts focus on unmet therapeutic needs such as diabetes,
organ transplantation, ophthalmology and oncology. The industrial pole
of L’ Aquila (Abruzzo) is home to a world class biotechnology plant
developing drugs for Primary Care for the markets of about 40 countries
worldwide. Dompé has its offices also in Albania, France, Germany, Great
Britain, Spain and United States (New York).



For more information: www.dompe.com
and www.dompetrials.com



Forward looking statements



This press release makes reference to certain information that may
not coincide with expected future results. Dompé firmly believes in the
soundness and reasonableness of the concepts expressed. However, some of
the information is subject to a certain degree of indetermination in
relation to its research and development activities and the necessary
verifications to be performed by regulatory bodies. Therefore, as of
today, Dompé cannot guarantee that the expected results will be
consistent with the information provided above.



1 M. Sacchetti, and A. Lambiase, Diagnosis and management of
neurotrophic keratitis. Clin Ophthalmol 8 (2014) 571-9.
2
Idem
3 R. Levi Montalcini, The nerve growth
factor 35 years later
, Science 1987




Contacts


Dompé
Laura Sprea, +39 02 58383567 | +39 3355745188
Corporate
Communications Senior Specialist

laura.sprea@dompe.com

Japan Market Overview for Patient Monitoring Equipment 2017… 2017年05月23日 21時21分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan
Market Overview for Patient Monitoring Equipment 2017 - MedView"

report to their offering.




Despite growing demand for quality patient monitoring solutions, some
hospitals cannot afford high-cost monitoring platforms in light of
budget constraints. In addition, the shrinking hospital profit margins,
reimbursement cuts and consolidation within industry (i.e. private
practices closing in favor of security of hospital affiliation) all
reduce the total market opportunity and is resulting in more rapid ASP
declines. Moreover, given the lack of reimbursement from alternate care
setting devices, low growth is expected in many of the patient
monitoring market segments.



In light of an aging population as well as environmental and chemical
stressors the number of chronically ill patients within the population
has been steadily increasing. This includes those individuals being
diagnosed with heart disease, obesity, diabetes, high cholesterol and
high blood pressure among other conditions. Furthermore, these illnesses
are becoming more prevalent among younger demographics. As a result,
patient monitoring and diagnostic equipment will be in higher demand
facilitating increased investment into capital equipment and
disposables. Moreover, the ease of use, accuracy and affordability of
these devices will become an important factor in product development
within the home patient monitoring device market.



A trend that is currently prevailing across Japan relates to the
adoption of less-invasive, more accessible, patient-centric monitoring
device configurations. This is exemplified by the movement towards
wireless telemetry solutions and remote patient monitoring platforms in
the hospital.



Key Topics Covered:



1. Research Methodology



2. Japan Patient Monitoring Equipment Market Overview



2.1 Introduction



2.1.1 Monitoring Devices



2.1.2 Telehealth



2.2 Currency Exchange Rate



2.3 Market Overview



2.4 Trend Analysis By Segment



2.5 Drivers And Limiters



2.6 Competitive Market Share Analysis



2.7 Company Profiles



2.7.1 Boston Scientific



2.7.2 Edwards Lifesciences



2.7.3 GE Healthcare



2.7.4 Honeywell Life Sciences



2.7.5 Masimo



2.7.6 Medtronic



2.7.7 Mindray Medical



2.7.8 Natus Medical



2.7.9 Nihon Kohden



2.7.10 Nonin Medical



2.7.11 Omron Healthcare



2.7.12 Philips Healthcare



2.7.13 St. Jude Medical



2.7.14 Spacelabs Healthcare



2.7.15 Welch Allyn



For more information about this report visit http://www.researchandmarkets.com/research/lkzf8z/japan_market




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Patient
Monitoring Equipment

Japan Market Report for Fetal and Neonatal Monitoring 2017 … 2017年05月23日 21時12分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan
Market Report for Fetal and Neonatal Monitoring 2017 - MedCore"

report to their offering.




The fetal and neonatal monitoring market included fetal monitors for
both antepartum and intrapartum monitoring, in addition to critical care
monitors for premature infants.



The neonatal monitoring market represented the majority of the total
fetal and neonatal monitoring market. Neonatal monitoring is driven by
the demand for high cost continuous critical care monitoring in any
hospital with a maternity ward or neonatal intensive care unit (NICU).
Fetal monitoring encompassed the remainder of the market and is driven
by increased public awareness of technology for monitoring the
development of a fetus.



Over the forecast period the neonatal monitoring segment is expected to
account for a growing percentage of the total market. This subtle shift
may be attributed to a tendency for hospitals to invest in fetal
monitors featuring improved, albeit more expensive, wireless
connectivity options among other updated features. By 2023, however, the
revenue mix will stabilize and only nominal fluctuations are expected in
the long-term.



Growth in these mature markets is generally minimal considering that
equipment is usually purchased on a replacement basis. In recent years,
however, hospitals have begun to purchase equipment that can be
integrated with their hospital information systems and improve clinical
workflows. Consequently, as hospitals continue to replace their
monitors, they will instead opt for more advanced devices with updated
features, such as wireless patient connectivity and device networking
capabilities. This trend will help to stabilize the market for fetal and
neonatal monitors over the forecast period.



Key Topics Covered:



1. Research Methodology



2. Product Assessment



3. Fetal And Neonatal Monitoring Market



Companies Mentioned




  • A&D Medical


  • Boston Scientific


  • Cadwell


  • Charmcare Co


  • Contec Medical


  • Contec Medical Systems


  • Creative Medical


  • Edan


  • Electrical Geodesics Inc


  • Fukuda Denshi


  • GE Healthcare


  • Generic Label,


  • Goldway


  • Honeywell


  • Jerry Medical Instruments


  • Jumper


  • Mediana


  • Medtronic


  • Mekics Co. Ltd


  • Micromed


  • Mindray


  • Natus Medical


  • Neuro-Force


  • Neurosoft Company


  • Nihon Kohden


  • Nonin


  • Smiths Medical


  • Sorin Medical


  • Spacelabs Healthcare


  • St. Jude Medical


  • Technomed Europe


  • Wagner Industrial Electronics


  • Welch Allyn


  • Zondan Medical



For more information about this report visit http://www.researchandmarkets.com/research/9cfqk9/japan_market




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Maternal
and Neonatal Care
, Patient
Monitoring Equipment

Japan: Total Launches Construction of the Miyako Solar Park 2017年05月23日 18時09分

PARIS--(BUSINESS WIRE)--Regulatory News:



Total Solar, a 100% owned Total (Paris:FP) (LSE:TTA) (NYSE:TOT)
subsidiary dedicated to solar activities, has launched construction of
its second solar power plant in Japan. The 25-megawatt-peak photovoltaic
power plant in Miyako, in Iwate province, is expected to start up in
2018 and will provide clean and reliable electricity to over 8,000
households.




The solar market offers significant growth potential. Following the
start-up of the Nanao solar plant in March this year, the Miyako Solar
Park will further contribute to the diversification of Japan’s energy
mix,”
said Julien Pouget, Senior Vice-President Renewables at Total.



The plant is designed to fully meet Japan’s stringent
earthquake-resistant building standards. The facility will be equipped
with over 76,000 high-efficiency SunPower solar panels, providing
maximum performance. The plant will be connected to the electricity
distribution grid to supply energy through the regional utility company.



Total and Solar



Total, the majority shareholder of SunPower since 2011, is active across
the entire photovoltaic value chain, from manufacturing cells to
designing large-scale turnkey solar power plants and to installing
residential or commercial rooftop systems. More than 7GW of solar
capacity has already been deployed by Total, SunPower and their partners
since 2011.



Total Solar is a 100% owned subsidiary of the Total Group, which is
spearheading Total’s own solar activities. Its objective is to
accelerate the Group’s development in the production and sale of solar
electricity in Europe and worldwide, by developing solar power plants
and distributed photovoltaic systems at the sites of industrial or
commercial customers.



* * * *



About Total



Total is a global integrated energy producer and provider, a leading
international oil and gas company, and a major player in solar energy
with SunPower and Total Solar. Our 98,000 employees are committed to
better energy that is safer, cleaner, more efficient, more innovative
and accessible to as many people as possible. As a responsible corporate
citizen, we focus on ensuring that our operations in more than 130
countries worldwide consistently deliver economic, social and
environmental benefits. total.com



Cautionary note



This press release, from which no legal consequences may be drawn, is
for information purposes only. The entities in which TOTAL S.A. directly
or indirectly owns investments are separate legal entities. TOTAL S.A.
has no liability for their acts or omissions. In this document, the
terms “Total” and “Total Group” are sometimes used for convenience where
general references are made to TOTAL S.A. and/or its subsidiaries.
Likewise, the words “we”, “us” and “our” may also be used to refer to
subsidiaries in general or to those who work for them.

This
document may contain forward-looking information and statements that are
based on a number of economic data and assumptions made in a given
economic, competitive and regulatory environment. They may prove to be
inaccurate in the future and are subject to a number of risk factors.
Neither TOTAL S.A. nor any of its subsidiaries assumes any obligation to
update publicly any forward-looking information or statement, objectives
or trends contained in this document whether as a result of new
information, future events or otherwise.



TOTAL S.A.
Capital : 6 207 262 032,50 €
542 051 180 R.C.S.
Nanterre
total.com




Contacts


Total
Mike SANGSTER
Nicolas FUMEX
Kim HOUSEGO
Romain
RICHEMONT
Tel. : + 44 (0)207 719 7962
Fax : + 44 (0)207 719
7959
or
Robert HAMMOND (U.S.)
Tel. : +1 713-483-5070
Fax
: +1 713-483-5629

OKI Launches ATM-Recycler G8, a Strategic ATM Model for Eme… 2017年05月23日 11時00分


- Providing higher speed, greater capacity and IoT for improved ATM
operating efficiency -


TOKYO--(BUSINESS WIRE)--OKI (TOKYO:6703) today announced the launch of a new cash-recycling ATM,
ATM-Recycler G8, targeting overseas markets. Incorporating expertise
accumulated by OKI in Japanese and international markets, this ATM is a
strategic product in response to higher speed and greater capacity for
expanding cash demand and higher future scalability. As part of plans to
grow its mechatronics business in overseas markets, OKI plans to sell
150,000 units of this model over the next five years in emerging markets
like India and Southeast Asia, where market expansion is expected.




The very large volume of cash circulating in emerging markets has
generated demand for increased efficiency in teller operations at
financial institutions. In these markets, due in particular to demand on
individual and corporate customers to automate cash deposit handling,
cash-recycling ATMs, reducing the intervals of cash
replenishment/collection and enabling efficient cash management, are
emerging as a key element of the social infrastructure.



The newly introduced ATM-Recycler G8 realizes higher utilization rates
and reduction in total operating costs thanks to various improvements,
including the industry’s largest banknote capacity (based on OKI
research; 12% more than the previous model), 50% faster processing
speeds, 20% reduction in installation weight and other advances. In
addition, the ATM-Recycler G8 is designed to accommodate future
environmental changes surrounding ATM, including integration with
operation management system leveraging Internet of things (IoT) and
artificial integration (AI), and new service expansion responded to
Fintech.



“OKI has led the way in ATM technological innovations as a major vendor
in this field since pioneering the development of cash-recycling ATMs in
the Japanese market in 1982,” says Kenichi Tamura, Senior Vice President
and Head of Mechatronics Systems Business Division. “Introduced in 2009,
the ATM-Recycler G7 handles currencies of multiple countries and
continues to be adopted in the global ATM market, which until its
introduction had been dominated by cash dispensers. The ATM-Recycler G7
is currently in use in 11 countries. Moving forward, leveraging its
track record and the trust it has gained in the field of cash-recycling
ATMs, OKI will continue delivering solutions to increase ATM added value
in response to future changes in payment methods while advancing market
growth with the new ATM-Recycler G8.”



[Sales plan]
Price: Open
Shipment begins: May 2017
Sales
target: 150,000 units over five years



About OKI Electric Industry (OKI)



Founded in 1881, OKI Electric Industry is Japan's leading
telecommunications manufacturer in the Info-telecom field. Headquartered
in Tokyo, Japan, OKI provides top-quality products, technologies, and
solutions to customers through its info-telecom systems and printer
operations. Its various business divisions function synergistically to
bring to market exciting new products and technologies that meet a wide
range of customer needs in various sectors. Visit OKI's global website
at http://www.oki.com/.



Notes:




  • The names of the companies and products mentioned in this document are
    the trademarks or registered trademarks of the respective companies
    and organizations.




Contacts


Press contact:
OKI Electric Industry Co., Ltd.
Mayuko
Noto, +81-3-3501-3835
Public Relations Division
press@oki.com
or
Customer
contact:

Global Strategic Planning Department
Global
Mechatronics Systems Division
OKI Mechatronics Systems Business
Division
Phone: +81-27-325-1111



SII Semiconductor Corporation: S-35710M Built-in 32.768kHz … 2017年05月23日 10時00分


- Reduces operating current from microcomputers and other systems with
dedicated periodical time management during engine shutdown -


CHIBA, Japan--(BUSINESS WIRE)--SII Semiconductor Corporation, a subsidiary of Seiko Instruments Inc.
introduces the new S-35710M built-in 32.768kHz quartz crystal
convenience timer for automotive applications. The S-35710M exhibits
very low current consumption as compared to the implementation of the
embedded microcontroller timer functions. The S-35710M is suitable for
management of relative time*1 and reduces system standby
current.








The S-35710M is a 2-in-1*2 timer product with an IC and
Quartz Crystal built into a single package reducing the number of
external components and producing an accurately matched Oscillator and
Crystal.



The S-35710M is suitable for time management during system sleep periods*3
after engine shut-down. The alarm time can be programmed in one-second
increments from one second to 194 days. Using this timer with its
ultra-low current consumption of only 250nA typical, reduces the system
standby current.



Influenced by fuel evaporative emission regulations, including EURO 6*4
(Europe), demand for periodic status management during engine shut-down
is critical. In addition, blank detection capability is required for
electric vehicles to monitor the status of the battery when it is not in
use or while charging.



The S-35710M comes in a lead-free and halogen-free 8-pin HSOP-8Q package.








































 

*1

 

Relative time: The time interval from the time when an event occurs:
e.g. “output an interrupt signal at xx minutes after the MCU stops.”




In contrast, absolute time denotes clock time: e.g. “Output an
interrupt signal at xx:xx AM/PM every day.”



*2


2-in-1: A type of package that is made up from two components (a
timer IC and a Quartz Crystal).

*3



During system sleep periods: The period while the electronic
control unit (ECU) is in sleep mode (power saving mode).



*4


EURO 6: European regulations that define the emission regulatory
values of air pollutants from automobiles, which includes the fuel
evaporative emission regulations.



To manage these values, time measurement during engine shut-down is
important.

 


Data Sheet
http://datasheet.sii-ic.com/en/automotive_convenience_timer/S35710M_E.pdf



About SII Semiconductor Corporation
SII Semiconductor
Corporation, a semiconductor manufacturer in Seiko Instruments Group,
offers analog semiconductor products such as Power Management ICs,
EEPROMs, Sensors, Timer ICs, Amplifiers and ASSPs; featuring small size,
low current consumption and high accuracy.
http://www.sii-ic.com/en/




Contacts


Seiko Instruments Inc.
Nobuo Abe, +81-43-211-1111 (Japanese inquiry
only)
Corporate Communications
pr@sii.co.jp
Online
Inquiry: https://krs.bz/sii/m/sii_inquiry_en



Bifold Doors Market - Trends and Forecasts by Technavio 2017年05月23日 07時23分

LONDON--(BUSINESS WIRE)--#Construction--Technavio’s latest report on the global
bifold doors market
provides an analysis of the most
important trends expected to impact the market outlook from 2017-2021. Technavio
defines an emerging trend as a factor that has the potential to
significantly impact the market and contribute to its growth or decline.








Gaurav Mohindru, a lead analyst from Technavio, specializing in research
on the construction
sector, says, “Booming residential market and large-scale investments
in commercial projects, such as new hospitals and office space, are
expected to increase the demand for bifold doors across the globe
.”



The use of bifold
doors
in the housing and residential building sector has been
increasing in recent years primarily because of the growing appreciation
of performance benefits such as compact footprint, flexibility, and ease
of maintenance of bifold doors. The growing demand for homes in urban
areas and mixed-use buildings is also driving the demand for bifold
doors. Bifold doors improve ventilation in the house.



This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing



Buy 1 Technavio report and get the second for 50% off. Buy 2
Technavio reports and get the third for free.



The top three emerging trends driving the global bifold doors market according
to Technavio research analysts are:



Evolution toward cellular polyvinyl chloride (PVC) bifold doors



Cellular PVC bifold doors were developed as a response to customer
requests for wood bifold doors that resist rot. Cellular PVC bifold
doors are also developed from PVC. Cellular PVC is different from
extruded hollow vinyl as it features a foam or a cell structure inside
it.



Cellular PVC is a wood replacement product made of PVC that is
molded into forms. Cellular PVC is in a different state when compared
with standard PVC, enabling it to be cut and shaped much like wood
without the disadvantages in wood
,” according to Gaurav.



Emergence of automation and remote operation



Automation and remote operation have become more popular in new bifold
door offerings. For example, Total Support Services (Security) in 2014
completed bifold loading bay for an office building in Bevis Marks,
London. The system allows users to open, close, and stop the bifold via
a keypad. Other companies such as Folding Motion offers a
remote-operated system designed for use in bifold doors.



Progression in smart glass



Bifold doors are no longer considered as an object to fill the openings
in buildings. In the current scenario, bifold doors are expected to
perform multiple functions such as keeping out heat/cold, letting in
light, being aesthetically attractive, noise attenuation, needing lower
maintenance, and using energy-efficient materials.



Smart glass in bifold doors consists of a glass or glazing whose light
transmission properties are altered when voltage, light, or heat is
applied. Glass changes from translucent to transparent, that is,
changing from blocking some (or all) wavelengths of light to letting
light pass through.



The key vendors are as follows:




  • Andersen


  • JELD-WEN


  • Pella


  • YKK


  • Ply Gem



Browse Related Reports:




Become a Technavio
Insights member
and access all three of these reports for a
fraction of their original cost. As a Technavio Insights member, you
will have immediate access to new reports as they’re published in
addition to all 6,000+ existing reports covering segments like
unit
operations
, engineering
tools
, and tools
and components
. This subscription nets you thousands in
savings, while staying connected to Technavio’s constant transforming
research library, helping you make informed business decisions more
efficiently.



About Technavio



Technavio
is a leading global technology research and advisory company. The
company develops over 2000 pieces of research every year, covering more
than 500 technologies across 80 countries. Technavio has about 300
analysts globally who specialize in customized consulting and business
research assignments across the latest leading edge technologies.



Technavio analysts employ primary as well as secondary research
techniques to ascertain the size and vendor landscape in a range of
markets. Analysts obtain information using a combination of bottom-up
and top-down approaches, besides using in-house market modeling tools
and proprietary databases. They corroborate this data with the data
obtained from various market participants and stakeholders across the
value chain, including vendors, service providers, distributors,
re-sellers, and end-users.



If you are interested in more information, please contact our media team
at media@technavio.com.




Contacts


Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

mTAB® Expands Global Marketing Research Capabilities 2017年05月23日 04時00分

ANAHEIM, Calif.--(BUSINESS WIRE)--#datavisualization--mTAB, a U.S.-based leading provider of survey data analysis and
visualization solutions, today announced an expansion of its global
capabilities. Through the acquisition of Gamma Associates in the U.K.,
establishment of an office in Japan, and a partnership with Analytic
Edge in China, mTAB will provide enhanced in-market support for clients.




“We’re so pleased to unite our two companies to provide our client base
with the global support they expect,” said Alex Gelman, CEO of mTAB.
“Gamma’s focus on quality and customer success fits perfectly with our
values at mTAB. Gamma’s data visualization software, mTABView®, will
become one of the core pillars of the mTAB platform and growth story.”



Since 1990, Gamma has been mTAB’s partner in Europe. The two businesses
will be fully integrated under Gelman’s leadership, enabling mTAB’s
global clients to access a more seamless customer experience.



Additionally, today mTAB announced a significant expansion into Asia.
mTAB has been working closely with leading Japanese companies since
1996, and establishing a local office will further strengthen these
relationships.



“As we plan to expand our business globally, establishing an operating
entity in this important market was a natural decision for us,” said
Keiko Yoshimi, head of the newly formed mTAB Asia Pacific office.



In China, the growing market research industry is increasingly demanding
the same tools that mTAB provides in its Japanese, European and American
markets. To support the Chinese market, mTAB has formed a strategic
partnership with market research training firm, Analytic Edge.



“The Chinese market is so unique and large that it requires in-market
presence,” said Junbo Zhu, founder of Analytic Edge.



With the expansion, clients can expect a seamless user experience
through a fully integrated software and services delivery platform in
the comfort of their own language and time zone.



For further information visit www.mtabsurveyanalysis.com.



About mTAB



mTAB enables companies to maximize value from past and present marketing
research by providing fully serviced web-based software that makes large
non-uniform datasets easy to analyze, insightful and immediately
accessible for everyone. mTAB makes it easy for anyone to discover
stories behind the research data warehouse to help make key business
decisions.




Contacts


mTAB
Katie Duffey, 1-714-693-3110
kduffey@mtabsurveyanalysis.com



mTAB®、マーケティング調査活動をグローバルに拡大 2017年05月23日 04時00分

米カリフォルニア州アナハイム--(BUSINESS WIRE)--(ビジネスワイヤ) --
米国を拠点に調査データ分析・可視化ソリューションを提供するmTABは本日、世界的な活動拡大を発表しました。英国のガンマ・アソシエーツの買収、日本での法人設立、中国のアナリティック・エッジとの提携を通じて、mTABはお客さまへの市場内サポートを強化します。




mTABのアレックス・ゲルマン最高経営責任者(CEO)は、次のように述べています。「私たちは、2つの会社が統合して顧客が期待する世界的サポートを提供できることをうれしく思います。ガンマの品質とお客さまの成功に対する姿勢は、mTABの価値観と完全に合致しています。ガンマのデータ可視化ソフトウエアのmTABView®は、mTABプラットフォームと我々の成長物語の中核的な柱のひとつになるでしょう。」



1990年以来、ガンマはmTABの欧州パートナーとして活動してきました。両社は、ゲルマン氏の下で完全に統合され、世界各地のmTABのお客様に、よりシームレスな顧客体験を提供することを可能にします。



加えて、mTABは本日、アジアへの大規模な拡大を発表しました。mTABは、1996年から日本の大手企業と緊密に協力しており、現地に事業所を設立することで、これらの関係がさらに強化されます。



新たに設立されたmTABアジアパシフィック代表者のヨシミ・ケイコ氏は、次のように述べています。「mTAB事業のグローバル化を計画する上で、この重要な市場に事業所を設立することは当社にとって自然な決定でした。」



中国では、成長する市場調査業界で、mTABが日本、欧州、米国の市場で提供しているのと同様なツールがますます求められています。中国市場をサポートするために、mTABは市場調査研修企業のアナリティック・エッジと戦略的提携を結びました。



アナリティック・エッジ創業者のジュンボ・ズー氏は、次のように述べています。「中国市場は非常にユニークで大きいため、市場内に実際に存在を置くことが不可欠です。」



この拡大により、お客様は統合されたソフトウエア&サービス提供プラットフォームを通じて、それぞれの言語と時間帯という気楽さでシームレスなサービスを期待いただけます。



詳細については、www.mtabsurveyanalysis.comをご覧ください。



mTABについて



mTABが提供するフルサービスのウェブベース・ソフトウエアにより、企業は過去・現在のマーケティング調査の価値を最大化することを可能にします。私たちのソフトウエアは、不均一、また膨大なデータセットを誰でも分析しやすく、即時に利用可能にします。mTABを使用することで、重要なビジネス上の意思決定、調査データの背後にある物語をあらゆるレベルのユーザーが発見できるようアシストします。



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。


Contacts


mTAB
Katie Duffey, 1-714-693-3110
kduffey@mtabsurveyanalysis.com

According to THE SAGE GROUP, 1 Million or More Japanese Cit… 2017年05月22日 23時22分

BEAUFORT, S.C.--(BUSINESS WIRE)--$CLI #CLI--A new analysis published by THE SAGE GROUP concludes that
atherosclerotic peripheral arterial disease (PAD) afflicts 8-10 million
in Japan.




“Although it is commonly believed that PAD is a ‘Western’ disease with a
significantly lower prevalence in Asians, our research indicates this is
not the case,” stated Mary L. Yost, President of THE SAGE GROUP. “We
believe that PAD prevalence is only modestly lower. For various reasons,
it has generally been underestimated in Japan.”



As with other cardiovascular diseases, age, smoking, diabetes,
hypertension, high cholesterol, chronic kidney disease, race and family
history are the key PAD and CLI risk factors. The relative risk of PAD
increases 2X-3X with every decade, current smoking increases the risk
2X-5X and diabetes 2X-4X. Furthermore, PAD is more virulent in
diabetics. Diabetics tend to have more severe ischemia, a greater number
of amputations, higher mortality, and die at a younger age.



Commenting on risk factors in Japan, Yost observed, “Over the last
several decades, the prevalence of diabetes has risen significantly.
Japan has a high percentage of younger-onset diabetes, which increases
the risk of cardiovascular complications, including PAD. In addition,
the population is quite elderly (the oldest in the world) with a high
prevalence of other PAD risk factors, including hypertension, smoking
and chronic kidney disease. Current smoking is much more prevalent in
Japan than in the U.S.



“Unless the Japanese people have some type of genetic protection against
the adverse impact of atherosclerotic risk factors, the prevalence of
PAD is likely reasonably similar to that in other populations,” she
concluded.



About the Report: Japan Peripheral Artery Disease and Critical Limb
ischemia Prevalence and Incidence of



The report contains a comprehensive analysis of the current prevalence
of diabetes, PAD and CLI in Japan. PAD and CLI prevalence and incidence
are estimated for 2015-2030. The number of patients with intermittent
claudication is also included in the analysis of symptomatic disease.



Additional information: http://thesagegroup.us/pages/reports/japan-pad-cli.php.



THE SAGE GROUP, a research and consulting company, specializes in
peripheral vascular disease in the lower limbs, specifically chronic
venous disease (CVD), PAD, CLI, intermittent claudication (IC), diabetic
foot ulcers (DFU) and the costs and consequences of amputation.
Additional information: www.thesagegroup.us.




Contacts


THE SAGE GROUP
Harrington Witherspoon, 404-816-0746
witherspoon@thesagegroup.us



Keio Plaza Hotel Tokyo Hosts the Exhibition of "Noh" Japane… 2017年05月22日 23時00分


Introducing Wooden Masks, Costumes from the Renowned Noh Play
“Hagoromo” Feather Robe


TOKYO--(BUSINESS WIRE)--#art--Keio
Plaza Hotel Tokyo
, one of Japan’s most prestigious international
hotels located in Shinjuku, Tokyo, will host a special exhibition
entitled “Enjoying Japan’s Traditional Performing Art Noh” from
June 1st to 29th, 2017. This is the second
consecutive year that the hotel will host a special Noh
exhibition in cooperation with the National
Noh Theatre.
This year’s exhibition focuses upon “Hagoromo (Feather
Robe)”, a famous Noh play based upon the celestial maiden legend,
and will display traditional carved wooden Noh masks, intricately
woven Noh costumes, and other related artistic props used in Noh
performances. During this exhibition, a special performance of
“Hagoromo” will be held by prominent Noh performer Yoshimasa
Kanze on June 13th followed by a special luncheon. Another
unique opportunity to see this classic stage art up close will be during
a free Noh demonstration in the Main Lobby, on June 21st
at 5:00 p.m. This short demonstration is for both visitors and staying
guests.








Noh
has been performed for over 600 years since its creation in the
Muromachi Period, and is the oldest theatrical art performed in the
world. In recognition of the highly refined acting and artistic
performances of Noh and its influence upon various genre of
modern art around the world to this day, Noh was registered as a
UNESCO World Intangible Cultural Heritage in 2008. Our hotel is pleased
to provide its guests, 75% of whom are overseas visitors from 100
different countries, with the opportunity to enjoy the Noh Play
“Hagoromo” exhibition as part of our Japanese cultural experience
programs.



Full
Version of Press Release



About the Keio Plaza Hotel



Keio
Plaza Hotel Tokyo
is one of Japan’s
leading international hotels. Our hotel boasts of over 20 restaurants
and bars, and we host a wide range of local and international guests who
visit us for our welcoming facilities, warm hospitality and unique
services that allow them to experience Japanese culture, including our Hello
Kitty themed rooms
, wedding
kimono experience
, tea
ceremony
, ikebana
experience
and many
others
. For more information, please visit our website,
YouTube,
Facebook
or Instagram.




Contacts


Keio Plaza Hotel Tokyo
Sunaho Nakatani, +81-3-5322-8010
Public
Relations Manager
s-nakatani@keioplaza.co.jp



Otsuka Announces Results of Phase 3 Data on Tolvaptan 2017年05月22日 21時00分


Under Development for ADPKD in U.S.




  • Primary and key secondary endpoints were positive for tolvaptan vs.
    placebo in an additional Phase 3 clinical trial that examined the
    efficacy and safety of tolvaptan in autosomal dominant polycystic
    kidney disease (ADPKD)


  • The data are intended to address the Complete Response Letter (CRL)
    issued by the FDA for a New Drug Application (NDA) for tolvaptan in
    ADPKD in 2013


  • Trial results will be submitted for presentation at a nephrology
    medical congress in the second half of 2017


TOKYO--(BUSINESS WIRE)--Otsuka
Pharmaceutical Co., Ltd.
(Otsuka) announces positive top-line
results from an additional Phase 3 clinical trial of tolvaptan in adult
patients with ADPKD.



The primary endpoint of the trial was the change in estimated glomerular
filtration rate (eGFR) from pre-treatment baseline levels to
post-treatment assessment. In patients treated with tolvaptan the
reduction in eGFR was significantly less than in patients treated with
placebo (p<0.0001). eGFR is an estimate of the sum of the filtration
rates of all single functional nephrons (filtering units) in the
kidneys, measured through creatinine-based estimation equations.1
The difference observed in this study represents a 35% reduction in the
loss of kidney function compared to placebo in these patients over the
course of one year. The key secondary endpoint was a comparison of the
efficacy of tolvaptan treatment versus placebo in reducing the decline
of annualized eGFR slope across all measured time points in the study.
These data also showed significant benefit from tolvaptan vs. placebo
(p<0.0001).



The trial was completed to supply confirmatory data to the previous study2
to address the Complete Response Letter (CRL) issued by the U.S. Food
and Drug Administration (FDA) in 2013 for a New Drug Application (NDA)
for tolvaptan in the treatment of adults with ADPKD.



The Phase 3, multicenter, international, randomized-withdrawal,
placebo-controlled, double-blind trial compared the efficacy and safety
of tolvaptan (45 to 120 mg/day) to placebo. Trial enrollees were adults
18 to 65 years of age with ADPKD-induced chronic kidney disease between
late stage 2 to early stage 4 (eGFR ranging from 65-25 mL/min) and not
previously treated with tolvaptan. A total of 1,370 patients were
randomized to either tolvaptan or placebo and were treated for a period
of 12 months.3



There were no new safety issues identified for tolvaptan during the
trial. As in the prior study,2 tolvaptan resulted in more
patients than placebo with increased (>3x upper limit of normal (ULN))
levels of liver enzymes alanine aminotransferase (ALT; 5.6% vs. 1.2%)
and aspartate aminotransferase (AST; 3.5% vs. 0.9%); however, none of
these patients exhibited total bilirubin greater than 2x ULN. The most
common adverse events associated with tolvaptan (incidence >5% and at
least 1% more frequent than placebo) included diarrhea (6.9% vs. 3.4%),
fatigue (6.8% vs 3.5%) and polyuria (5.3% vs. 1.6%).



Results from the trial will be submitted for presentation at a
nephrology medical congress in the second half of 2017.



About Tolvaptan and ADPKD



Tolvaptan is a selective vasopressin V2-receptor antagonist.
By selectively blocking vasopressin at the V2-receptor,
tolvaptan has been shown to decrease cyst-cell proliferation and fluid
secretion, ultimately reducing cyst development.4 In a
previous Phase 3 clinical trial, tolvaptan was associated with reduced
kidney growth and slowed decline of kidney function.2



ADPKD, a multi-systemic disease that is caused by inherited or acquired
genetic mutation(s), is characterized by the formation and enlargement
of cysts.5 Cyst growth and proliferation eventually lead to
kidney damage, and often cause complications that include pain and
hypertension.6,7 Up to 50% of patients require renal
replacement therapy by the age of 60.6 In addition to the
physical effects, ADPKD causes psychological and emotional burden for
those living with the disease and their loved ones.8



Tolvaptan is approved for the treatment of adult patients with ADPKD in
Japan, the EU and other countries (see local prescribing information for
specific indications in each country).



About Otsuka



Otsuka Pharmaceutical is a global healthcare company with the corporate
philosophy: “Otsuka – people creating new products for better health
worldwide.” Otsuka researches, develops, manufactures and markets
innovative and original products, with a focus on pharmaceutical
products to meet unmet medical needs and nutraceutical products for the
maintenance of everyday health.



In pharmaceuticals, Otsuka is a leader in the challenging area of mental
health and also has research programs on several under-addressed
diseases including tuberculosis, a significant global public health
issue. These commitments illustrate how Otsuka is a “big venture”
company at heart, applying a youthful spirit of creativity in everything
it does.



Otsuka Pharmaceutical is a subsidiary of Otsuka Holdings Co., Ltd.,
headquartered in Tokyo, Japan, with 2016 consolidated sales of
approximately $11 billion.



All Otsuka stories start by taking the road less travelled. Learn more
about Otsuka in the U.S. at www.otsuka-us.com
and connect with us on LinkedIn
and
Twitter at @OtsukaUS.
Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/.



_________________



1 Lascano M., Poggio E. Kidney function assessment by
creatinine-based estimation equations. Cleveland Clinic, Center For
Continuing Education. 2010. [Accessed May 15, 2017] http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/kidney-function/



2 Torres VE, Harris PC et al. Tolvaptan in patients with
autosomal dominant polycystic kidney disease. NEJM. 2012;367 (25):
2407-2418



3 Torres VE, Devuyst, O et al. Rationale and design of a
clinical trial investigating tolvaptan safety and efficacy in autosomal
dominant polycystic kidney disease. Am J Nephrol. 2017; 45 (3),
257-266



4 Reif, GA, Yamaguchi, T et al. Tolvaptan inhibits
ERK-dependent cell proliferation, Cl – secretion, and in vitro cyst
growth of human ADPKD cells stimulated by vasopressin. Am J Physiol
Renal Physiol; 2011; 301:F1005-F1013



5 Tan Y, Blumenfeld J, and Rennert H. Autosomal dominant
polycystic kidney disease: genetics, mutations and microRNAs. Biochimica
Biophysica Acta. 2011;1812:1202-1212



6 Torra, R. Polycystic kidney disease. Medscape. 2017.
[Accessed May 19, 2017] http://emedicine.medscape.com/article/244907-overview



7 Thong KM, Ong ACM. The natural history of autosomal
dominant polycystic kidney disease: 30-year experience from a single
centre. QJM. 2013;2-8



8 Baker A, King D et al. Understanding the physical and
emotional impact of early-stage ADPKD: experiences and perspectives of
patients and physicians. Clin Kidney J. 2015; 8(5): 531–537


Contacts


Otsuka Pharmaceutical
(In Japan)
Jeffrey Gilbert,
81-3-6361-7379
Leader, Pharmaceutical Public Relations
Gilbert.jeffrey@otsuka.jp
or
(In
the U.S.)
Otsuka America Pharmaceutical, Inc.
Kimberly
Whitefield, +1-609-535-9259
Corporate Communications
kimberly.whitefield@otsuka-us.com

L&T Technology Services Limited Positioned in Winners Circl… 2017年05月22日 20時30分


Strong capabilities in Smart Manufacturing, Manufacturing IoT &
Automation, Visual Data Analytics, Robotics, Digital Clone & 3D Printing
among others




BANGALORE, India--(BUSINESS WIRE)--#3Dprinting--L&T Technology Services Limited (NSE: LTTS), a leading global pure-play
engineering services company, announced it has been positioned in the
“Winners Circle” by HfS Research, The Services Research Company™ in its
maiden Industry 4.0 Services Blueprint Assessment. HfS Research is a
leading independent global analyst firm for the business and technology
services industry.






L&T Technology Services was rated as having strong global capabilities
in domains such as Manufacturing Data Analytics, Robots, Manufacturing
Automation, Digital Clone Simulation, 3D Printing, Manufacturing IoT,
Cybersecurity, AR in Manufacturing and Visual Analytics in
Manufacturing, according to HfS.



For the report, HfS Research assessed a dozen service providers on use
cases and several end-to-end digitalization process areas to help
clients improve productivity on the manufacturing shop floor. L&T
Technology Services is the only pure-play engineering services company
in the HfS Winners Circle.



LTTS has worked with customers through the Smart Manufacturing value
chain – from smart components and machines to digital and connected
factories – and is now enabling enterprises to gain a competitive
advantage from implementation of Industry 4.0 through manufacturing
process optimization, streamlined supply chain, and enhanced inventory
and resource management.



The report’s Industry 4.0 vision covers a variety of
manufacturing-related areas, including improving costs, efficiency, time
savings and flexibility in manufacturing. Industry 4.0 is a smarter
manufacturing approach that uses technology to connect the whole
enterprise with digitized manufacturing operations for greater autonomy
and flexibility.



The HfS report notes that LTTS has developed a broad portfolio of
proprietary technologies and platforms, including its IoT platform
UBIQWEISE, virtual simulation tool VISIT, energy monitoring solution
WAGES, and InspectAR, an augmented reality solution for plants, and
these solutions will enable its customers to accelerate implementations
and realize the benefits of Industry 4.0.



“L&T Technology Services’ deep understanding of Plant Engineering and
track record of making products and manufacturing smarter, established
it in the Winners Circle. The company’s outstanding engineering heritage
and skilled workforce enable LTTS to solve complex factory problems.
LTTS’ current client engagements are spread across multiple
sub-verticals within the manufacturing industry, thereby enabling the
company to utilize this cross vertical knowledge for further
innovation,” said Mr Pareekh Jain, Managing Director, India at HfS
Research.



Dr Keshab Panda, CEO & Managing Director, L&T Technology Services
Limited, said: “Industry 4.0 is the backbone of the new age of
industrial and plant innovation and being positioned in the winner’s
circle is a testimony to the depth of our offerings and solutions which
are being used globally by our customers across the Smart Manufacturing
domain.



“Through its digital engineering solutions, L&T Technology Services will
continue to successfully address multiple areas of technology and
engineering which need to come together to create plants of the future,”
Dr Panda added.



About L&T Technology Services Limited:



L&T Technology Services Limited is a subsidiary of Larsen & Toubro
Limited focused on Engineering and R&D Services (ER&D) addressing global
customers including Fortune 500 companies. A leading pure-play
engineering services company, L&T Technology Services offers
consultancy, design, development and testing services across the product
and process development life cycle for various industrial products,
medical devices, transportation, telecom & hi-tech, and the process
industries. Digital Engineering portfolio of offerings from L&T
Technology Services help build Smart Products & Services and offer Smart
Manufacturing services and solutions to customers. The company also
offers services and solutions in software engineering, embedded systems,
mechanical & manufacturing engineering, value engineering and plant &
process engineering.



Headquartered in India, L&T Technology Services Limited has more than
11,000 employees, 12 global delivery centers in India and overseas, 27
sales offices in India, North America Europe, the Middle East and Asia
and 34 labs in India as of March 31, 2017. For additional information
about L&T Technology Services log on to www.LntTechservices.com.


Contacts


L&T Technology Services Limited
Aniruddha Basu, +91-80-67675173
Aniruddha.Basu@LntTechservices.com

IBMが世界的な特許及び商標ポートフォリオを管理するため、 ア… 2017年05月22日 20時00分

ボストン--(BUSINESS WIRE)--(ビジネスワイヤ) --本日、知財管理と特許分析に関するソフトウェアおよびサービスにおいて世界をリードするAnaqua,Inc.は、
IBMが世界的な特許及び商標ポートフォリオを管理するために、アナクアのソリューションを採用したことを発表しました。




「IBMのようなグローバル・イノベーション・リーダーによって選ばれたことは誠に光栄です。」また、「私たちは、世界で最も洗練されたの知財運用業務の1つをサポートする機会を得られたことを大変うれしく思います。」と、アナクアのCEO
であるボブ・ロミオは述べています。



IBMの先進的なクラウドプラットフォームでホストされるアナクアの知財管理システムをIBMが採用した理由は、アナクアの知財管理業務に関する深い知識、洗練かつ完成されたソリューション、また、最新の技術を積極的にソフトウェアに取り入れるという開発方針にあります。



アナクアは、先般、優先的なグローバル・クラウド・プロバイダーとしてIBMクラウドを採用しました。東京とアムステルダムにあるIBMクラウド・データセンターを通じ、日本やオランダへも進出を果たし、世界的に事業を拡大しています。また、IBMは、六大陸に渡る19カ国に55以上のクラウド・データセンターを設置し、世界的なクラウド基盤を提供しています。



IBMは、2016年中に80,88件の米国特許を取得し、米国特許取得数の年間記録を更新すると同時に24年間連続で首位となっています。



*****



アナクア について



アナクアは、企業や法律事務所を支援し、知的財産をより競争優位にする企業です。アナクアのソフトウェアプラットフォームは、ビッグデータ分析による知見、重要なツール類、ベストプラクティスのワークフローやサービスを1つの効率的で知的な環境に統合しているため、ユーザーはより効率的に知財業務を行い、より迅速に、より適切な判断を下すことができます。世界的な有名ブランドや最も革新的な製品の多くが、アナクアのプラットフォーム上で、概念化され、評価され、権利化され、収益化されています。アナクアは、コカコーラ、フォード、キンバリークラーク、ブリティシュアメリカンタバコの知財管理のリーダー達により2004年に設立された非公開企業です。




Contacts


Anaqua
Tony
Catinella, +1 (617) 375-2626
広報マネージャー
acatinella@Anaqua.com



Anaqua Intellectual Property Management Platform to Manage … 2017年05月22日 20時00分

BOSTON--(BUSINESS WIRE)--#IP--Anaqua,
Inc.
, a leading provider of intellectual property management and
analytics software and services, today announced that IBM has selected
Anaqua’s solution to manage its global patent and trademark portfolio.




“It is a tremendous honor to be selected by a global innovation leader
like IBM,” said Bob Romeo, CEO of Anaqua. “We are excited over the
opportunity to support one of the world’s most sophisticated IP
operations.”



IBM chose Anaqua’s intellectual property management platform because of
its deep knowledge of IP processes and a sophisticated out-of-the-box
solution, combined with an aggressive technical roadmap that ensures
incorporation of the latest technology into the software, which is
hosted on IBM’s industry leading Cloud platform.



Anaqua recently
selected IBM Cloud
as its preferred global cloud provider and is
expanding its global presence into Japan and the Netherlands via IBM
Cloud data centers in Tokyo and Amsterdam. IBM's global footprint
includes more than 55 cloud data centers in 19 countries across six
continents.



IBM has been the leading recipient of U.S. patents for 24 consecutive
years, including a record-setting
total
of 8,088 patents granted to its inventors in 2016.



ABOUT ANAQUA
Anaqua
helps corporations and law firms turn intellectual property into
competitive advantage. Its software platform combines insight from big
data analytics with critical tools, best practice workflows and services
into one efficient, intelligent environment that helps IP practices work
more efficiently and make better decisions faster. Many of the
best-known brands and most innovative products were conceptualized,
evaluated, protected and monetized through the ANAQUA platform. Founded
in 2004 by IP leaders from The Coca-Cola Company, Ford Motor Company,
Kimberly-Clark and British American Tobacco, Anaqua is a privately held
company.




Contacts


Anaqua
Tony
Catinella, 617-375-2626
Public Relations Manager
acatinella@Anaqua.com



FUJIFILM KYOWA KIRIN BIOLOGICS Announces Marketing Authoris… 2017年05月22日 15時30分

TOKYO--(BUSINESS WIRE)--FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. (President & CEO: Hideaki
Nomura; “Fujifilm Kyowa Kirin Biologics”) announces that on May 18,
2017, the European Medicines Agency (EMA) has accepted for review the
Marketing Authorisation Application (MAA) for FKB327, an adalimumab
biosimilar candidate to the fully human anti-TNF-α*1
monoclonal antibody, Humira®.



In December 2014, Fujifilm Kyowa Kirin Biologics began a Phase 3 global
clinical study of FKB327 at sites in the US, Europe and other countries
to compare the efficacy and safety profile of FKB327 with Humira®(reference
product) in patients with moderate to severe rheumatoid arthritis*2.
In this study, FKB327 met the primary endpoint and prespecified criteria
for equivalence, and there were no significant differences in the rate
of adverse events between FKB327 and Humira®. Based on the
top-line results, announced on October 19, 2016, Fujifilm Kyowa Kirin
Biologics decided to file the MAA for FKB327 to EMA in April 2017.



“We are delighted that EMA has accepted the application,” said Hideaki
Nomura, President & CEO of Fujifilm Kyowa Kirin Biologics. “The
acceptance of this filing brings us one step closer to meeting the
demand for high quality and affordable biopharmaceuticals.”



Fujifilm Kyowa Kirin Biologics was established by FUJIFILM Corporation
(President & COO: Kenji Sukeno; “Fujifilm”) and Kyowa Hakko Kirin Co.,
Ltd. (President and CEO: Nobuo Hanai; “Kyowa Hakko Kirin”) on March 27,
2012 as a company for the development, manufacture, and marketing of
biosimilars.



Fujifilm Kyowa Kirin Biologics creates revolutionary production
processes and reduces the production cost of biosimilars by merging the
technologies in advanced production, quality control and analysis which
Fujifilm has developed over many years through its photographic film
business, with the proprietary technologies and know-how accumulated by
Kyowa Hakko Kirin through its biopharmaceutical R&D and manufacture. As
the results of this partnership, the goal of Fujifilm Kyowa Kirin
Biologics is to develop and manufacture reliable, high quality,
cost-competitive biosimilar products that it will commercialise in a
timely manner. Through this strategy, Fujifilm Kyowa Kirin Biologics
aims to attain a leading position in the expanding biosimilar market.
For more information about Fujifilm Kyowa Kirin Biologics, please visit http://fujifilmkyowakirin-biologics.com/en/.

















 

*1

 

TNF-α (tumor necrosis factor alpha) is a cytokine that is involved
in inhibition of tumorigenesis and defense against infection.
Overexpression of TNF-α is implicated in a range of inflammatory
diseases, including rheumatoid arthritis and psoriasis.

*2


Rheumatoid arthritis is an inflammatory autoimmune disorder that
affects the joints, in particular arms and legs. It typically
results in painful joints and joint degeneration, leading to
deterioration of the daily functional activities. The disease may
also cause malaise as one of the general symptoms.



Contacts


FUJIFILM Corporation
Kana Matsumoto, +81-3-6271-2000
Corporate
Communications Division
or
Kyowa Hakko Kirin Co., Ltd.
Hiroki
Nakamura
Corporate Communications Department
media@kyowa-kirin.co.jp

Poxel Presents Imeglimin Japanese Phase 1 Results and Mecha… 2017年05月22日 15時00分



  • Phase 1 data in Japanese subjects demonstrated Imeglimin was safe,
    well tolerated and exhibited a similar pharmacokinetic profile to what
    was observed in Caucasian subjects



  • Mechanistic data shows Imeglimin’s benefit on beta cell protection
    and details its unique insulin secretion pathway in response to glucose



LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company
focused on the development of innovative treatments for metabolic
disorders, including type 2 diabetes, announced today the presentation
of a comprehensive summary of the Phase 1 data of Imeglimin in Japanese
subjects (healthy volunteers) and additional preclinical mechanistic
data on Imeglimin’s unique mechanism of action in insulin secretion in
response to glucose. The data were presented in two oral presentations
at the 9th Scientific Meeting of the Asian Association for
the Study of Diabetes (AASD) in Nagoya, Japan. Imeglimin has completed
Phase 1 and Phase 2 development in approximately 1,200 patients and
subjects in the U.S., EU and Japan and is ready for Phase 3 development.




“We are honored to have the opportunity to present at this prestigious
scientific diabetes meeting. The presentations include Imeglimin Phase 1
results from the study conducted in Japanese subjects, as well as
important mechanistic data, which we believe may be in part related to
the robust Phase 2b efficacy results seen in Japanese patients,” said
Thomas Kuhn, CEO of Poxel. “Diabetes is a growing health concern in
Asia, and Japan is a key focus and an integral part of our business
strategy. We are encouraged that Imeglimin could become an innovative
new treatment option for Japanese patients with type 2 diabetes. Based
on its differentiated product profile, Imeglimin is a prime candidate
for first-line monotherapy and as an add-on to other glucose lowering
therapies. We anticipate that the Phase 3 program for Imeglimin in Japan
will be initiated during the fourth quarter of 2017.”



In the first presentation titled “Safety, Tolerability and
Pharmacokinetics of Imeglimin in Healthy Japanese Subjects,”
Poxel’s
Chief Scientific Officer presented a summary of the full data set
from the double-blind, randomized and placebo-controlled Phase 1 study
in 48 Japanese subjects. The data demonstrated a good tolerability
profile of up to 6,000 mg with no safety signals identified after a
seven-day multiple-dose regimen. The pharmacokinetics observed in
Japanese subjects was consistent with previous observations in the
Caucasian study.



The second oral presentation titled “Imeglimin Increases Insulin
Secretion in Response to Glucose as a Unique Mechanism of Action
Depending on NAD Synthesis,”
provides data that further strengthens
the understanding of Imeglimin’s unique mechanism of action resulting in
an improvement of insulin secretion in response to glucose. This
response has been shown in different preclinical models of diabetes as
well as in type 2 diabetic patients. This increase in insulin secretion
in response to glucose was demonstrated to be dependent on Imeglimin’s
effect on nicotinamide adenine dinucleotide (NAD) biosynthesis, a
crucial component of mitochondrial function. In addition to improving
beta cell function, Imeglimin has also been shown to preserve the
beta-cell mass, which could potentially delay disease progression.
Furthermore, a synergistic effect between Imeglimin and GLP-1 on insulin
secretion in response to glucose was observed, highlighting a distinct
mode of action compared to GLP-1. In addition to being a prime candidate
for monotherapy, these data also support use of Imeglimin in combination
therapy with GLP-1 agonists and DPPIV inhibitors.



“We have made significant progress in understanding how Imeglimin’s
unique dual mechanism of action improves both insulin sensitivity and
insulin secretion, which are the two key defects that cause type 2
diabetes,” commented Sebastien Bolze, Pharm.D, PhD, Poxel’s Chief
Scientific Officer and Executive Vice President, Non-Clinical
Development. “Imeglimin’s effect on insulin secretion could be
particularly well-suited for Japanese type 2 diabetes patients because
they may experience an early defect of insulin secretion. This important
effect may have also contributed in part to the strong efficacy seen in
our Phase 2b study in Japanese patients.”



Both presentations from the 9th scientific meeting of the
AASD are available on the Company’s website under “Scientific
Publications” or by using the following link http://poxel.com/our-science/scientific-publications.php



About Imeglimin
Imeglimin is the first clinical candidate in
a new chemical class of oral agents called the Glimins. Imeglimin has a
unique mechanism of action (MOA) that targets mitochondrial
bioenergetics. Imeglimin acts on the three main target organs involved
in glucose homeostasis: the liver, muscle, and the pancreas. This MOA
has the potential for glucose lowering benefits, as well as the
potential to prevent endothelial dysfunction, which can provide
protective effects on micro- and macro-vascular defects induced by
diabetes. The additional protective effect on beta-cell survival and
function may lead to a delay in disease progression. This unique mode of
action compared to existing treatments for type 2 diabetes makes
Imeglimin a prime candidate in all stages of the current anti-diabetic
treatment paradigm, including monotherapy or as an add-on to other
glucose lowering therapies for the treatment of patients with type 2
diabetes.



About Poxel SA
Poxel uses its development expertise in
metabolism to advance a pipeline of drug candidates focused on the
treatment of metabolic disorders, including type 2 diabetes. We have
successfully completed our Phase 2 clinical program for our
first-in-class lead product, Imeglimin, which targets mitochondrial
dysfunction, in the U.S., EU and Japan. Our second program, PXL770, a
direct AMPK activator, is in Phase 1 development. We intend to generate
further growth through strategic partnerships and pipeline development.
(Euronext: POXEL, www.poxel.com)




Contacts


Poxel SA
Jonae R. Barnes, +1 617-818-2985
Senior
Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
or
Investor
relations / Media - EU/US

MacDougall Biomedical Communications
Gretchen
Schweitzer or Stephanie May, + 49 89 2424 3494 or + 49 175 571 1562
smay@macbiocom.com
or
Investor
relations / Media - France

NewCap
Florent Alba/Nicolas
Mérigeau, + 33 1 44 71 98 55
poxel@newcap.fr



Toyoda Gosei Establishes New Automotive Parts Plant in Guja… 2017年05月22日 14時00分

KIYOSU, Japan--(BUSINESS WIRE)--Toyoda Gosei Co., Ltd. is establishing a new plant to meet growing
automobile production in India and the expected increase in demand for
airbags as stricter safety regulations are adopted.








The new plant is located in the western Indian state of Gujarat. It will
be a branch plant of Toyoda Gosei Minda India Private Limited (TGMIN), a
subsidiary of Toyoda Gosei. The new Gujarat Plant will begin supplying
airbags, weatherstrips and other automotive parts to Suzuki Motor
Gujarat (SMG) in the second half of fiscal 2018. The investment in the
production facility is 732 million rupees.



Toyoda Gosei views India as an important market, and has been expanding
production capacity in the country. After the new plant comes on line,
Toyoda Gosei will have a production network of five plant locations in
India. Total sales in India were approximately 14 billion JPY in FY2016,
and the company aims to expand this 1.4-fold to approximately 20 billion
JPY by 2021*1.



*Calculated at 1 rupee = JPY1.6




























































Outline of Gujarat Plant (New Plant)



 

1. Plant name

 

Toyoda Gosei Minda India Gujarat Plant

 

2. Location


Mandal, Gujarat, India (approx. 30 km from SMG)

 


3. Start of production




Second half FY2018

 

4. Capital expenditure


732 million rupees

 

5. Products



Safety systems (airbags, steering wheels)
Weatherstrips etc.



 

6. Area



Land: Approx. 20,000 m2
Buildings: Approx. 8,500 m2



 

7. No. of employees


Approx. 330 (predicted as of end of March 2021)

 

8. Sales

 

Approx. 2.5 billion rupees (forecast for FY2021)

 












































































Outline of TGMIN (reference)



 


1.



 


Company name



 

Toyoda Gosei Minda India Private Limited

 


2.



 


Location
(Headquarters plant)




Neemrana, Rajasthan, India

 


3.



 


Established




April 2008

 


4.



 


Capital




3.29 billion rupees

 


5.



 


Shareholders





Toyoda Gosei Co., Ltd.
Minda Investments Limited
Toyota
Tsusho Corp.



 


6.



 


Products





Safety systems (airbags, steering wheels)
Weatherstrips etc.



 


7.



 


No. of employees




1,324 (as of March 2017)

 


8.



 


Sales



 


Approx. 3.9 billion rupees (FY2016 results)
Approx. 8.0
billion rupees (FY2021 forecast)



 



About Toyoda Gosei
Established in 1949 and headquartered in
Kiyosu, Aichi Prefecture, Japan, Toyoda Gosei is a leading specialty
manufacturer of rubber and plastic automotive parts and LEDs. Today, the
Toyoda Gosei Group provides a variety of high-quality products
internationally, with a network of approximately 100 plants and offices
in 18 countries and regions. Through its flexible, integrated global
supply system and leading-edge technologies for automotive safety,
comfort, and environmental preservation, Toyoda Gosei is a global
supplier that aims to deliver the highest levels of quality, innovation,
and satisfaction to customers worldwide
.




Contacts


Toyoda Gosei Co., Ltd.
Takatomo Abe
inquiry@mail.toyoda-gosei.co.jp

株式会社ピューズ・人とくるまのテクノロジー展2017 横浜出展の… 2017年05月22日 08時00分

東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 電気自動車の車両開発、テクニカルコンサルティング、部品販売を行う(株)ピューズ
(本社:東京、代表取締役社長:大沼伸人、www.pues.co.jp)は、2017年5月24日(水)から26日(金)まで、パシフィコ横浜・展示ホール(横浜市西区)で開催される(公社)自動車技術会主催
自動車技術展「人とくるまのテクノロジー展2017横浜」(画像: http://www.pues.co.jp/images/170519_pers01.jpg)にグループ会社の(株)東京アールアンドデー(www.tr-d.co.jp)、東京R&Dコンポジット工業(株)(www.trdc.co.jp)と3社で共同出展いたします。




本展示会では、「電気バス用バッテリパック(UN-ECE-R100.02の安全基準認証済)」(画像:http://www.pues.co.jp/release/nbc.jpg)、「電動小型車両用急速充電器(DC48V対応)」、「モータ」、「インバータ」、「バッテリ制御システム(BMS)」、「絶縁劣化検知センサー(CEL4)」「燃料電池試験モジュール」(画像:http://www.pues.co.jp/images/170519_fc-test-module01.jpghttp://www.pues.co.jp/images/170519_fc-test-module02.jpg)など次世代自動車技術に繋がる幅広い要素を展示いたします。



■会期:2017年5月24日(水)~26日(金)AM10:00 ~ PM6:00 (26日のみPM5:00)



■場所:パシフィコ横浜・展示ホール(横浜市西区みなとみらい一丁目1番1号)



■小間番号:(株)ピューズ【350】



■展示会オフィシャルサイト:http://expo.jsae.or.jp/


Contacts


【本件に関する問い合わせ先】
株式会社ピューズ
担当:商事部 淺野 晃司
TEL:046-226-5501
FAX:046-226-5505
MAIL:asano.koji@pues.co.jp

SoftBank Vision Fund Announces First Major Close 2017年05月20日 23時30分


In Addition to the Public Investment Fund, SoftBank Group and
Mubadala, Initial Investors in Global Technology Fund include Apple,
Foxconn, Qualcomm and Sharp



SoftBank Vision Fund Seeks to Accelerate Information Revolution


SAINT HELIER, Jersey--(BUSINESS WIRE)--The SoftBank Vision Fund (the “Fund”) today announced its first major
close with over U.S.$93 billion of committed capital. In addition to
SoftBank Group Corp (“SBG”) and the Public Investment Fund of the
Kingdom of Saudi Arabia (“PIF”) as previously announced, investors in
the Fund also include the Mubadala Investment Company of the United Arab
Emirates (“Mubadala”), Apple Inc. (“Apple”), Foxconn Technology Group
(“Foxconn”), Qualcomm Incorporated (“Qualcomm”) and Sharp Corporation
("Sharp"). The Fund is targeting a total of U.S.$100 billion of
committed capital, with a final close within six months.







SBG created the SoftBank Vision Fund as a result of its strongly held
belief that the next stage of the Information Revolution is underway,
and building the businesses that will make this possible will require
unprecedented large scale long-term investment. Additionally, the Fund’s
portfolio companies are expected to significantly benefit from SBG's
global scale and operational expertise, as well as its ecosystem of
group portfolio companies (including Sprint and Yahoo Japan); this will
thereby help them to accelerate their own growth profile.



The Fund will be SBG’s primary vehicle to realise its SoftBank 2.0
vision, with preferred access to investments of U.S. $100 million or
more that meet the Fund's investment strategy.



Masayoshi Son, Chairman & CEO of SoftBank Group Corp. said:



“Technology has the potential to address the biggest challenges and
risks facing humanity today. The businesses working to solve these
problems will require patient long-term capital and visionary strategic
investment partners with the resources to nurture their success.
SoftBank has long made bold investments in transformative technologies
and supported disruptive entrepreneurs. The SoftBank Vision Fund is
consistent with this strategy and will help build and grow businesses
creating the foundational platforms of the next stage of the Information
Revolution.”



H.E. Yasir Al Rumayyan, Managing Director of the Public Investment Fund
of the Kingdom of Saudi Arabia, added:



“Our investment in the SoftBank Vision Fund alongside other sovereign
and corporate investors is an important part of our overall investment
strategy. We are building a portfolio that is diversified across
sectors, asset classes and geographies, and expect the Vision Fund to
act as a platform to access a range of exciting, emerging opportunities
in the technology sector. We expect that this will, in turn, help enable
the Public Investment Fund’s role in supporting the Kingdom of Saudi
Arabia’s Vision 2030 strategy to develop a diversified, knowledge-based
economy.”



Khaldoon Khalifa Al Mubarak, Group CEO of Mubadala Investment Company,
said:



“Our participation in the SoftBank Vision Fund perfectly complements
Mubadala’s strategy as a long-term global investor and partner to the
technology sector’s high-growth companies. Technology and innovation are
central to the UAE’s economic diversification strategy, and we believe
the Vision Fund has the scale to deploy significant capital into these
disruptive industries that are shaping the future.”



Investment Strategy



The Fund will target meaningful, long-term investments in companies and
foundational platform businesses that seek to enable the next age of
innovation.



The Fund will seek to acquire minority and majority interests in both
private and public companies, from emerging technology businesses to
established, multi-billion dollar companies requiring substantial growth
funding.



The Fund is expected to be active across a wide range of technology
sectors, including but not limited to: IoT, artificial intelligence,
robotics, mobile applications and computing, communications
infrastructure and telecoms, computational biology and other data-driven
business models, cloud technologies and software, consumer internet
businesses and financial technology.



The Fund will have the right to acquire certain investments already
acquired (or agreed to be acquired) by the SoftBank Group, including
24.99% of its holding in ARM, and investments in Guardant Health,
Intelsat, NVIDIA, OneWeb and SoFi.



Key Leadership



The Fund will be advised by wholly-owned subsidiaries of SBG, known
collectively as “SB Investment Advisers”.



Rajeev Misra will serve as the CEO of SB Investment Advisers and will be
a member of the Investment Committee. He will play a key role in all
Fund transactions, supported by a highly-experienced global team across
offices in London, San Carlos, and Tokyo.



Nizar Al-Bassam and Dalinc Ariburnu of newly formed Centricus, who
advised on structuring and fund raising efforts for the Vision Fund,
will continue their roles as advisers.



ARM group




  • SBG’s commitment to invest U.S. $28 billion in the Fund will be
    partially satisfied through the in-kind contribution of approximately
    24.99% of the shares in ARM Holdings plc, at a value of approximately
    U.S.$8.2 billion.


  • ARM will continue to be a consolidated subsidiary of SBG. SBG will
    continue to control (directly and indirectly) 100% of the voting
    rights of ARM, through its retained ownership of approximately 75.01%
    of the shares and its ownership of the entities managing and advising
    the Fund.


  • In the course of discussions with certain investors in the Fund, a
    portion of ARM was requested to be transferred into the Fund based on
    the shared vision on the huge growth potential of ARM


  • There will be no change to the Board, governance structure or
    operations of ARM as a result of the transfer.


  • The investors in the Fund will not gain any special commercial
    benefits from ARM’s operating business.



Relationship to SoftBank Group Corp.




  • The Fund’s general partner is a wholly-owned subsidiary of SBG, as are
    each of the SB Investment Advisers, including the Fund’s primary
    investment adviser, SB Investment Advisers (UK) Limited.


  • SBG has subscribed for commitments of U.S. $28 billion to the Fund to
    be contributed through a combination of equity in ARM and cash on
    hand. The Fund will be consolidated by SBG for accounting purposes.


  • While the Fund will be the primary investment vehicle for investments
    in excess of U.S.$100 million consistent with the Fund’s investment
    strategy, SBG (and its subsidiaries) may continue to make certain
    investments outside of the Fund, including (but not limited to)
    investments in early stage VC, strategic investments done at the
    operating company level, and/or other investments which do not fall
    within the Fund’s investment strategy and criteria.



This statement is issued by SVF GP (Jersey) Limited, as general
partner of SoftBank Vision Fund L.P.



ENDS



Advisers



Linklaters LLP acted as fund counsel and provided tax support. Kirkland
& Ellis LLP acted as US regulatory counsel to the Fund, and Carey Olsen
as Jersey fund counsel. Mori Hamada & Matsumoto and Maples & Calder
provided additional legal and regulatory support. PwC provided tax,
operational build and programme delivery support. Aztec Group will
provide ongoing administration services. Goldman Sachs International
acted as financial advisor. Milltown Partners provided strategic
communications support.



Legal disclaimers



THE INFORMATION CONTAINED HEREIN (THE “INFORMATION”) IS SUBJECT
TO THE FOLLOWING DISCLAIMERS, NOTES AND QUALIFICATIONS.



No Offer. The distribution to you of the Information is made for
informational purposes only and does not constitute an offer to sell or
a solicitation of an offer to buy limited partnership interests in
SoftBank Vision Fund L.P. (together with, as the context may require,
any parallel fund, feeder fund, co-investment vehicle or alternative
investment vehicle, the “Fund”). The Information is not intended
to be relied upon as the basis for an investment decision, and is not,
and should not be assumed to be, complete. The contents of the
Information are not to be construed as legal, business or tax advice,
and each prospective investor in the Fund should consult its own
attorney, business advisor and tax advisor as to legal, business and tax
advice.



Forward-Looking Information. To the extent presented herein, any
projections or other estimates included in the Information, including
estimates of returns or performance, are forward-looking statements and
are based upon certain assumptions. Other events which were not taken
into account may occur and may significantly affect the actual returns
or performance of the Fund and/or any of the companies in which the
Fund, SoftBank Group Corp. (together with its subsidiaries, “SoftBank”)
or any of their applicable affiliates have invested or may invest. Any
assumptions should not be construed to be indicative of the actual
events which will occur. Actual events are difficult to project and
depend upon factors that are beyond the control of the Fund, SoftBank,
the manager of the Fund (the “Manager”), the general partner of
the Fund (the “General Partner”) and their respective affiliates,
members, partners, stockholders, other beneficial owners, managers,
directors, officers, employees, representatives, advisers or agents.
Certain assumptions have been made to simplify the presentation and,
accordingly, actual results may differ, perhaps materially, from those
presented herein. There can be no assurance that any specific investment
referenced herein will be profitable, that the Fund will achieve results
comparable to those presented or that investors in the Fund will not
lose any or all of their invested capital.



No Reliance. None of SoftBank, the Fund, the Manager, the General
Partner or any of their applicable affiliates makes any representations
or warranties, express or implied, as to the accuracy or completeness of
the Information. SoftBank, the Fund, the Manager, the General Partner
and their applicable affiliates will not be liable with respect to use
or reliance upon any of the Information in the evaluation of a potential
investment in the Fund or otherwise with the Manager, the General
Partner, SoftBank of any of their applicable affiliates. The Information
speaks as of the date hereof, or where applicable as of the date
indicated herein, and none of SoftBank, the Manager, the General
Partner, the Fund or their respective affiliates, members, partners,
stockholders, managers, directors, officers, employees or agents have
any obligation to update any of the Information.



Certain Estimates. To the extent presented herein, any
projections or estimates regarding the number, size or type of
investments that the Fund may make (or other similar information) are
estimates based only on the Manager’s intent as of the date of such
statements and are subject to change due to market conditions and/or
other factors.



Date and Accuracy of Information. The Information contained
herein speaks as of the date hereof or as of the specific date(s) noted
herein, as applicable. The Fund, the Manager, the General Partner,
SoftBank and their respective affiliates, members, partners,
stockholders, other beneficial owners, managers, directors, officers,
employees, representatives, advisers and agents do not have any
obligation to update any of the Information. . None of the Fund, the
Manager, the General Partner, SoftBank or any of their applicable
affiliates makes any representation or warranty, express or implied, as
to the accuracy or completeness of the information contained herein, and
nothing contained herein should be relied upon as a promise or
representation as to past or future performance of the Fund, any
investment or any other entity. The Fund, the Manager, the General
Partner, SoftBank or any of their applicable subsidiaries or affiliates,
and its and their respective members, partners, stockholders, other
beneficial owners, managers, directors, officers, employees,
representatives, agents and advisors advisers cannot be held liable for
the use of, and reliance upon, such materials and information and any
opinions, estimates, forecasts and findings contained herein.



Suitability. None of SoftBank, the Fund, the Manager, the General
Partner or any of their applicable affiliate represents that the
Information is all-inclusive or that the Information contains all
information that may be desirable, necessary or required to properly
evaluate a potential investment with SoftBank, the Fund, the Manager,
the General Partner and/or their applicable affiliates.



Any investment or investment activity to which this Information relates
is available only to (i) persons falling within any of the categories of
“investment professionals” as defined in Article 14(5) of the Financial
Services and Markets Act 2000 (Promotion of Collective Investment
Schemes) (Exemptions) Order 2001, as amended (the “CIS Order”) and
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the “FPO”); (ii) persons falling
within any of the categories of “high-net-worth entities” as described
in Article 22(2) of the CIS Order and Article 49(2) of the FPO; or (iii)
any other person to whom it may otherwise lawfully be communicated (all
such persons together being referred to as “Exempt Persons”) on an
invitation basis and will be engaged in only with such Exempt Persons.
Furthermore, procedures are in place to assess the status of investment
participants. Accordingly, persons who are not Exempt Persons (in
particular, persons who would be classified as “retail clients” under
the FCA rules) must not rely on this Information.



In the case of persons outside the United Kingdom, investments or
investment services referred to in the Information are only available on
an invitation basis and are subject to procedures to assess status and
suitability. For the avoidance of doubt, investments or investment
services referred to in the Information are not available to private or
retail customers.



SoftBank and/or the Manager do not and will not act for you. In
particular, SoftBank and/or the Manager do not and will not advise you
or provide any other investment services to you and will not be
responsible for providing you with any protections. No employee of, or
other person associated with, SoftBank and/or the Manager has the
authority to represent otherwise.




Contacts


USA
Sard Verbinnen & Co
Paul Kranhold / Megan
Bouchier
softbank-svc@sardverb.com
+1
415 618 8750
or
EMEA, MENA, UK
Finsbury
Rollo
Head / Andy Parnis
softbank@finsbury.com
+44
(0) 20 7251 3801
or
JAPAN
SoftBank Media Relations
sbpr@softbank.co.jp
+81
3 6889 2300
or
INDIA
SoftBank
Paroma Roy
Chowdhury
paroma@softbank.com
+91
(124) 4131400
or
Website
More information can be
found at https://softbank-ia.com/





Top 5 Vendors in the Nuclear Fuels Market From 2017 to 2021… 2017年05月20日 05時03分

LONDON--(BUSINESS WIRE)--#Energy--Technavio
has announced the top five leading vendors in their recent global
nuclear fuels market
report. This research report also
lists 19 other prominent vendors that are expected to impact the market
during the forecast period.








There is a growing need for emission-free power generation capacities
around the globe due to the increasing awareness about reducing the use
of fossil fuels, especially in thermal power plants. It was noted that a
quarter of the existing fossil fuel plants worldwide are in operation
for more than 30 years.



Competitive vendor landscape



Due to the lack of government support and the reducing gas prices, which
is attracting investments toward gas power plants, the global nuclear
fuel market is witnessing a decline in its growth. The market is
diversified by the presence of international and regional vendors. In
developed and developing economies, regional vendors are more prominent,
thus increasing the competition for market share with the international
players.



A growing number of regional vendors are focusing on R&D activities
in the new market areas such as nuclear fission and new generation
nuclear reactors. This research is expected to result in more reliable
and efficient next-generation nuclear power plants
,” says
Thanikachalam Chandrasekaran, a lead power
research analyst from Technavio.



Looking for more information on this market? Request
a free sample report



Technavio’s sample reports are free of charge and contain multiple
sections of the report including the market size and forecast, drivers,
challenges, trends, and more.



Top five nuclear
fuels
market vendors



ARMZ Uranium Holding Company



ARMZ Uranium Holding Company is involved in the development of uranium
mining at various stages of its lifecycle, ranging from exploration to
industrial production. The company is also involved in the development
of brown coal production, thermal and electrical power generation,
sulfuric acid production, building mining equipment, rendering drilling,
exploration support, design, and engineering services.



Cameco



Cameco is one of the largest uranium producers in the world. Its
activities include the operations and investments spanning the whole
nuclear fuel cycle, from exploration to fuel manufacturing. The other
segments of the company comprise the fuel services division, which is
the main source of profits and supports the company's uranium segment,
thus allowing them to integrate across the fuel cycle vertically.



Energy Resources of Australia



Energy Resources of Australia is involved in the supply of uranium.
Apart from uranium supply, the company also has a stockpile of ore
reserves. Energy Resources of Australia is involved in uranium mining.



Japan Oil, Gas and Metals National Corporation



Japan Oil, Gas and Metals National Corporation is involved in the supply
of funds for the exploration of oil and gas, coal, geothermal energy,
and metallic minerals. It is also involved in operations in the
development of hydrocarbons, coal resources, geothermal resources, and
metallic mineral resources.



KazAtomProm



KazAtomProm is involved in geological exploration, natural uranium
mining, production of uranium products, production of quartz,
metallurgical silicon, PV cells and plates, renewable energy sources,
design of heating pump units, bulk concentrate of rare-earth metals,
beryllium, tantalum, niobium products, generation of electrical and
heating power, and production of distillate drinking water.



Browse Related Reports:




Become a Technavio
Insights member
and access all three of these reports for a
fraction of their original cost. As a Technavio Insights member, you
will have immediate access to new reports as they’re published in
addition to all 6,000+ existing reports covering segments like oil and
gas, energy storage, and smart grid. This subscription nets you
thousands in savings, while staying connected to Technavio’s constant
transforming research library, helping you make informed business
decisions more efficiently.



About Technavio



Technavio
is a leading global technology research and advisory company. The
company develops over 2000 pieces of research every year, covering more
than 500 technologies across 80 countries. Technavio has about 300
analysts globally who specialize in customized consulting and business
research assignments across the latest leading edge technologies.



Technavio analysts employ primary as well as secondary research
techniques to ascertain the size and vendor landscape in a range of
markets. Analysts obtain information using a combination of bottom-up
and top-down approaches, besides using in-house market modeling tools
and proprietary databases. They corroborate this data with the data
obtained from various market participants and stakeholders across the
value chain, including vendors, service providers, distributors,
re-sellers, and end-users.



If you are interested in more information, please contact our media team
at media@technavio.com.








Contacts


Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

豊田合成とダイセルの協力関係強化及び資本提携に関するお知らせ 2017年05月19日 20時21分

愛知県清須市--(BUSINESS WIRE)--(ビジネスワイヤ) -- 豊田合成株式会社(本社:愛知県清須市、社長:宮﨑
直樹、以下「豊田合成」)と株式会社ダイセル(本社:大阪市北区、社長:札場
操、以下「ダイセル」)は、今後のビジネスにおける協力関係強化と資本提携において合意いたしました。






自動車産業は、電気自動車・燃料電池車・自動運転の進展など大きな環境変化の中にあり、自動車部品についても将来を見据えた様々な変化・進化が求められています。こうした状況に対応するため、豊田合成、ダイセルの両社は「安全性の分野」及び合成樹脂材料における「新素材の分野」を中心に協力関係を強化するとともに資本提携を行い、より良い製品の市場供給を図ってまいります。













































1.



 


協力関係強化のイメージ





<対象製品(一例を記載)>



・ セーフティ分野 : エアバッグ



・ 燃料系分野   : フューエルキャップ、フューエルチューブ 等

 


2.





資本提携の内容





豊田合成・ダイセル両社が同等金額の普通株式を持ち合う形での資本提携に合意いたしました。



両社は、取得価格の総額として各々約10億円を目安に取得します。



Contacts


〔本プレスリリースに関するお問い合わせ先〕
豊田合成(株)
総務部 広報室
淺倉 正二郎
阿部 貴知
052-400-1452
inquiry@mail.toyoda-gosei.co.jp

Toyoda Gosei and Daicel Announce Enhanced Cooperation and C… 2017年05月19日 20時21分

KIYOSU, Japan--(BUSINESS WIRE)--Toyoda Gosei Co., Ltd. and Daicel Corporation (Osaka, Japan) have agreed
to enhance cooperation in future business and enter into a capital
tie-up.








The automobile industry is undergoing significant changes with the
emergence of electric vehicles, fuel cell vehicles and self-driving
vehicles. Automotive parts makers need to look ahead to the many changes
and continuing evolution of the industry. To improve their ability to
adapt to these circumstances and provide better products to the market,
Toyoda Gosei and Daicel will strengthen their cooperative relationship,
centered on the fields of safety and new plastics materials, and enter
into a capital tie-up.








































1.



 


Enhanced Cooperation






Target Products (examples)





• Safety: Airbags



• Fuel system: Fuel caps, fuel tubes, other products



 


2.





Content of Capital Tie-up





Toyoda Gosei and Daicel have agreed to a capital tie-up in the form
of cross-holdings of common stock by each company in equal amounts.
The acquisition price is expected to be a total of about 1 billion
yen for each company.



Contacts


Toyoda Gosei Co., Ltd.
Takatomo Abe
inquiry@mail.toyoda-gosei.co.jp

Toshiba's Low Power Consumption Photocoupler Achieves High … 2017年05月19日 18時54分


- Realizes advantages of low power consumption, low threshold input
current and low supply current




TOKYO--(BUSINESS WIRE)--Toshiba
Corporation
's (TOKYO:6502) Storage & Electronic Devices Solutions
Company today unveiled “TLX9310,” a low power consumption photocoupler
housed in a 5pin SO6 package for high speed communication in automotive
applications. Mass production shipments start today.






Integration of a high-power infrared LED and high-gain/high-speed
integrated circuit photo IC chip cuts power consumption to below a
quarter that of Toshiba’s current output type ICs (TLX9304, TLX9376,
TLX9378) and will reduce consumption during standby and driving of
automotive applications.



The latest Gartner market report recognizes Toshiba as the leading
manufacturer of optocouplers by sales in 2015 and 2016, with 23% of
sale-based market share in CY2016. (Source: Gartner, Inc. “Market Share:
Semiconductor Devices and Applications, Worldwide, 2016” 30 March 2017)



Toshiba will continue to deliver products that meet the needs of
customers by promoting the development of a diverse portfolio of
photocouplers and photorelays tailored to market trends.



Applications




  • Automotive Battery Management (BMS) for signal communication


  • For signal communication of other automotive application equipment



Features




  • Operating temperature -40 to 105oC; Storage temperature -55
    to 125oC


  • Threshold input current: 1.0mA (max) @IO=-3.2mA, VO>2.4V


  • High-level/low-level supply current: 0.3mA (max) @IF=0mA/2mA


  • Propagation delay time (max): 250ns (max) @VIN=3.3V, RT=820Ω


  • Propagation delay skew (device to device) (max): 65ns @VIN=3.3V,
    RT=820Ω


  • Totem pole output

































































































 


Main Specifications




(Unless otherwise specified, Ta=-40 to 105oC, VDD=2.7
to 5.5V)



Part Number

 

TLX9310


Electrical
Characteristics



 


Low-level output voltage VOL




0.4 V (max)



High-level output voltage VOH




VDD-1.0 V (min)



Low-level supply current IDDL




0.3 mA (max)



High-level supply current IDDH




0.3 mA (max)



Threshold input current (L/H) IFLH




1.0 mA (max)


Switching
Characteristics




Propagation delay time tpLH/tpHL


250 ns (max)


Propagation delay skew tpsk


65 ns (max)


Isolation Characteristics
(@Ta=25 oC)




Isolation voltage


3750 Vrms (min)


Clearance


5.0 mm (min)


Creepage distances


5.0 mm (min)

Package


Name


5pin SO6

 

Size typ. (mm)

 

3.7×7.0×2.2

 


Follow the link below for more on the new product and Toshiba’s
photocoupler line-up for automotive applications.
https://toshiba.semicon-storage.com/ap-en/product/opto/photocoupler/automotive.html



Customer Inquiries:
Optoelectronic Device Sales & Marketing Dept.
Tel:
+81-3-3457-3431
https://toshiba.semicon-storage.com/ap-en/contact.html



Information in this document, including product prices and
specifications, content of services and contact information, is correct
on the date of the announcement but is subject to change without prior
notice.



About Toshiba
Toshiba Corporation, a
Fortune Global 500 company, channels world-class capabilities in
advanced electronic and electrical product and systems into three focus
business fields: Energy that sustains everyday life, that is cleaner and
safer; Infrastructure that sustains quality of life; and Storage that
sustains the advanced information society. Guided by the principles of
The Basic Commitment of the Toshiba Group, “Committed to People,
Committed to the Future”, Toshiba promotes global operations and is
contributing to the realization of a world where generations to come can
live better lives.



Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global
network of 550 consolidated companies employing 188,000 people
worldwide, with annual sales surpassing 5.6 trillion yen (US$50
billion). (As of March 31, 2016.)
To find out more about Toshiba,
visit www.toshiba.co.jp/index.htm




Contacts


Media Inquiries:
Toshiba Corporation
Storage & Electronic
Devices Solutions Company
Digital Marketing Department
Chiaki
Nagasawa, +81-3-3457-4963
semicon-NR-mailbox@ml.toshiba.co.jp

東芝:車載機器の高速通信用低消費電力フォトカプラの製品化に… 2017年05月19日 18時54分


~低入力電流と低供給電流を実現~




東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 株式会社東芝ストレージ&デバイスソリューション社は、低消費電力が求められる車載機器の高速通信用に、5pin
SO6パッケージの低消費電力フォトカプラ「TLX9310」を製品化し、本日から出荷を開始します。






新製品は、高出力の赤外発光ダイオードと高利得・高速の受光ICの組み合わせにより、既存製品[注1]に比べて1/4以下の低消費電力を実現しました。これにより車載機器での待機時や駆動時の消費電力削減に貢献します。



米大手ITアドバイザリ会社ガートナー社の最新レポートにおいて、当社は2015年から2016年にかけて、売り上げベースでシェアNo.1のフォトカプラメーカーと認定されました。また、そのレポートによると、当社は2016年に販売金額ベースで市場シェア23%を獲得しました。(出典:Gartner,
Inc. “Market Share: Semiconductor Devices and Applications, Worldwide,
2016” 30 March 2017)



当社は、市場動向に合わせた多様なフォトカプラ・フォトリレーの開発を推進することで、お客様のニーズに応える製品を届け続けます。



応用機器



車載機器




  • バッテリマネジメント (BMS) のI/O信号通信


  • 機器内信号通信



新製品の主な特長




  • 動作温度定格: Topr=-40~105℃


  • 低スレッショルド入力電流: IFLH=1.0mA (max)


  • 低供給電流: IDDL, IDDH=0.3mA (max)


  • データ伝送レート: 5MBd (typ)@NRZ


  • 伝搬遅延時間: tPLH, tPHL=250ns (max)


  • 伝搬遅延スキュー: tpsk=65ns (max)


  • トーテムポール出力














































































































 


新製品の主な仕様




(特に指定のない限り、Ta=-40~105℃, VDD=2.7~5.5 V)



品番

 

TLX9310

絶対最大定格

 

動作温度 Topr (℃)



-40~105



電気的特性


ローレベル出力電圧 VOL max (V)


0.4


ハイレベル出力電圧 VOH min (V)


VDD-1.0


ローレベル供給電流 IDDL max (mA)


0.3


ハイレベル供給電流 IDDH max (mA)


0.3


スレッショルド入力電流 ( L→H) IFLH max (mA)


1.0


スイッチング特性




データ伝送レート typ. (MBd)@NRZ


5


伝搬遅延時間 tpLH max, tpHL max (ns)


250


伝搬遅延スキュー tpsk max (ns)


65


絶縁性能
(@Ta=25℃)




絶縁電圧 BVS min (Vrms)


3750


空間距離 min (mm)


5.0


沿面距離min (mm)


5.0

パッケージ


名称


5pin SO6

 

サイズ typ (mm)

 

3.7×7.0×2.2

 


[注1]: 既存製品 TLX9304, TLX9376, TLX9378



新製品を含む東芝の車載用フォトカプラ製品については下記ホームページをご覧ください。
https://toshiba.semicon-storage.com/jp/product/opto/photocoupler/automotive.html



お客様からの製品に関するお問い合わせ先:
オプトデバイス営業推進部
Tel: 03-3457-3431
https://toshiba.semicon-storage.com/jp/contact.html



*本資料に掲載されている情報(製品の価格/仕様、サービスの内容及びお問い合わせ先など)は、発表日現在の情報です。予告なしに変更されることがありますので、あらかじめご了承ください。




Contacts


報道関係の本資料に関するお問い合わせ先:
株式会社東芝 ストレージ&デバイスソリューション社
デジタルマーケティング部
長沢千秋
Tel:
03-3457-4963
e-mail: semicon-NR-mailbox@ml.toshiba.co.jp



PIKO TARO to Serve as Ambassador of WAKUWAKU JAPAN! 2017年05月19日 16時33分

TOKYO--(BUSINESS WIRE)--WAKUWAKU JAPAN CORPORATION (headquartered in Minato Ward, Tokyo,
Masafumi Kawanishi, President and CEO) has named PIKO TARO, the Japanese
singing sensation who skyrocketed to global fame with his single, PPAP,
to serve as an ambassador of WAKUWAKU JAPAN. In the year ahead, PIKO
TARO, together with WAKUWAKU JAPAN, will share the wonders of Japan
worldwide, throughout various countries and regions.








Startling advances have continued for PIKO TARO, with the video for his
PPAP hit song exceeding 110 million views (* see note). PPAP has become
exceedingly popular for use in television programs, commercials, and
events not only in Japan but throughout the world. With successful live
performances in March of this year at both the famed Budokan concert
hall in Tokyo as well as solo shows in Taiwan, PIKO TARO seems to be on
an unstoppable trajectory. His immense popularity among young and old,
men and women alike, has garnered him invitations to the US, France,
Belgium, South Korea, Taiwan, Singapore, and Thailand. Fans go crazy
wherever he performs.



With content currently being broadcast in eight different countries and
regions, WAKUWAKU JAPAN asked PIKO TARO to serve as an ambassador, to
help share the wonders of Japan. He responded that he was not only
interested in doing that but that he would be honored to serve as
ambassador of WAKUWAKU JAPAN. His first destination in that role was a
visit to Indonesia with WAKUWAKU JAPAN in May of 2017.
This joint
collaboration between WAKUWAKU JAPAN and PIKO TARO will bring new
excitement to the world and its citizens, and will create even more fans
of Japan.



* NOTE: as of April, 2017



[PIKO TARO’s Profile]
Name: PIKO TARO
Age: 53 years old
Date
Of Birth: 7 / 17 / 1963
Home Town: Chiba Prefecture
Blood
Type: A



WAKUWAKU JAPAN CORPORATION Profile




  • Company Name: WAKUWAKU JAPAN CORPORATION(http://www.wakuwakujapan.com/


  • Address: 7F Akasaka Enokizaka Building, 1-7-1 Akasaka, Minato-ku,
    Tokyo 107-0052


  • Established: May 1, 2015


  • Capital: 5.5 billion yen


  • President & CEO: Masafumi Kawanishi


  • Major shareholder: SKY Perfect JSAT 60%, Cool Japan Fund Inc. 40%


  • Official site: http://www.wakuwakujapan.tv/


  • Countries and regions currently broadcasting:
    Indonesia, Myanmar,
    Singapore, Thailand, Taiwan, Sri Lanka, Vietnam and Mongolia



The original source-language text of this announcement is the official,
authoritative version. Translations are provided as an accommodation
only, and should be cross-referenced with the source-language text,
which is the only version of the text intended to have legal effect.




Contacts


Direct inquiries:
WAKUWAKU JAPAN Corporation
Tomoko Karasawa /
Minyi REN, +81-3-5571-6880
Marketing Department
info@wakuwakujapan.com



Mitsubishi Electric, Nokia Bell Labs, UC San Diego Develop … 2017年05月19日 11時18分


High-speed operation of envelope-tracking power amplifier will help
reduce energy consumption of next-generation wireless base stations


TOKYO--(BUSINESS WIRE)--Mitsubishi
Electric Corporation
(TOKYO:6503), Nokia Bell Labs and the Center
for Wireless Communications at UC San Diego announced today their joint
development of the world’s first ultra-fast gallium nitride (GaN)
envelope-tracking power amplifier, which supports modulation bandwidth
up to 80MHz and is expected to reduce energy consumption in
next-generation wireless base stations. Technical details will be
presented during the IEEE MTT International Microwave Symposium (IMS)
2017, which will be held in Honolulu, Hawaii, USA from June 4 to 9.




To help meet the demand for increasing wireless capacity, mobile
technologies are shifting to next-generation systems that use complex
modulated signals with large peak-to-average power ratio (PAPR) and
extra-wide modulation bandwidth. This will require power amplifiers to
operate most of the time at backed-off power levels that are well below
their saturation levels. Generally, power amplifiers achieve high
efficiency near their saturation power levels, but significantly
degraded efficiency at backed off levels, as in the case of 4G LTE*
signals (>6dB PAPR). Envelope-tracking power amplifiers have been
studied extensively as a means to enhance power-amplifier efficiency,
but so far the supply-modulator circuit has been the bottleneck limiting
modulation bandwidth for advanced wireless communications, such as
LTE-Advanced.



The newly developed ultra-fast GaN envelope-tracking power amplifier
achieves state-of-art performance thanks in part to Mitsubishi
Electric’s high-frequency GaN transistor technology and design
innovation for the GaN supply-modulator circuit. Using Nokia Bell Labs’
real-time digital pre-distortion (DPD) system, the power amplifier has
demonstrated efficient operation even with 80MHz modulated LTE signals,
the world’s widest modulation bandwidth for this purpose as of May 19,
2017.



For the full text, please visit: http://www.mitsubishielectric.com/news




Contacts


Inquiries
Mitsubishi Electric
Corporation
Information Technology R&D Center
www.MitsubishiElectric.com/ssl/contact/company/rd/form.html
www.MitsubishiElectric.com/company/rd/
or
Media
Inquiries

Mitsubishi Electric Corporation
Takeyoshi Komatsu
Public
Relations Division
prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/news/



東芝:「人とくるまのテクノロジー展2017 横浜」への出展について 2017年05月19日 10時27分


未来の車載ソリューションに貢献する最新システムから電子デバイスや材料までを紹介



東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 株式会社東芝ストレージ&デバイスソリューション社は、5月24日から26日までパシフィコ横浜で開催される「人とくるまのテクノロジー展2017
横浜」に出展します。「くるまのある暮らしをもっと快適に」をコンセプトに、先進運転支援システム(ADAS)や次世代車載情報通信システム(IVI)などに向けて、画像認識プロセッサ「ViscontiTM」と電子ミラー表示技術を組み合わせて安心で快適な運転を支援する次世代コックピットソリューションや、自動車IoTソリューションなどの最新システムの提案から、半導体、ストレージ、電池などの電子デバイスや材料までの製品展示やデモを通して、未来の車載ソリューションの提案を行います。



「人とくるまのテクノロジー展2017 横浜」展示の概要



1. 開催日:2017年5月24日(水)~26日(金)
2. 会場: パシフィコ横浜
3. 展示ブース:東芝グループブース
(小間番号: ホールC 227)
4. 主な展示内容:



車載モータ制御ソリューション
センサレス/マイコンレス/半導体リレーでECU小型化に貢献
ソフト開発が不要な車載用3相ブラシレス・センサレス・モータプリドライバを紹介します。MOSFETは新プロセスにより小型軽量化・低ノイズ化を実現し、IPDは微細プロセスと小型パッケージでセット小型化に貢献します。



フォトカプラ混載IGBTゲートコントローラ
HEV・EVの走行安全と低燃費に貢献
信号系と駆動系の絶縁部にフォトカプラを混載することにより、耐ノイズ性と絶縁性の両立を実現します。さらに機能安全を考慮した多彩な検出・保護機能を搭載し、小型化に貢献します。



次世代コックピットソリューション
運転を支援しドライバーの負担を軽減
ドライバーのストレス軽減に貢献する次世代コックピットを紹介します。画像認識プロセッサによって周辺を監視し、電子化したミラーで死角を削減します。



ADAS向け画像認識プロセッサ Visconti™
クルマの安全を進化させる先進技術
先進運転支援システム(ADAS)に求められる高度な画像認識(低照度環境の歩行者検知・
サイクリスト検知)を高速・低消費電力で実現します。



車載用途に適した高信頼性ストレージ
コネクテッドカーを支える車載機器用e·MMC™/UFS、ナビゲーションシステム用SD、microSDメモリカードを紹介します。



※Viscontiは、株式会社東芝の登録商標です。
※"e·MMC"はJEDEC/MMCAの商標です
※本ページに記載されているシステムおよび製品名は、一般に各社の登録商標または商標です。



当社の展示内容のさらに詳しい内容については下記ホームページをご覧ください。
https://toshiba.semicon-storage.com/jp/design-support/exhibition/car17.html



*本資料に掲載されている情報(製品の価格/仕様、サービスの内容及びお問い合わせ先など)は、発表日現在の情報です。予告なしに変更されることがありますので、あらかじめご了承ください。




Contacts


報道関係の本資料に関するお問い合わせ先:
株式会社 東芝
ストレージ&デバイスソリューション社
デジタルマーケティング部
長沢千秋
Tel:
03-3457-4963
e-mail: semicon-NR-mailbox@ml.toshiba.co.jp

Rambus and Cybertrust Partner to Secure Connected Devices 2017年05月19日 05時30分


Cybertrust selects Rambus CryptoManager™ Infrastructure for secure
device management and software updates


SUNNYVALE, Calif.--(BUSINESS WIRE)--#HCE--Rambus
Inc.
 (NASDAQ:RMBS) today announced a partnership with Cybertrust
Japan Co., Ltd. (Cybertrust), a leading provider of Public Key
Infrastructure (PKI) solutions and a subsidiary of SoftBank Technology
Corp.(JPX First Section: 4726), to deliver secure key provisioning and
security services for connected devices spanning from enterprise
multi-function printers to connected cars.



This collaboration combines the Rambus CryptoManager
Infrastructure
, a secure provisioning and key management system, and
the Cybertrust PKI solution, to secure communication from
device-to-cloud and for over-the-air (OTA) software updates. The joint
solution brings two leading security providers together to deliver a
turn-key platform that addresses the increasingly complex security
challenges for connected devices.



“Connected device management including periodic OTA software and data
updates are critical for manufacturers and service providers,” said
Yasutoshi Magara, president, Cybertrust. “This joint solution optimizes
highly secure, in-field device updates, safeguarding sensitive
information and mitigating cyber-attacks.”



“We are excited to partner with Cybertrust, a leading security provider
committed to securing critical systems,” said Martin Scott, senior vice
president and general manager of the Rambus Security Division. “Our
combined expertise brings an innovative secure solution that delivers a
robust platform, shielding devices from attackers and securing these OTA
updates.”



Rambus CryptoManager Infrastructure provides secure key provisioning and
key management services for device lifecycle management. CryptoManager
provides lifecycle cryptographic security management necessary to secure
connected devices over public networks. Services include:




  • Provisioning of keys during semiconductor and device manufacturing


  • Controlling critical test and debug traces


  • Enabling feature and device settings


  • Securing in-field key provisioning


  • Over-the air-updates of device software and firmware



For additional information on the CryptoManager platform, visit rambus.com/cryptomanager.



About Cybertrust PKI Service



Cybertrust is a comprehensive PKI vendor that offers a wide range of
products and services, including the issuance of certificate authorities
and the outsourcing of certificate issuance services.



Additional PKI services and solutions include:




  • UniCert of in-house certificate authority issuance service


  • Customer-branded certificate authority (Managed PKI)


  • Cybertrust-branded user certificate issuing service (Personal ID)


  • Terminal authentication certificate issuing service (Device ID)



We also offer consulting services to address a range of PKI
requirements, including management operations, system linkages, as well
as information security and risk management services for enterprises.



Additional information is available at https://www.cybertrust.ne.jp/pki/.



About Cybertrust



Cybertrust is the largest certification organization in Japan and has
been the first commercial e-certificate authority in Japan to provide
electronic certification services including SSL / TLS certificates for
over 20 years. Terminal compatible with multi OS and multi form factor
Electronic authentication service "Device ID" is the No. 1 achievement
in Japan. We will aim to realize a society where users can receive
services safely and securely by providing electronic authentication
services even in IoT devices whose usage forms and uses expand.
Additional information is available at https://www.cybertrust.ne.jp/.



Follow Rambus:
Company website: rambus.com
Rambus blog: rambus.com/blog
Twitter: @rambusinc
LinkedIn: www.linkedin.com/company/rambus
Facebook: www.facebook.com/RambusInc



About Rambus Security



Rambus Security is dedicated to providing a secure foundation for a
connected world. Our innovative solutions span areas including tamper
resistance, network security, mobile payment, smart ticketing
and trusted transaction services. Rambus foundational technologies
protect nearly nine billion licensed products annually, providing secure
access to data and creating an economy of digital trust between our
customers and their customer base. Additional information is
available at rambus.com/security.



About Rambus



Rambus creates innovative hardware and software technologies, driving
advancements from the data center to the mobile edge. Our chips,
customizable IP cores, architecture licenses, tools, software, services,
training and innovations improve the competitive advantage of our
customers. We collaborate with the industry, partnering with leading
ASIC and SoC designers, foundries, IP developers, EDA companies and
validation labs. Our products are integrated into tens of billions of
devices and systems, powering and securing diverse applications,
including Big Data, Internet of Things (IoT), mobile payments, and smart
ticketing. At Rambus, we are makers of better. For more information,
visit rambus.com.




Contacts


Rambus
Agnes Toan, 408-462-8905
Corporate Communications
atoan@rambus.com
or
Cybertrust
Kenji
Sasaki, +81-3-6234-3800
President’s Office
Kenji.sasaki@cybertrust.ne.jp

企業をしらべれば人生が変わる! -就活やビジネスを成功に導くユーレット活用術-
スポンサードリンク
Ullet経審

他社比較

help他社比較するには?


注目情報

他社比較
「味の素はどっち?」いろんな会社を比較してみよう!
Ulletニュース
過去の掲載記事等の一覧。

マイリスト

ページ

ここに企業名をドラッグ&ドロップすると、リストに追加することが出来ます。

戻る次へ

閲覧履歴

ページ

ここに閲覧した企業の履歴が表示されます。

戻る次へ

関連サービス

Ulletモバイル
何時でもどこでも携帯で見れる!
Ullet経審 New
160,000社の決算書データ公開。売上高や評点別ランキングも。
aera 西野グローバルIT研究所 環境新聞・ユーレット合同企画『CO2と経営』
Ulletモバイル試験運用開始 QRコードを読込